0001628280-22-027550.txt : 20221101 0001628280-22-027550.hdr.sgml : 20221101 20221101160619 ACCESSION NUMBER: 0001628280-22-027550 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221101 DATE AS OF CHANGE: 20221101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 221350236 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 10-Q 1 abt-20220930.htm 10-Q abt-20220930
000000180012-312022Q3falseP12M00000018002022-01-012022-09-300000001800exch:XCHI2022-01-012022-09-300000001800exch:XNYS2022-01-012022-09-3000000018002022-09-30xbrli:shares00000018002022-07-012022-09-30iso4217:USD00000018002021-07-012021-09-3000000018002021-01-012021-09-30iso4217:USDxbrli:shares00000018002021-12-310000001800us-gaap:CommonStockMember2022-06-300000001800us-gaap:CommonStockMember2021-06-300000001800us-gaap:CommonStockMember2022-07-012022-09-300000001800us-gaap:CommonStockMember2021-07-012021-09-300000001800us-gaap:CommonStockMember2022-09-300000001800us-gaap:CommonStockMember2021-09-300000001800us-gaap:TreasuryStockCommonMember2022-06-300000001800us-gaap:TreasuryStockCommonMember2021-06-300000001800us-gaap:TreasuryStockCommonMember2022-07-012022-09-300000001800us-gaap:TreasuryStockCommonMember2021-07-012021-09-300000001800us-gaap:TreasuryStockCommonMember2022-09-300000001800us-gaap:TreasuryStockCommonMember2021-09-300000001800us-gaap:RetainedEarningsMember2022-06-300000001800us-gaap:RetainedEarningsMember2021-06-300000001800us-gaap:RetainedEarningsMember2022-07-012022-09-300000001800us-gaap:RetainedEarningsMember2021-07-012021-09-300000001800us-gaap:RetainedEarningsMember2022-09-300000001800us-gaap:RetainedEarningsMember2021-09-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000001800us-gaap:NoncontrollingInterestMember2022-06-300000001800us-gaap:NoncontrollingInterestMember2021-06-300000001800us-gaap:NoncontrollingInterestMember2022-07-012022-09-300000001800us-gaap:NoncontrollingInterestMember2021-07-012021-09-300000001800us-gaap:NoncontrollingInterestMember2022-09-300000001800us-gaap:NoncontrollingInterestMember2021-09-300000001800us-gaap:CommonStockMember2021-12-310000001800us-gaap:CommonStockMember2020-12-310000001800us-gaap:CommonStockMember2022-01-012022-09-300000001800us-gaap:CommonStockMember2021-01-012021-09-300000001800us-gaap:TreasuryStockCommonMember2021-12-310000001800us-gaap:TreasuryStockCommonMember2020-12-310000001800us-gaap:TreasuryStockCommonMember2022-01-012022-09-300000001800us-gaap:TreasuryStockCommonMember2021-01-012021-09-300000001800us-gaap:RetainedEarningsMember2021-12-310000001800us-gaap:RetainedEarningsMember2020-12-310000001800us-gaap:RetainedEarningsMember2022-01-012022-09-300000001800us-gaap:RetainedEarningsMember2021-01-012021-09-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000001800us-gaap:NoncontrollingInterestMember2021-12-310000001800us-gaap:NoncontrollingInterestMember2020-12-310000001800us-gaap:NoncontrollingInterestMember2022-01-012022-09-300000001800us-gaap:NoncontrollingInterestMember2021-01-012021-09-3000000018002020-12-3100000018002021-09-30abt:segment0000001800country:USus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberabt:KeyEmergingMarketsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2022-07-012022-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2021-07-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberabt:KeyEmergingMarketsMember2021-07-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2021-07-012021-09-300000001800abt:OtherEmergingMarketsMembercountry:USus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2022-07-012022-09-300000001800abt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2022-07-012022-09-300000001800abt:OtherEmergingMarketsMembercountry:USus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2021-07-012021-09-300000001800abt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMember2021-07-012021-09-300000001800abt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2021-07-012021-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2022-07-012022-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2021-07-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMember2021-07-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2021-07-012021-09-300000001800abt:PediatricNutritionalsMemberabt:NutritionalProductsMembercountry:USus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800abt:PediatricNutritionalsMemberabt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:PediatricNutritionalsMemberabt:NutritionalProductsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800abt:PediatricNutritionalsMemberabt:NutritionalProductsMembercountry:USus-gaap:OperatingSegmentsMember2021-07-012021-09-300000001800abt:PediatricNutritionalsMemberabt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2021-07-012021-09-300000001800abt:PediatricNutritionalsMemberabt:NutritionalProductsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000001800abt:NutritionalProductsMembercountry:USus-gaap:OperatingSegmentsMemberabt:AdultNutritionalsMember2022-07-012022-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberabt:AdultNutritionalsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberabt:AdultNutritionalsMember2022-07-012022-09-300000001800abt:NutritionalProductsMembercountry:USus-gaap:OperatingSegmentsMemberabt:AdultNutritionalsMember2021-07-012021-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberabt:AdultNutritionalsMemberus-gaap:NonUsMember2021-07-012021-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberabt:AdultNutritionalsMember2021-07-012021-09-300000001800abt:NutritionalProductsMembercountry:USus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800abt:NutritionalProductsMembercountry:USus-gaap:OperatingSegmentsMember2021-07-012021-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2021-07-012021-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000001800abt:CoreLaboratoryMembercountry:USus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-07-012022-09-300000001800abt:CoreLaboratoryMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:CoreLaboratoryMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-07-012022-09-300000001800abt:CoreLaboratoryMembercountry:USus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2021-07-012021-09-300000001800abt:CoreLaboratoryMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2021-07-012021-09-300000001800abt:CoreLaboratoryMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2021-07-012021-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:MolecularMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:MolecularMemberus-gaap:NonUsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:MolecularMember2022-07-012022-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:MolecularMember2021-07-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:MolecularMemberus-gaap:NonUsMember2021-07-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:MolecularMember2021-07-012021-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMember2022-07-012022-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMember2021-07-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2021-07-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMember2021-07-012021-09-300000001800country:USabt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-07-012022-09-300000001800abt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-07-012022-09-300000001800country:USabt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2021-07-012021-09-300000001800abt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2021-07-012021-09-300000001800abt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2021-07-012021-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-07-012022-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2021-07-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2021-07-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2021-07-012021-09-300000001800abt:RhythmManagementMembercountry:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800abt:RhythmManagementMembercountry:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2021-07-012021-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMember2022-07-012022-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMember2021-07-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMemberus-gaap:NonUsMember2021-07-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMember2021-07-012021-09-300000001800abt:HeartFailureMembercountry:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800abt:HeartFailureMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:HeartFailureMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800abt:HeartFailureMembercountry:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000001800abt:HeartFailureMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2021-07-012021-09-300000001800abt:HeartFailureMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMember2022-07-012022-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMember2021-07-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMemberus-gaap:NonUsMember2021-07-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMember2021-07-012021-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberabt:StructuralHeartMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMember2022-07-012022-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMember2021-07-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberabt:StructuralHeartMember2021-07-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMember2021-07-012021-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMember2022-07-012022-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMember2021-07-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMemberus-gaap:NonUsMember2021-07-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMember2021-07-012021-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberabt:DiabetesCareMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMember2022-07-012022-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMember2021-07-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberabt:DiabetesCareMember2021-07-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMember2021-07-012021-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-07-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2021-07-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000001800country:USus-gaap:CorporateNonSegmentMember2022-07-012022-09-300000001800us-gaap:CorporateNonSegmentMemberus-gaap:NonUsMember2022-07-012022-09-300000001800us-gaap:CorporateNonSegmentMember2022-07-012022-09-300000001800country:USus-gaap:CorporateNonSegmentMember2021-07-012021-09-300000001800us-gaap:CorporateNonSegmentMemberus-gaap:NonUsMember2021-07-012021-09-300000001800us-gaap:CorporateNonSegmentMember2021-07-012021-09-300000001800country:US2022-07-012022-09-300000001800us-gaap:NonUsMember2022-07-012022-09-300000001800country:US2021-07-012021-09-300000001800us-gaap:NonUsMember2021-07-012021-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberabt:KeyEmergingMarketsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2022-01-012022-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2021-01-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMemberabt:KeyEmergingMarketsMember2021-01-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2021-01-012021-09-300000001800abt:OtherEmergingMarketsMembercountry:USus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2022-01-012022-09-300000001800abt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2022-01-012022-09-300000001800abt:OtherEmergingMarketsMembercountry:USus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2021-01-012021-09-300000001800abt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMember2021-01-012021-09-300000001800abt:OtherEmergingMarketsMemberus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2021-01-012021-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2022-01-012022-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2021-01-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMemberus-gaap:NonUsMember2021-01-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2021-01-012021-09-300000001800abt:PediatricNutritionalsMemberabt:NutritionalProductsMembercountry:USus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800abt:PediatricNutritionalsMemberabt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:PediatricNutritionalsMemberabt:NutritionalProductsMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800abt:PediatricNutritionalsMemberabt:NutritionalProductsMembercountry:USus-gaap:OperatingSegmentsMember2021-01-012021-09-300000001800abt:PediatricNutritionalsMemberabt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2021-01-012021-09-300000001800abt:PediatricNutritionalsMemberabt:NutritionalProductsMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000001800abt:NutritionalProductsMembercountry:USus-gaap:OperatingSegmentsMemberabt:AdultNutritionalsMember2022-01-012022-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberabt:AdultNutritionalsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberabt:AdultNutritionalsMember2022-01-012022-09-300000001800abt:NutritionalProductsMembercountry:USus-gaap:OperatingSegmentsMemberabt:AdultNutritionalsMember2021-01-012021-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberabt:AdultNutritionalsMemberus-gaap:NonUsMember2021-01-012021-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberabt:AdultNutritionalsMember2021-01-012021-09-300000001800abt:NutritionalProductsMembercountry:USus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800abt:NutritionalProductsMembercountry:USus-gaap:OperatingSegmentsMember2021-01-012021-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2021-01-012021-09-300000001800abt:NutritionalProductsMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000001800abt:CoreLaboratoryMembercountry:USus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-01-012022-09-300000001800abt:CoreLaboratoryMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:CoreLaboratoryMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-01-012022-09-300000001800abt:CoreLaboratoryMembercountry:USus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2021-01-012021-09-300000001800abt:CoreLaboratoryMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2021-01-012021-09-300000001800abt:CoreLaboratoryMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2021-01-012021-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:MolecularMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:MolecularMemberus-gaap:NonUsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:MolecularMember2022-01-012022-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:MolecularMember2021-01-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:MolecularMemberus-gaap:NonUsMember2021-01-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberabt:MolecularMember2021-01-012021-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMember2022-01-012022-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMember2021-01-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2021-01-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:PointOfCareMemberabt:DiagnosticProductsMember2021-01-012021-09-300000001800country:USabt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-01-012022-09-300000001800abt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-01-012022-09-300000001800country:USabt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2021-01-012021-09-300000001800abt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2021-01-012021-09-300000001800abt:RapidDiagnosticsMemberus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2021-01-012021-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2022-01-012022-09-300000001800country:USus-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2021-01-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMemberus-gaap:NonUsMember2021-01-012021-09-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2021-01-012021-09-300000001800abt:RhythmManagementMembercountry:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800abt:RhythmManagementMembercountry:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2021-01-012021-09-300000001800abt:RhythmManagementMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMember2022-01-012022-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMember2021-01-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMemberus-gaap:NonUsMember2021-01-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:ElectrophysiologyMember2021-01-012021-09-300000001800abt:HeartFailureMembercountry:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800abt:HeartFailureMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:HeartFailureMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800abt:HeartFailureMembercountry:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000001800abt:HeartFailureMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2021-01-012021-09-300000001800abt:HeartFailureMemberabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMember2022-01-012022-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMember2021-01-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMemberus-gaap:NonUsMember2021-01-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:VascularMember2021-01-012021-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberabt:StructuralHeartMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMember2022-01-012022-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMember2021-01-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberabt:StructuralHeartMember2021-01-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:StructuralHeartMember2021-01-012021-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMember2022-01-012022-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMember2021-01-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMemberus-gaap:NonUsMember2021-01-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:NeuromodulationMember2021-01-012021-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberabt:DiabetesCareMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMember2022-01-012022-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMember2021-01-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMemberabt:DiabetesCareMember2021-01-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberabt:DiabetesCareMember2021-01-012021-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2022-01-012022-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800country:USabt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMemberus-gaap:NonUsMember2021-01-012021-09-300000001800abt:MedicalDevicesMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000001800country:USus-gaap:CorporateNonSegmentMember2022-01-012022-09-300000001800us-gaap:CorporateNonSegmentMemberus-gaap:NonUsMember2022-01-012022-09-300000001800us-gaap:CorporateNonSegmentMember2022-01-012022-09-300000001800country:USus-gaap:CorporateNonSegmentMember2021-01-012021-09-300000001800us-gaap:CorporateNonSegmentMemberus-gaap:NonUsMember2021-01-012021-09-300000001800us-gaap:CorporateNonSegmentMember2021-01-012021-09-300000001800country:US2022-01-012022-09-300000001800us-gaap:NonUsMember2022-01-012022-09-300000001800country:US2021-01-012021-09-300000001800us-gaap:NonUsMember2021-01-012021-09-300000001800abt:DiagnosticProductsMember2022-09-300000001800abt:MedicalDevicesMember2022-09-3000000018002022-10-012022-01-012022-09-30xbrli:pure00000018002022-10-012022-09-3000000018002024-10-012022-01-012022-09-3000000018002024-10-012022-09-300000001800us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-09-300000001800us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-09-300000001800us-gaap:EquitySecuritiesMember2022-09-300000001800us-gaap:EquitySecuritiesMember2021-12-310000001800us-gaap:OtherInvestmentsMember2022-09-300000001800us-gaap:OtherInvestmentsMember2021-12-310000001800abt:StJudeMedicalIncMemberus-gaap:EquitySecuritiesMember2022-09-300000001800abt:WalkVascularLLCMember2021-09-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-07-012022-09-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2021-07-012021-09-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-07-012022-09-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-012021-09-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-07-012022-09-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-07-012021-09-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-09-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-09-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-09-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-09-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-09-300000001800abt:EstablishedPharmaceuticalProductsMember2022-09-300000001800abt:NutritionalProductsMember2022-09-300000001800abt:MedicalDevicesMember2022-07-012022-09-300000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMember2021-04-012021-06-300000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:FixedAssetWriteDownsMember2021-04-012021-06-300000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:InventoryRelatedChargesMember2021-04-012021-06-300000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:OtherExitCostsMember2021-04-012021-06-300000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMember2021-07-012021-12-310000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:OtherExitCostsMember2021-07-012021-12-310000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:InventoryRelatedChargesMember2021-01-012021-12-310000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:FixedAssetWriteDownsMember2021-01-012021-12-310000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:OtherExitCostsMember2021-01-012021-12-310000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMember2021-01-012021-12-310000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:InventoryRelatedChargesMember2021-12-310000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:FixedAssetWriteDownsMember2021-12-310000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:OtherExitCostsMember2021-12-310000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMember2021-12-310000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:InventoryRelatedChargesMember2022-01-012022-09-300000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:FixedAssetWriteDownsMember2022-01-012022-09-300000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:OtherExitCostsMember2022-01-012022-09-300000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMember2022-01-012022-09-300000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:InventoryRelatedChargesMember2022-09-300000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:FixedAssetWriteDownsMember2022-09-300000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMemberabt:OtherExitCostsMember2022-09-300000001800abt:COVID19TestManufacturingNetworkRestructuringPlanMember2022-09-300000001800abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember2022-01-012022-09-300000001800abt:CostOfGoodsAndServicesSoldMemberabt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember2022-01-012022-09-300000001800us-gaap:ResearchAndDevelopmentExpenseMemberabt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember2022-01-012022-09-300000001800us-gaap:SellingGeneralAndAdministrativeExpensesMemberabt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember2022-01-012022-09-300000001800abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember2021-01-012021-12-310000001800abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember2021-12-310000001800abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember2022-09-300000001800us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000001800abt:RestrictedStockAwardsMember2022-01-012022-09-300000001800us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300000001800us-gaap:EmployeeStockOptionMember2022-09-300000001800abt:A255LongTermNotesDue2022Member2022-03-152022-03-150000001800abt:A255LongTermNotesDue2022Member2022-03-150000001800us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000001800us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000001800us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-09-300000001800us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2022-09-300000001800us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2021-12-310000001800abt:YenDenominatedLongTermDebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-09-300000001800abt:YenDenominatedLongTermDebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310000001800abt:YenDenominatedLongTermDebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000001800abt:YenDenominatedLongTermDebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000001800us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000001800us-gaap:FairValueHedgingMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000001800us-gaap:FairValueHedgingMemberabt:DeferredIncomeTaxesAndOtherAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000001800us-gaap:FairValueHedgingMemberabt:DeferredIncomeTaxesAndOtherAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000001800us-gaap:FairValueHedgingMemberabt:PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000001800us-gaap:FairValueHedgingMemberabt:PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000001800abt:PrepaidExpensesAndOtherReceivablesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000001800abt:PrepaidExpensesAndOtherReceivablesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000001800us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000001800us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000001800abt:PrepaidExpensesAndOtherReceivablesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2022-09-300000001800abt:PrepaidExpensesAndOtherReceivablesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2021-12-310000001800us-gaap:NondesignatedMemberus-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2022-09-300000001800us-gaap:NondesignatedMemberus-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2021-12-310000001800us-gaap:LongTermDebtMemberus-gaap:DebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000001800us-gaap:LongTermDebtMemberus-gaap:DebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000001800us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2022-07-012022-09-300000001800us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2021-07-012021-09-300000001800us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000001800us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2021-01-012021-09-300000001800us-gaap:DebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-07-012022-09-300000001800us-gaap:DebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-012021-09-300000001800us-gaap:DebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-09-300000001800us-gaap:DebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-09-300000001800us-gaap:FairValueHedgingMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-07-012022-09-300000001800us-gaap:FairValueHedgingMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-012021-09-300000001800us-gaap:FairValueHedgingMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-09-300000001800us-gaap:FairValueHedgingMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-09-300000001800us-gaap:ForeignExchangeForwardMember2022-07-012022-09-300000001800us-gaap:ForeignExchangeForwardMember2021-07-012021-09-300000001800us-gaap:ForeignExchangeForwardMember2022-01-012022-09-300000001800us-gaap:ForeignExchangeForwardMember2021-01-012021-09-300000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:EquitySecuritiesMember2022-09-300000001800us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:EquitySecuritiesMember2022-09-300000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:EquitySecuritiesMember2021-12-310000001800us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:EquitySecuritiesMember2021-12-310000001800us-gaap:OtherAggregatedInvestmentsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-300000001800us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:OtherAggregatedInvestmentsMember2022-09-300000001800us-gaap:OtherAggregatedInvestmentsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310000001800us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:OtherAggregatedInvestmentsMember2021-12-310000001800us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-300000001800us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-09-300000001800us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310000001800us-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310000001800us-gaap:FairValueMeasurementsRecurringMember2022-09-300000001800us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-09-300000001800us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000001800us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-09-300000001800us-gaap:FairValueMeasurementsRecurringMember2021-12-310000001800us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000001800us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000001800us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000001800abt:LegalProceedingsAndEnvironmentalExposuresMembersrt:MinimumMember2022-09-300000001800abt:LegalProceedingsAndEnvironmentalExposuresMembersrt:MaximumMember2022-09-300000001800abt:LegalProceedingsAndEnvironmentalExposuresMember2022-09-300000001800us-gaap:PensionPlansDefinedBenefitMember2022-07-012022-09-300000001800us-gaap:PensionPlansDefinedBenefitMember2021-07-012021-09-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-07-012022-09-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012021-09-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-09-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-09-300000001800srt:MinimumMember2022-09-300000001800srt:MaximumMember2022-09-300000001800us-gaap:OperatingSegmentsMember2022-07-012022-09-300000001800us-gaap:OperatingSegmentsMember2021-07-012021-09-300000001800us-gaap:OperatingSegmentsMember2022-01-012022-09-300000001800us-gaap:OperatingSegmentsMember2021-01-012021-09-300000001800us-gaap:MaterialReconcilingItemsMember2022-07-012022-09-300000001800us-gaap:MaterialReconcilingItemsMember2021-07-012021-09-300000001800us-gaap:MaterialReconcilingItemsMember2022-01-012022-09-300000001800us-gaap:MaterialReconcilingItemsMember2021-01-012021-09-300000001800abt:NutritionalProductsMember2022-07-012022-09-300000001800abt:NutritionalProductsMember2022-01-012022-09-300000001800abt:MedicalDevicesMember2022-01-012022-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to
Commission File No. 1-2189
ABBOTT LABORATORIES
An Illinois Corporation
I.R.S. Employer Identification No.
36-0698440
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
Telephone: (224) 667-6100
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Shares, Without Par ValueABT
New York Stock Exchange
Chicago Stock Exchange, Inc.
Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer x
Accelerated Filer o
Non-Accelerated Filer o
Smaller reporting company o
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of September 30, 2022, Abbott Laboratories had 1,743,573,777 common shares without par value outstanding.

Abbott Laboratories
Table of Contents
2


Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited)
(dollars in millions except per share data; shares in thousands)
Three Months Ended Nine Months Ended
September 30September 30
2022202120222021
Net sales$10,410 $10,928 $33,562 $31,607 
Cost of products sold, excluding amortization of intangible assets4,629 4,423 14,549 13,771 
Amortization of intangible assets498 520 1,517 1,533 
Research and development782 672 2,163 1,980 
Selling, general and administrative2,731 2,767 8,275 8,276 
Total operating cost and expenses8,640 8,382 26,504 25,560 
Operating earnings1,770 2,546 7,058 6,047 
Interest expense141 133 404 402 
Interest (income)(55)(10)(95)(32)
Net foreign exchange (gain) loss19 4 16 7 
Other (income) expense, net(93)(74)(253)(214)
Earnings before taxes1,758 2,493 6,986 5,884 
Taxes on earnings323 393 1,086 802 
Net Earnings$1,435 $2,100 $5,900 $5,082 
Basic Earnings Per Common Share$0.82 $1.18 $3.35 $2.85 
Diluted Earnings Per Common Share$0.81 $1.17 $3.32 $2.83 
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share1,752,968 1,774,516 1,756,209 1,776,870 
Dilutive Common Stock Options10,685 14,483 11,638 14,407 
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options1,763,653 1,788,999 1,767,847 1,791,277 
Outstanding Common Stock Options Having No Dilutive Effect5,445 2,740 2,655 2,694 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
3
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Comprehensive Income
(Unaudited)
(dollars in millions)
Three Months EndedNine Months Ended
September 30September 30
2022202120222021
Net Earnings$1,435 $2,100 $5,900 $5,082 
Foreign currency translation gain (loss) adjustments(1,008)(391)(1,429)(762)
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $11 and $36 in 2022 and $18 and $54 in 2021
56 78 172 211 
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $50 and $96 in 2022 and $50 and $98 in 2021
213 139 186 257 
Other comprehensive income (loss)(739)(174)(1,071)(294)
Comprehensive Income$696 $1,926 $4,829 $4,788 
September 30,
2022		December 31,
2021
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments$(7,268)$(5,839)
Net actuarial (losses) and prior service (costs) and credits(2,498)(2,670)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other321 135 
Accumulated other comprehensive income (loss)$(9,445)$(8,374)
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
4
Abbott Laboratories and Subsidiaries
Condensed Consolidated Balance Sheet
(Unaudited)
(dollars in millions)
September 30,
2022		December 31,
2021
Assets
Current Assets:
Cash and cash equivalents$9,594 $9,799 
Short-term investments313 450 
Trade receivables, less allowances of $520 in 2022 and $519 in 2021
6,408 6,487 
Inventories:
Finished products3,407 3,081 
Work in process726 694 
Materials1,601 1,382 
Total inventories5,734 5,157 
Prepaid expenses and other receivables2,796 2,346 
Total Current Assets24,845 24,239 
Investments764 816 
Property and equipment, at cost19,306 19,364 
Less: accumulated depreciation and amortization10,617 10,405 
Net property and equipment8,689 8,959 
Intangible assets, net of amortization10,850 12,739 
Goodwill22,284 23,231 
Deferred income taxes and other assets5,369 5,212 
$72,801 $75,196 
Liabilities and Shareholders’ Investment
Current Liabilities:
Trade accounts payable$4,133 $4,408 
Salaries, wages and commissions1,426 1,625 
Other accrued liabilities5,475 5,181 
Dividends payable820 831 
Income taxes payable394 306 
Current portion of long-term debt1,117 754 
Total Current Liabilities13,365 13,105 
Long-term debt15,297 17,296 
Post-employment obligations, deferred income taxes and other long-term liabilities8,255 8,771 
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued
— — 
Common shares, without par value Authorized — 2,400,000,000 shares
Issued at stated capital amount — Shares: 2022: 1,985,919,440; 2021: 1,985,273,421
24,560 24,470 
Common shares held in treasury, at cost — Shares: 2022: 242,345,663; 2021: 221,191,228
(14,555)(11,822)
Earnings employed in the business35,115 31,528 
Accumulated other comprehensive income (loss)(9,445)(8,374)
Total Abbott Shareholders’ Investment35,675 35,802 
Noncontrolling Interests in Subsidiaries209 222 
Total Shareholders’ Investment35,884 36,024 
$72,801 $75,196 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
5
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
Three Months Ended September 30
20222021
Common Shares:
Balance at June 30
Shares: 2022: 1,985,676,735; 2021: 1,982,553,488
$24,429 $24,153 
Issued under incentive stock programs  
Shares: 2022: 242,705; 2021: 550,366
12 26 
Share-based compensation123 113 
Issuance of restricted stock awards(4)(7)
Balance at September 30  
Shares: 2022: 1,985,919,440; 2021: 1,983,103,854
$24,560 $24,285 
Common Shares Held in Treasury:
Balance at June 30
Shares: 2022: 234,456,992; 2021: 209,736,139
$(13,720)$(10,340)
Issued under incentive stock programs  
Shares: 2022: 528,436; 2021: 545,860
31 26 
Purchased  
Shares: 2022: 8,417,107; 2021: 5,626,606
(866)(685)
Balance at September 30  
Shares: 2022: 242,345,663; 2021: 214,816,885
$(14,555)$(10,999)
Earnings Employed in the Business:
Balance at June 30$34,487 $29,053 
Net earnings1,435 2,100 
Cash dividends declared on common shares (per share — 2022: $0.47; 2021: $0.45)
(822)(799)
Effect of common and treasury share transactions15 22 
Balance at September 30$35,115 $30,376 
Accumulated Other Comprehensive Income (Loss):
Balance at June 30$(8,706)$(9,066)
Other comprehensive income (loss)(739)(174)
Balance at September 30$(9,445)$(9,240)
Noncontrolling Interests in Subsidiaries:
Balance at June 30$226 $229 
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases(17)(13)
Balance at September 30$209 $216 
The accompanying notes to condensed consolidated financial statements are an integral part of this statement.
6
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
Nine Months Ended September 30
20222021
Common Shares:
Balance at January 1
Shares: 2022: 1,985,273,421; 2021: 1,981,156,896
$24,470 $24,145 
Issued under incentive stock programs
Shares: 2022: 646,019; 2021: 1,946,958
36 91 
Share-based compensation572 536 
Issuance of restricted stock awards(518)(487)
Balance at September 30
Shares: 2022: 1,985,919,440; 2021: 1,983,103,854
$24,560 $24,285 
Common Shares Held in Treasury:
Balance at January 1
Shares: 2022: 221,191,228; 2021: 209,926,622
$(11,822)$(10,042)
Issued under incentive stock programs
Shares: 2022: 4,808,575; 2021: 5,524,291
261 265 
Purchased
Shares: 2022: 25,963,010; 2021: 10,414,554
(2,994)(1,222)
Balance at September 30
Shares: 2022: 242,345,663; 2021: 214,816,885
$(14,555)$(10,999)
Earnings Employed in the Business:
Balance at January 1$31,528 $27,627 
Net earnings5,900 5,082 
Cash dividends declared on common shares (per share — 2022: $1.41; 2021: $1.35)
(2,475)(2,403)
Effect of common and treasury share transactions162 70 
Balance at September 30$35,115 $30,376 
Accumulated Other Comprehensive Income (Loss):
Balance at January 1$(8,374)$(8,946)
Other comprehensive income (loss)(1,071)(294)
Balance at September 30$(9,445)$(9,240)
Noncontrolling Interests in Subsidiaries:
Balance at January 1$222 $219 
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases(13)(3)
Balance at September 30$209 $216 
The accompanying notes to condensed consolidated financial statements are an integral part of this statement.
7
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(dollars in millions)
Nine Months Ended September 30
20222021
Cash Flow From (Used in) Operating Activities:
Net earnings$5,900 $5,082 
Adjustments to reconcile net earnings to net cash from operating activities —
Depreciation943 1,122 
Amortization of intangible assets1,517 1,533 
Share-based compensation570 534 
Trade receivables(409)(194)
Inventories(1,224)(471)
Other, net(42)(140)
Net Cash From Operating Activities7,255 7,466 
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment(1,167)(1,271)
Acquisitions of businesses and technologies, net of cash acquired— (187)
Proceeds from business dispositions48 134 
Sales (purchases) of other investment securities, net(3)(27)
Other14 14 
Net Cash From (Used in) Investing Activities(1,108)(1,337)
Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other37 (7)
Proceeds from issuance of long-term debt7 — 
Repayments of long-term debt(753)(45)
Purchases of common shares(3,110)(1,325)
Proceeds from stock options exercised126 173 
Dividends paid(2,486)(2,404)
Net Cash From (Used in) Financing Activities(6,179)(3,608)
Effect of exchange rate changes on cash and cash equivalents(173)(57)
Net Increase (Decrease) in Cash and Cash Equivalents(205)2,464 
Cash and Cash Equivalents, Beginning of Year9,799 6,838 
Cash and Cash Equivalents, End of Period$9,594 $9,302 
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
8
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2021. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

Note 2 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The following tables provide detail by sales category:

Three Months Ended September 30, 2022Three Months Ended September 30, 2021
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $993 $993 $— $936 $936 
Other— 333 333 — 329 329 
Total— 1,326 1,326 — 1,265 1,265 
Nutritionals —    
Pediatric Nutritionals357 470 827 586 514 1,100 
Adult Nutritionals329 639 968 333 675 1,008 
Total686 1,109 1,795 919 1,189 2,108 
Diagnostics —     
Core Laboratory281 938 1,219 291 1,001 1,292 
Molecular65 118 183 162 183 345 
Point of Care92 35 127 100 35 135 
Rapid Diagnostics1,303 839 2,142 1,394 746 2,140 
Total1,741 1,930 3,671 1,947 1,965 3,912 
Medical Devices —    
Rhythm Management263 270 533 266 305 571 
Electrophysiology225 244 469 192 293 485 
Heart Failure177 51 228 170 59 229 
Vascular213 393 606 219 425 644 
Structural Heart207 213 420 177 215 392 
Neuromodulation156 36 192 149 41 190 
Diabetes Care 423 744 1,167 323 798 1,121 
Total1,664 1,951 3,615 1,496 2,136 3,632 
Other3 — 3 6 5 11 
Total$4,094 $6,316 $10,410 $4,368 $6,560 $10,928 
9
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 2 — Revenue (Continued)
Nine Months Ended September 30, 2022Nine Months Ended September 30, 2021
(in millions)U.S.Int’lTotal U.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $2,826 $2,826 $— $2,672 $2,672 
Other— 870 870 — 843 843 
Total— 3,696 3,696 — 3,515 3,515 
Nutritionals —    
Pediatric Nutritionals1,108 1,491 2,599 1,622 1,637 3,259 
Adult Nutritionals1,016 2,027 3,043 1,006 1,987 2,993 
Total2,124 3,518 5,642 2,628 3,624 6,252 
Diagnostics —
Core Laboratory836 2,788 3,624 845 2,935 3,780 
Molecular308 507 815 431 651 1,082 
Point of Care284 110 394 289 112 401 
Rapid Diagnostics5,523 2,923 8,446 3,178 2,732 5,910 
Total6,951 6,328 13,279 4,743 6,430 11,173 
Medical Devices —
Rhythm Management775 830 1,605 776 881 1,657 
Electrophysiology667 773 1,440 580 823 1,403 
Heart Failure523 167 690 483 167 650 
Vascular650 1,228 1,878 684 1,292 1,976 
Structural Heart604 667 1,271 537 654 1,191 
Neuromodulation456 112 568 460 124 584 
Diabetes Care1,165 2,320 3,485 865 2,292 3,157 
Total4,840 6,097 10,937 4,385 6,233 10,618 
Other8 — 8 31 18 49 
Total$13,923 $19,639 $33,562 $11,787 $19,820 $31,607 

Remaining Performance Obligations

As of September 30, 2022, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $3.9 billion in the Diagnostics segment and approximately $433 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 60 percent of these remaining performance obligations over the next 24 months, approximately 16 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

10
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 2 — Revenue (Continued)
Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2021$520 
Unearned revenue from cash received during the period466 
Revenue recognized related to contract liability balance(508)
Balance at September 30, 2022$478 

Note 3 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended September 30, 2022 and 2021 were $1.429 billion and $2.092 billion, respectively, and for the nine months ended September 30, 2022 and 2021 were $5.876 billion and $5.061 billion, respectively.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2022 includes $362 million of pension contributions and the payment of cash taxes of approximately $987 million. The first nine months of 2021 includes $366 million of pension contributions and the payment of cash taxes of approximately $990 million.

The following summarizes the activity for the first nine months of 2022 related to the allowance for doubtful accounts as of September 30, 2022:

(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2021$313 
Provisions/charges to income10 
Amounts charged off and other deductions(49)
Balance at September 30, 2022$274 

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.
11
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 3 — Supplemental Financial Information (Continued)
The components of long-term investments as of September 30, 2022 and December 31, 2021 are as follows:

(in millions)September 30,
2022		December 31,
2021
Long-term Investments:
Equity securities$604 $748 
Other160 68 
Total$764 $816 

The decrease in Abbott’s long-term investments as of September 30, 2022 versus the balance as of December 31, 2021 primarily relates to a decrease in the value of investments held in a rabbi trust and the impact of equity method investment losses partially offset by an investment in long-term time deposits.

Abbott’s equity securities as of September 30, 2022, include $285 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott also holds certain investments as of September 30, 2022 with a carrying value of $228 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $83 million that do not have a readily determinable fair value.

In September 2021, Abbott acquired 100 percent of Walk Vascular, LLC (Walk Vascular), a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots. The purchase price, the allocation of acquired assets and liabilities, and the revenue and net income contributed by Walk Vascular since the date of acquisition are not material to Abbott’s condensed consolidated financial statements.

Note 4 — Changes In Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)202220212022202120222021
Balance at June 30$(6,260)$(5,230)$(2,554)$(3,738)$108 $(98)
Other comprehensive income (loss) before reclassifications(1,008)(391)15 16 278 70 
Amounts reclassified from accumulated other comprehensive income— — 41 62 (65)69 
Net current period comprehensive income (loss)(1,008)(391)56 78 213 139 
Balance at September 30$(7,268)$(5,621)$(2,498)$(3,660)$321 $41 
12
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 4 — Changes In Accumulated Other Comprehensive Income (Loss) (Continued)
Nine Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)20222021202220212022 2021
Balance at January 1$(5,839)$(4,859)$(2,670)$(3,871)$135 $(216)
Other comprehensive income (loss) before reclassifications(1,429)(762)45 26 289 138 
Amounts reclassified from accumulated other comprehensive income — — 127 185 (103)119 
Net current period comprehensive income (loss)(1,429)(762)172 211 186 257 
Balance at September 30$(7,268)$(5,621)$(2,498)$(3,660)$321 $41 

Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 11 for additional details.

Note 5 — Goodwill and Intangible Assets

The total amount of goodwill reported was $22.3 billion at September 30, 2022 and $23.2 billion at December 31, 2021. Foreign currency translation adjustments decreased goodwill by approximately $946 million in the first nine months of 2022. The amount of goodwill related to reportable segments at September 30, 2022 was $2.6 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $15.9 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first nine months of 2022.

The gross amount of amortizable intangible assets, primarily product rights and technology, was $26.9 billion and $27.7 billion as of September 30, 2022 and December 31, 2021, respectively. Accumulated amortization was $16.9 billion and $15.9 billion as of September 30, 2022 and December 31, 2021, respectively. Foreign currency translation adjustments decreased intangible assets by $250 million in the first nine months of 2022. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.1 billion in 2022, $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025 and $1.6 billion in 2026.

Indefinite-lived intangible assets, which relate to in-process R&D (IPR&D) acquired in a business combination, were approximately $807 million as of September 30, 2022 and $919 million as of December 31, 2021. In the third quarter of 2022, $111 million of impairment charges were recorded on the Research and development line of the Condensed Consolidated Statement of Earnings related to certain IPR&D intangible assets associated with the Medical Devices business segment.

Note 6 — Restructuring Plans

On May 27, 2021, Abbott management approved a restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with changes in the second quarter in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and the U.S. health authority’s updated guidance on testing for fully vaccinated individuals. In the second quarter of 2021, Abbott recorded charges of $499 million under this plan in Cost of products sold. The charge recognized in the second quarter of 2021 included fixed asset write-downs of $80 million, inventory-related charges of $248 million, and other exit costs, which included contract cancellations and employee-related costs of $171 million.
13
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 6 — Restructuring Plans (Continued)
In the second half of 2021, as the Delta and Omicron variants of COVID-19 spread and the number of new COVID-19 cases increased significantly, particularly in the U.S., demand for rapid COVID-19 tests increased significantly. As a result, in the second half of 2021, Abbott sold approximately $181 million of inventory that was previously estimated to have no net realizable value under the second quarter of 2021 restructuring action. In addition, the estimate of other exit costs was reduced by a net $58 million as Abbott fulfilled its purchase obligations under certain contracts for which a liability was recorded in the second quarter of 2021 or Abbott settled with the counterparty in the second half of 2021.

The following summarizes the activity related to this restructuring action and the status of the related accruals as of September 30, 2022:

(in millions)Inventory-
Related
Charges		Fixed Asset
Write-Downs		Other Exit
Costs		Total
Restructuring charges recorded in 2021$248 $80 $113 $441 
Payments— — (90)(90)
Other non-cash(248)(80)— (328)
Accrued balance at December 31, 2021— — 23 23 
Payments and other adjustments— — (10)(10)
Accrued balance at September 30, 2022$— $— $13 $13 

In 2021, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in Abbott’s diagnostic, established pharmaceutical, and nutritional businesses. In 2022 and 2021, Abbott management approved plans to streamline operations in its medical devices segment. Abbott recorded employees-related severance and other charges of approximately $12 million in the first nine months of 2022 of which approximately $5 million was recorded in Cost of products sold, approximately $2 million was recorded in Research and development, and approximately $5 million was recorded in Selling, general and administrative expense.

The following summarizes the activity for these restructurings:

(in millions)
Restructuring charges recorded in 2021$68 
Payments and other adjustments(7)
Accrued balance at December 31, 202161 
Restructuring charges recorded in 202212 
Payments and other adjustments(39)
Accrued balance at September 30, 2022$34 


14
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)

Note 7 — Incentive Stock Program

In the first nine months of 2022, Abbott granted 2,634,647 stock options, 514,205 restricted stock awards and 5,427,697 restricted stock units under its incentive stock program. At September 30, 2022, approximately 87 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at September 30, 2022 is as follows:

OutstandingExercisable
Number of shares 29,048,449 23,310,464 
Weighted average remaining life (years)
5.44.6
Weighted average exercise price $70.22 $59.69 
Aggregate intrinsic value (in millions)
$901 $890 

The total unrecognized share-based compensation cost at September 30, 2022 amounted to approximately $600 million which is expected to be recognized over the next three years.

Note 8 — Debt and Lines of Credit

On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.

Note 9 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.9 billion at September 30, 2022 and $8.6 billion at December 31, 2021, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September 30, 2022 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At September 30, 2022 and December 31, 2021, Abbott held the gross notional amounts of $10.3 billion and $12.2 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan of approximately $413 million and $521 million as of September 30, 2022 and December 31, 2021, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts with notional values totaling approximately $2.9 billion at September 30, 2022 and December 31, 2021 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.
15
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 9 — Financial Instruments, Derivatives and Fair Value Measures (Continued)

The following table summarizes the amounts and location of certain derivative financial instruments as of September 30, 2022 and December 31, 2021:

Fair Value - AssetsFair Value - Liabilities
(in millions)September 30,
2022		Dec. 31,
2021		Balance Sheet CaptionSeptember 30,
2022		Dec. 31,
2021		Balance Sheet Caption
Interest rate swaps designated as fair value hedges$— $87 Deferred income taxes and other assets$166 $— Post-employment obligations, deferred income taxes and other long-term liabilities
Foreign currency forward exchange contracts:
Hedging instruments760 222 Prepaid expenses and other receivables66 65 Other accrued liabilities
Others not designated as hedges148 70 Prepaid expenses and other receivables141 32 Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary— — n/a413 521 Long-term debt
$908 $379 $786 $618 

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September 30, 2022 and 2021.

Gain (loss) Recognized in Other
Comprehensive Income (loss)		Income (expense) and Gain (loss)
Reclassified into Income
Three Months
Ended September 30		Nine Months
Ended September 30		Three Months
Ended September 30		Nine Months
Ended September 30
(in millions)20222021202220212022202120222021Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges$350 $96 $442 $142 $79 $(92)$149 $(207)Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary24 4 108 41 — — — — n/a
Interest rate swaps designated as fair value hedgesn/an/an/an/a(85)(14)(253)(81)Interest expense

16
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 9 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
Losses of $27 million and $18 million were recognized in the three months ended September 30, 2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Gains of $225 million and $15 million were recognized in the nine months ended September 30, 2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

The carrying values and fair values of certain financial instruments as of September 30, 2022 and December 31, 2021 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

September 30, 2022December 31, 2021
(in millions)Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Long-term Investment Securities:
Equity securities$604 $604 $748 $748 
Other160 160 68 68 
Total Long-term Debt(16,414)(15,821)(18,050)(21,152)
Foreign Currency Forward Exchange Contracts:   
Receivable position908 908 292 292 
(Payable) position(207)(207)(97)(97)
Interest Rate Hedge Contracts:    
Receivable position— — 87 87 
(Payable) position(166)(166)— — 

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

17
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 9 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement
(in millions)Outstanding
Balances		Quoted
Prices in
Active
Markets		Significant
Other
Observable
Inputs		Significant
Unobservable
Inputs
September 30, 2022:
Equity securities$293 $293 $— $— 
Foreign currency forward exchange contracts908 — 908 — 
Total Assets$1,201 $293 $908 $— 
Fair value of hedged long-term debt$2,685 $— $2,685 $— 
Interest rate swap derivative financial instruments166 — 166 — 
Foreign currency forward exchange contracts207 — 207 — 
Contingent consideration related to business combinations138 — — 138 
Total Liabilities$3,196 $— $3,058 $138 
December 31, 2021:
Equity securities$402 $402 $— $— 
Interest rate swap derivative financial instruments 87 — 87 — 
Foreign currency forward exchange contracts292 — 292 — 
Total Assets$781 $402 $379 $— 
Fair value of hedged long-term debt$2,926 $— $2,926 $— 
Foreign currency forward exchange contracts97 — 97 — 
Contingent consideration related to business combinations130 — — 130 
Total Liabilities$3,153 $— $3,023 $130 

The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.

Note 10 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

18
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 10 — Litigation and Environmental Matters (Continued)
Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $40 million to $50 million. The recorded accrual balance at September 30, 2022 for these proceedings and exposures was approximately $45 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

Note 11 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three and nine months ended September 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:

Defined Benefit PlansMedical and Dental Plans
Three Months
Ended Sept. 30		Nine Months
Ended Sept. 30		Three Months
Ended Sept. 30		Nine Months
Ended Sept. 30
(in millions)20222021202220212022202120222021
Service cost - benefits earned during the period$92 $98 $282 $294 $13 $14 $38 $42 
Interest cost on projected benefit obligations74 62 225 186 9 8 27 25 
Expected return on plan assets(231)(211)(701)(633)(8)(6)(23)(20)
Net amortization of:
Actuarial loss, net58 79 174 238 2 7 8 21 
Prior service cost (credit)— — 1 1 (6)(7)(18)(21)
Net cost (credit)$(7)$28 $(19)$86 $10 $16 $32 $47 

Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first nine months of 2022 and 2021, $362 million and $366 million, respectively, were contributed to defined benefit plans. In the first nine months of 2022 and 2021, $28 million and $26 million, respectively, were contributed to the post-employment medical and dental plans.

Note 12 — Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2022 and 2021, taxes on earnings include approximately $36 million and $97 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2022, taxes on earnings also include approximately $20 million of tax expense as the result of the resolution of various tax positions related to prior years.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $75 million to $100 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.
19
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 13 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.

20
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 13 — Segment Information (Continued)
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

 Net Sales to External CustomersOperating Earnings
Three Months
Ended Sept. 30		Nine Months
Ended Sept. 30		Three Months
Ended Sept. 30		Nine Months
Ended Sept. 30
(in millions)20222021202220212022 2021 2022 2021
Established Pharmaceutical Products$1,326 $1,265 $3,696 $3,515 $331 $293 $831 $682 
Nutritional Products1,795 2,108 5,642 6,252 69 431 550 1,388 
Diagnostic Products3,671 3,912 13,279 11,173 1,352 1,652 5,631 4,429 
Medical Devices3,615 3,632 10,937 10,618 1,039 1,160 3,272 3,375 
Total Reportable Segments10,407 10,917 33,554 31,558 2,791 3,536 10,284 9,874 
Other 3 11 8 49 
Net sales$10,410 $10,928 $33,562 $31,607 
Corporate functions and benefit plan costs(115)(204)(352)(450)
Net interest expense (86)(123)(309)(370)
Share-based compensation (a) (123)(114)(570)(534)
Amortization of intangible assets(498)(520)(1,517)(1,533)
Other, net (b)(211)(82)(550)(1,103)
Earnings before taxes$1,758 $2,493 $6,986 $5,884 
______________________________________
(a)
Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)
Other, net for the three and nine months ended September 30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment and $111 million of charges related to the impairment of IPR&D intangible assets. Other, net for the three and nine months ended September 30, 2022 and 2021 also includes integration costs associated with the acquisition of Alere and restructuring charges. Restructuring charges in 2021 include Abbott’s restructuring plan for its COVID-19 test manufacturing network. Other, net for the nine months ended September 30, 2021 also includes costs related to certain litigation.
21
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

Financial Review — Results of Operations

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.

The following tables detail sales by reportable segment for the three and nine months ended September 30. Percent changes are versus the prior year and are based on unrounded numbers.

Net Sales to External Customers
(in millions)Three Months Ended
September 30, 2022		Three Months Ended
September 30, 2021		Total
Change		Impact of
Foreign
Exchange		Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products$1,326 $1,265 4.9 %(7.3)%12.2 %
Nutritional Products1,795 2,108 (14.9)(4.6)(10.3)
Diagnostic Products3,671 3,912 (6.2)(5.6)(0.6)
Medical Devices3,615 3,632 (0.5)(6.9)6.4 
Total Reportable Segments10,407 10,917 (4.7)(6.0)1.3 
Other3 11 n/mn/mn/m
Net Sales$10,410 $10,928 (4.7)(6.0)1.3 
Total U.S.$4,094 $4,368 (6.3)— (6.3)
Total International$6,316 $6,560 (3.7)(10.0)6.3 

Net Sales to External Customers
(in millions)Nine Months Ended
September 30, 2022		Nine Months Ended
September 30, 2021		Total
Change		Impact of
Foreign
Exchange		Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products$3,696 $3,515 5.2 %(6.4)%11.6 %
Nutritional Products5,642 6,252 (9.8)(3.4)(6.4)
Diagnostic Products13,279 11,173 18.9 (4.2)23.1 
Medical Devices10,937 10,618 3.0 (5.4)8.4 
Total Reportable Segments33,554 31,558 6.3 (4.7)11.0 
Other8 49 n/mn/mn/m
Net Sales$33,562 $31,607 6.2 (4.7)10.9 
Total U.S.$13,923 $11,787 18.1 — 18.1 
Total International$19,639 $19,820 (0.9)(7.4)6.5 

Notes:
In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

n/m = Percent change is not meaningful
22
The 1.3 percent increase in total net sales during the third quarter of 2022, excluding the impact of foreign exchange, reflected growth in the Medical Devices and Established Pharmaceutical Products segments partially offset by lower Nutritional Products sales as well as a year-over-year decline in COVID-19 testing-related revenues. Abbott’s COVID-19 testing-related sales totaled approximately $1.7 billion during the third quarter of 2022 and approximately $1.9 billion during the third quarter of 2021. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales decreased 3.1 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 3.2 percent. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the third quarter as the relatively stronger U.S. dollar decreased total international sales by 10.0 percent and total sales by 6.0 percent.

The 10.9 percent increase in total net sales during the first nine months of 2022, excluding the impact of foreign exchange, reflected demand for Abbott’s rapid diagnostic tests to detect COVID-19 as well as growth in the Medical Devices and Established Pharmaceutical Products segments partially offset by lower Nutritional Products sales. Abbott’s COVID-19 testing-related sales totaled approximately $7.3 billion during the first nine months of 2022 and approximately $5.4 billion during the first nine months of 2021. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased 0.1 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 4.9 percent. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the first nine months as the relatively stronger U.S. dollar decreased total international sales by 7.4 percent and total sales by 4.7 percent.

Due to the unpredictability of the duration and impact of the current COVID-19 pandemic, the future extent to which the COVID-19 pandemic will have a material effect on Abbott’s business, financial condition or results of operations is uncertain.

The table below provides detail by sales category for the nine months ended September 30. Percent changes are versus the prior year and are based on unrounded numbers.

(in millions)Sept. 30,
2022		Sept. 30,
2021		Total
Change		Impact of
Foreign
Exchange		Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products —
Key Emerging Markets$2,826 $2,672 5.8 %(6.4)%12.2 %
Other Emerging Markets870 843 3.2 (6.3)9.5 
Nutritionals —
International Pediatric Nutritionals1,491 1,637 (8.9)(4.3)(4.6)
U.S. Pediatric Nutritionals1,108 1,622 (31.7)— (31.7)
International Adult Nutritionals2,027 1,987 2.0 (7.0)9.0 
U.S. Adult Nutritionals1,016 1,006 1.0 — 1.0 
Diagnostics —
Core Laboratory3,624 3,780 (4.1)(5.7)1.6 
Molecular815 1,082 (24.7)(2.8)(21.9)
Point of Care394 401 (1.6)(1.2)(0.4)
Rapid Diagnostics8,446 5,910 42.9 (3.8)46.7 
Medical Devices —
Rhythm Management1,605 1,657 (3.2)(4.5)1.3 
Electrophysiology1,440 1,403 2.6 (5.6)8.2 
Heart Failure690 650 6.2 (2.4)8.6 
Vascular1,878 1,976 (5.0)(4.9)(0.1)
Structural Heart1,271 1,191 6.7 (6.1)12.8 
Neuromodulation568 584 (2.7)(2.1)(0.6)
Diabetes Care3,485 3,157 10.4 (7.0)17.4 
23
Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets for Established Pharmaceutical Products increased 12.2 percent in the first nine months of 2022, led by double-digit growth in several countries, including India and China, and therapeutic areas, including gastroenterology, central nervous system/pain management, and respiratory products. Other Emerging Markets, excluding the effect of foreign exchange, increased by 9.5 percent in the first nine months of 2022.

International Pediatric Nutritional sales, excluding the effect of foreign exchange, decreased 4.6 percent in the first nine months of 2022 versus the comparable 2021 period. The decrease reflects the impact of challenging market dynamics in the infant category in Greater China partially offset by higher sales volumes in various countries in Southeast Asia and Latin America. International Adult Nutritional sales, excluding the effect of foreign exchange, increased 9.0 percent, reflecting double digit growth of the Ensure® and Glucerna® brands in several countries in Southeast Asia and China. In the first nine months of 2022, U.S. Adult Nutritional sales increased 1.0 percent.

In U.S. Pediatric Nutritionals, Abbott initiated a voluntary recall in February 2022 of certain infant powder formula products manufactured at its facility in Sturgis, Michigan and stopped production at the facility. On May 16, 2022, Abbott entered into a consent decree with the U.S. Food and Drug Administration (FDA) on the steps necessary to resume production and maintain the Sturgis facility and operations. On July 1, Abbott restarted partial production at the facility starting with its specialty formula EleCare® and metabolic formulas. Subsequently, Abbott restarted Similac® production. The consent decree does not affect any other Abbott plant or operation.

During the first three quarters of 2022, Abbott took various actions to mitigate the impact of the recall on the supply of formula in the U.S. These actions included the shipment of infant formula powder into the U.S. from Abbott's FDA-registered facility in Ireland; prioritization of infant formula production at its Columbus, Ohio facility; conversion of other liquid manufacturing lines into manufacturing Similac liquid ready-to-feed product; increased production of powder infant formula at its Casa Grande, Arizona manufacturing site; and importation of product from its facility in Spain as permitted by the FDA.

The 31.7 percent decrease in U.S. Pediatric Nutritional sales in the first nine months of 2022 reflects the impact of the recall and the Sturgis production stoppage partially offset by increased demand for Abbott’s Pedialyte® products. U.S. sales of infant powder formula brands associated with the recall were $277 million and $900 million in the first nine months of 2022 and 2021, respectively.

The 23.1 percent increase in Diagnostic Products sales in the first nine months of 2022, excluding the impact of foreign exchange, was driven by demand for Abbott’s portfolio of COVID-19 tests in Rapid Diagnostics and growth in routine diagnostic testing in Molecular Diagnostics. In Core Laboratory Diagnostics, sales increased 1.6 percent in the first nine months of 2022, excluding the effect of foreign exchange, due to the higher volume of routine diagnostic testing from the continued roll-out of the Alinity® platform and an expanded menu of tests. These increases were partially offset by lower sales of Abbott’s laboratory-based tests for the detection of COVID-19 IgG and IgM antibodies, which determine if someone was previously infected with the COVID-19 virus, as well as market disruptions in China due to COVID-19 quarantine restrictions in various cities primarily during the second quarter of 2022. In the first nine months of 2022 and 2021, Core Laboratory Diagnostics IgG and IgM antibody testing-related sales on Abbott’s ARCHITECT and Alinity i platforms were $51 million and $159 million, respectively. In the first nine months of 2022, Core Laboratory Diagnostics sales decreased 1.3 percent, excluding COVID-19 testing-related sales, and increased 4.6 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.

The 21.9 percent decrease in Molecular Diagnostics sales in the first nine months of 2022, excluding the effect of foreign exchange, was driven by lower demand for Abbott’s laboratory-based molecular tests for COVID-19 partially offset by growth in the base business from increased routine molecular testing. In the first nine months of 2022 and 2021, Molecular Diagnostics COVID-19 testing-related sales were $375 million and $699 million, respectively. In the first nine months of 2022, Molecular Diagnostics sales increased 14.9 percent, excluding COVID-19 testing-related sales, and increased 19.4 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.

In Rapid Diagnostics, sales increased 46.7 percent in the first nine months of 2022, excluding the effect of foreign exchange, due to the demand for Abbott’s COVID-19 tests on its rapid testing platforms, including the Panbio® system, the ID NOW® platform, and the BinaxNOW® COVID-19 Ag Card test. In the first nine months of 2022 and 2021, Rapid Diagnostics COVID-19 testing-related sales were $6.9 billion and $4.5 billion, respectively. In the first nine months of 2022, Rapid Diagnostics sales increased 11.8 percent, excluding COVID-19 testing-related sales, and increased 14.6 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales. These increases reflect higher sales
24
of ID NOW tests for flu, strep, and respiratory syncytial virus (RSV) as well as growth in various other Rapid Diagnostics products.

Excluding the effect of foreign exchange, total Medical Devices sales grew 8.4 percent in the first nine months of 2022, driven by growth in Diabetes Care, Electrophysiology, Structural Heart and Heart Failure. Growth in Diabetes Care sales was driven by continued growth of FreeStyle Libre®, Abbott’s continuous glucose monitoring system, in the U.S. and internationally. FreeStyle Libre sales totaled $3.1 billion in the first nine months of 2022, which reflected a 22.8 percent increase, excluding the effect of foreign exchange, over the first nine months of 2021 when FreeStyle Libre sales totaled $2.7 billion. During the third quarter of 2022, Abbott launched its FreeStyle Libre 3 system in the U.S., which automatically delivers up-to-the-minute glucose readings and 14-day accuracy in a wearable sensor.

During the first nine months of 2022, procedure volumes across Abbott’s cardiovascular and neuromodulation businesses were negatively impacted by new surges of COVID-19 in various geographies as well as intermittent COVID-19 lockdown restrictions in China and healthcare staffing challenges throughout the nine months. Despite such challenges, overall volume trends improved in several businesses versus the first nine months of 2021. In Electrophysiology, the 8.2 percent growth, excluding the effect of foreign exchange, reflects the increase in procedure volumes and the continued roll‑out of Abbott’s EnSite® X EP System with Ensite Omnipolar Technology (OT), a new cardiac mapping platform available in the U.S., Japan and across Europe. In January 2022, Abbott announced FDA clearance for the EnSite® X EP System with EnSite OT. The system leverages the Advisor® HD Grid Catheter to provide a 360‑degree view of the heart without regard to the orientation of the catheter in the heart.

Growth in Structural Heart during the first nine months of 2022, excluding the effect of foreign exchange, was 12.8 percent, driven by growth across several areas of the business, including Amplatzer®_Amulet® Left Atrial Appendage Occluder, which offers immediate closure of the left atrial appendage, an area in the heart where blood clots can form and MitraClip®, Abbott's market-leading device for the minimally invasive treatment of mitral regurgitation, a leaky heart valve. In Vascular, sales during the first nine months of 2022, excluding the impact of foreign exchange, were virtually unchanged as higher endovascular sales were offset by the negative effect of lower average pricing for drug-eluting stents (DES) in the U.S. and a lag in the recovery of percutaneous coronary intervention case rates compared to many other cardiovascular procedures.

In the first nine months of 2022, Medical Devices received various other product approvals. In February 2022, Abbott received FDA approval for an expanded indication for its CardioMEMS® HF system, a small implantable sensor and remote monitoring system that can detect early warning signs of worsening heart failure. In April 2022, Abbott announced FDA approval for its Aveir® single-chamber leadless pacemaker for the treatment of patients in the U.S. with slow heart rhythms.

The gross profit margin percentage was 50.7 percent for the third quarter of 2022 compared to 54.8 percent for the third quarter of 2021. The decrease reflects the continued impact of the voluntary product recall and Sturgis manufacturing stoppage in the Nutritional business during the first half of 2022 as well as the prioritization of infant formula sales related to the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). The decrease also reflects higher manufacturing and supply chain costs across Abbott's businesses, including inflation, commodities and distribution expenses as well as lower COVID-19 testing-related sales in 2022 and the nonrecurrence of a favorable change in estimate in the third quarter of 2021 related to a previously recognized restructuring plan.

The gross profit margin was 52.1 percent for the first nine months of 2022 compared to 51.6 percent for the first nine months of 2021. The increase reflects the nonrecurrence of 2021 restructuring charges and the impact of higher sales of COVID-19 rapid tests during the first nine months of 2022. These favorable impacts were partially offset by the impact of the voluntary product recall and Sturgis manufacturing stoppage in the Nutritional business as well as higher manufacturing and supply chain costs across Abbott's businesses, including inflation and higher commodity and distribution expenses. The future extent to which inflation, supply chain disruptions, and unfavorable foreign exchange rates will have a material effect on Abbott's operating results is uncertain.

Research and development (R&D) expenses increased $110 million, or 16.2 percent, in the third quarter of 2022 and increased $183 million, or 9.2 percent, in the first nine months of 2022 compared to the prior year. The increase in the third quarter primarily reflects the impairment of certain in-process R&D intangible assets in the third quarter of 2022. The increase in the first nine months was also driven by higher spending on various projects to advance products in development partially offset by the favorable impact of foreign exchange.

25
Selling, general and administrative (SG&A) expenses decreased $36 million, or 1.3 percent, in the third quarter of 2022 compared to the prior year as higher selling and marketing spending to drive growth across various businesses was more than offset by the favorable impact of foreign exchange. SG&A expenses were virtually unchanged in the first nine months of 2022 compared to the prior year as higher selling and marketing spending was offset by the nonrecurrence of certain 2021 litigation costs and the favorable impact of foreign exchange.

Other (Income) Expense, net

Other income, net increased from $74 million of income in the third quarter of 2021 to $93 million of income in the third quarter of 2022 and from $214 million of income in the first nine months of 2021 to $253 million of income in the first nine months of 2022. The increases in the third quarter and the first nine months of 2022 were primarily due to higher income in 2022 related to the non-service cost components of net pension and post-retirement medical benefit costs. In the first nine months of 2022, the higher year-to-date income related to the non-service cost components was partially offset by the nonrecurrence of a gain on the sale of an equity method investment that occurred in the second quarter of 2021.

Interest Expense, net

Interest expense, net declined $37 million in the third quarter of 2022 and $61 million in the first nine months of 2022 versus 2021 due to the impact of higher interest rates and cash and short-term investment balances on interest income and the repayment of debt in the first quarter of 2022 partially offset by the impact of interest rate hedge contracts related to certain fixed-rate debt.

Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2022 and 2021, taxes on earnings include approximately $36 million and $97 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2022, taxes on earnings also include approximately $20 million of tax expense as the result of the resolution of various tax positions related to prior years.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $75 million to $100 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.

Liquidity and Capital Resources September 30, 2022 Compared with December 31, 2021

The decrease in cash and cash equivalents from $9.8 billion at December 31, 2021 to $9.6 billion at September 30, 2022 primarily reflects share repurchases, the payment of dividends, capital expenditures, and the repayment of debt partially offset by the cash generated from operations in the first nine months of 2022. Working capital was $11.5 billion at September 30, 2022 and $11.1 billion at December 31, 2021. The increase in working capital in 2022 primarily reflects an increase in inventory partially offset by an increase in the current portion of long-term debt and a decrease in cash and cash equivalents.

In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first nine months of 2022 totaled approximately $7.3 billion, a decrease of $211 million from the prior year primarily due to an increased investment in working capital partially offset by higher operating earnings. Net cash from operating activities includes $362 million of pension contributions and the payment of cash taxes of approximately $987 million in 2022. Net cash from operating activities includes $366 million of pension contributions and the payment of cash taxes of approximately $990 million in 2021.

On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.

In September 2019, the board of directors authorized the early redemption of up to $5 billion of outstanding long-term notes. As of September 30, 2022, $2.15 billion of the $5 billion authorization remains available.

At September 30, 2022, Abbott’s long-term debt rating was AA- by Standard & Poor’s Corporation and A1 by Moody’s Investors Service. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources, including lines of credit of $5.0 billion which expire in 2025.

26
In December 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott’s common shares from time to time. The new authorization was in addition to the $1.081 billion portion of the share repurchase program authorized in 2019 that was unused as of December 31, 2021. In the first nine months of 2022, Abbott repurchased 25.7 million of its common shares for $2.965 billion which fully utilized the authorization remaining under the 2019 share repurchase program and a portion of the 2021 authorization. As of September 30, 2022, $3.116 billion remains available for repurchase under the 2021 repurchase program.

In each of the first three quarters of 2022, Abbott declared a quarterly dividend of $0.47 per share on its common shares, which represents an increase of 4.4 percent over the $0.45 per share dividend declared in each of the first three quarters of 2021.

Legislative Issues

Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the 2021 Annual Report on Form 10-K.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

27
PART I. FINANCIAL INFORMATION

Item 4.     Controls and Procedures

(a)Evaluation of disclosure controls and procedures. The Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Robert E. Funck, Jr., evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(b)Changes in internal control over financial reporting. During the quarter ended September 30, 2022, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.     Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations as described in our Annual Report on Form 10-K for the year ended December 31, 2021 and our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

(c)Issuer Purchases of Equity Securities

Period
(a) Total
Number of
Shares (or
Units)
Purchased(1)
(b) Average
Price Paid per
Share (or
Unit)		(c) Total Number
of Shares (or
Units) Purchased
as Part of
Publicly
Announced Plans
or Programs
(d) Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs(2)
July 1, 2022 - July 31, 2022— $— — $3,981,169,070 
August 1, 2022 - August 31, 20221,050,000 102.567 1,050,000 3,873,473,475 
September 1, 2022 - September 30, 20227,363,597 102.895 7,363,597 3,115,796,433 
Total8,413,597 $102.854 8,413,597 $3,115,796,433 
______________________________________
1.These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

2.On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time.

28
Item 6.     Exhibits
Exhibit No.Exhibit
3.1
31.1
31.2
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.
32.1
32.2
101The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter and nine months ended September 30, 2022, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements.
104Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101).
29
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ABBOTT LABORATORIES
By:/s/ Robert E. Funck, Jr.
Robert E. Funck, Jr.
Executive Vice President, Finance
and Chief Financial Officer
Date: November 1, 2022
30
 EX-31.1 2 q3202210qex311.htm EX-31.1 Document

Exhibit 31.1
Certification of Chief Executive Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Robert B. Ford, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4.Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5.Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s auditors and the audit committee of Abbott’s board of directors:
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.
Date: November 1, 2022/s/ Robert B. Ford
Robert B. Ford
Chairman of the Board and Chief Executive Officer

 EX-31.2 3 q3202210qex312.htm EX-31.2 Document

Exhibit 31.2
Certification of Chief Financial Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Robert E. Funck, Jr., certify that:
1.I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4.Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5.Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s auditors and the audit committee of Abbott’s board of directors:
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.
Date: November 1, 2022/s/ Robert E. Funck, Jr.
Robert E. Funck, Jr.
Executive Vice President, Finance
and Chief Financial Officer

 EX-32.1 4 q3202210qex321.htm EX-32.1 Document

Exhibit 32.1
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended September 30, 2022 as filed with the Securities and Exchange Commission (the “Report”), I, Robert B. Ford, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Robert B. Ford
Robert B. Ford
Chairman of the Board and Chief Executive Officer
November 1, 2022
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-32.2 5 q3202210qex322.htm EX-32.2 Document

Exhibit 32.2
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended September 30, 2022 as filed with the Securities and Exchange Commission (the “Report”), I, Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Robert E. Funck, Jr.
Robert E. Funck, Jr.
Executive Vice President, Finance
and Chief Financial Officer
November 1, 2022
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-101.SCH 6 abt-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Supplemental Financial Information link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Restructuring Plans link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Incentive Stock Program link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Debt and Lines of Credit link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Litigation and Environmental Matters link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Post-Employment Benefits link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Taxes on Earnings link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Supplemental Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Restructuring Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Incentive Stock Program (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Post-Employment Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Revenue - Segments (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Revenue - Other Contract Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Supplemental Financial Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Supplemental Financial Information - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Goodwill and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Restructuring Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Restructuring Plans - Streamline of Operations and Improve Efficiencies (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Incentive Stock Program - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Incentive Stock Program - Options (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Debt and Lines of Credit (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Litigation and Environmental Matters (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Post-Employment Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Post-Employment Benefits - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Taxes on Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 abt-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 abt-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 abt-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] Amounts reclassified from accumulated other comprehensive income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Increase (Decrease) in Shareholders' Investment Increase (Decrease) in Stockholders' Equity [Roll Forward] Provisions/charges to income Accounts Receivable, Credit Loss Expense (Reversal) Entity Address, Postal Zip Code Entity Address, Postal Zip Code Reduction of restructuring estimate Restructuring Reserve, Accrual Adjustment Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies [Member] The restructuring plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses. Neuromodulation Neuromodulation [Member] It represents the neuromodulation, segment of the entity. Acquisitions of businesses and technologies, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired, And Research and Development in Process The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase, and research and development assets. Debt Instrument [Axis] Debt Instrument [Axis] Dividends paid Payments of Ordinary Dividends, Common Stock Property and equipment, at cost Property, Plant and Equipment, Gross Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Pediatric Nutritionals Pediatric Nutritionals [Member] It represents the pediatric nutritionals, segment of the entity. Accrued balance at beginning of the period Accrued balance at end of the period Restructuring Reserve Inventories: Inventory, Net [Abstract] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Other Payments for (Proceeds from) Other Investing Activities Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation Depreciation Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases Noncontrolling Interests Share of Income Net of Distributions and Share Repurchases and Business Combinations This element represent Noncontrolling Interests' share of income, net of distributions, share repurchases and business combinations. Interest rate percentage Debt Instrument, Interest Rate, Stated Percentage Schedule of derivatives gain (loss) in OCI and earnings Derivative Instruments, Gain (Loss) [Table Text Block] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Net cost (credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Repayments of debt Repayments of Debt Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Purchased Treasury Stock, Value, Acquired, Cost Method Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Net Earnings Net earnings Net Income (Loss) Attributable to Parent Outstanding Common Stock Options Having No Dilutive Effect (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Document and Entity Information Document Information [Line Items] Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] Prior service cost (credit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Equity Component [Domain] Equity Component [Domain] Interest expense Interest Expense [Member] Molecular Molecular [Member] It represents the molecular, segment of the entity. Total Assets Assets, Fair Value Disclosure Restructuring Plan [Axis] Restructuring Plan [Axis] Estimation of possible loss Loss Contingency, Estimate of Possible Loss Common shares held in treasury, at cost — Shares: 2022: 242,345,663; 2021: 221,191,228 Treasury Stock, Common, Value Cumulative foreign currency translation (loss) adjustments Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Net actuarial (losses) and prior service (costs) and credits Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Hedging Designation [Domain] Hedging Designation [Domain] Derivative Instrument [Axis] Derivative Instrument [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Quoted Prices in Active Markets Fair Value, Inputs, Level 1 [Member] Cost of Products Sold Cost of Goods and Services Sold [Member] Cost of Goods and Services Sold Interest rate hedge contracts, (payable) position Interest Rate Fair Value Hedge Liability at Fair Value Stock options outstanding, weighted-average remaining life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Payment of cash taxes Payments for Other Taxes Award Type [Axis] Award Type [Axis] Net Cash From Operating Activities Net Cash Provided by (Used in) Operating Activities Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Long-term debt Long-Term Debt, Excluding Current Maturities Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] Cash Flow From (Used in) Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Business acquisition, percentage acquired Business Acquisition, Percentage of Voting Interests Acquired Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Diabetes Care Diabetes Care [Member] It represents the Diabetes Care, segment of the entity. Effect of common and treasury share transactions Effect of Common and Treasury Share Transactions This element represents the effect on retained earning due to common and treasury stock transactions. Preferred shares, issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Restructuring Type [Axis] Restructuring Type [Axis] Severance costs Severance Costs Inventory- Related Charges Inventory-related charges [Member] Represents the information pertaining to fixed asset inventory related charges . Segments [Axis] Segments [Axis] Debt and Lines of Credit Debt Disclosure [Text Block] Entity Shell Company Entity Shell Company Structural Heart Structural Heart [Member] It represents the structural heart, segment of the entity. Heart Failure Heart Failure [Member] It represents the Heart Failure, segment of the entity. Rhythm Management Rhythm Management [Member] It represents the rhythm management, segment of the entity. Gain (loss) Recognized in Other Comprehensive Income (loss) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Consolidation Items [Domain] Consolidation Items [Domain] Schedule of changes in contract liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Other Other Investments [Member] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Schedule of accumulated other comprehensive income (loss), net of taxes Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total Assets Assets Amounts charged off and other deductions Accounts Receivable, Allowance for Credit Loss, Writeoff Debt Disclosure [Abstract] Debt Disclosure [Abstract] Key Emerging Markets Key Emerging Markets [Member] It represents the key emerging markets, segment of the entity. Issued under incentive stock programs Stock Issued During Period, Value, Incentive Stock Programs Stock Issued During Period, Value, Incentive Stock Programs Income Statement Location [Axis] Income Statement Location [Axis] Summary of Investment Holdings [Line Items] Summary of Investment Holdings [Line Items] Pension contributions Company contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Equity securities Equity Securities, FV-NI, Current Interest Rate Swap Interest Rate Swap [Member] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Current portion of long-term debt Long-Term Debt, Current Maturities Net Cash From (Used in) Financing Activities Net Cash Provided by (Used in) Financing Activities Total Long-term Debt Long-Term Debt, Fair Value Inventory sold that was previously estimated to have no net realizable value Inventory No Net Realizable Value Sold The amount of inventory sold that was previously estimated to have no net realizable value. Investments Long-term Investment Securities: Long-Term Investments Salaries, wages and commissions Employee-related Liabilities, Current Earnings before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Segments [Domain] Segments [Domain] Interest cost on projected benefit obligations Defined Benefit Plan, Interest Cost Summary of the amounts and location of certain derivative financial instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Award Type [Domain] Award Type [Domain] Total unrecognized compensation cost, recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Exercisable options, weighted-average remaining life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restructuring Plan [Domain] Restructuring Plan [Domain] Other non-cash Restructuring Reserve, Settled without Cash Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax St. Jude Medical St. Jude Medical, Inc. [Member] Represents information relating to acquisition of St. Jude Medical, Inc. Schedule of carrying values and fair values of certain financial instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Derivative Contract [Domain] Derivative Contract [Domain] Prepaid expenses and other receivables Prepaid Expense and Other Receivables Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other receivables that are expected to be realized within one year or the normal operating cycle, if longer. Net Investment Hedging Net Investment Hedging [Member] Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold Maximum Length of Time Hedged in Cash Flow Hedge Entity Registrant Name Entity Registrant Name Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Decrease in goodwill due to foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Disclosure Text Block Supplement [Abstract] Disclosure Text Block Supplement [Abstract] Cumulative Foreign Currency Translation (Loss) Adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Entity Address, City or Town Entity Address, City or Town Yen-denominated long-term debt Yen-denominated long-term debt [Member] Represents information pertaining to yen denominated Long-term debt. Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Subsegments [Axis] Subsegments [Axis] Issuance of restricted stock awards Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Total Shareholders’ Investment Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Summary of Investment Holdings [Table] Summary of Investment Holdings [Table] Minimum Minimum [Member] Noncontrolling Interests in Subsidiaries Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Materials Inventory, Raw Materials, Net of Reserves Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Treasury Stock, Common Treasury Stock, Common [Member] Defined Benefit Plans Pension Plan [Member] Trading Symbol Trading Symbol Entity File Number Entity File Number Common shares held in treasury (in shares) Beginning balance, treasury stock, common (in shares) Ending balance, treasury stock, common (in shares) Treasury Stock, Common, Shares Trade accounts payable Accounts Payable, Trade, Current Estimated annual amortization expense, intangible assets, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Research and development Research and Development Expense Restricted stock awards granted during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Issued under incentive stock programs (in shares) Stock Issued During Period, Shares, Incentive Stock Programs Stock Issued During Period, Shares, Incentive Stock Programs Point of Care Point of Care [Member] It represents the point of care, segment of the entity. Post-Employment Benefits Postemployment Benefits Disclosure [Text Block] Taxes on Earnings Income Tax Disclosure [Text Block] Restricted stock units granted during period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Finished products Inventory, Finished Goods, Net of Reserves Amortization of intangible assets Amortization of intangible assets Amortization of Intangible Assets Basic Earnings Per Common Share (in dollars per share) Earnings Per Share, Basic Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Income (expense) and Gain (loss) Reclassified into Income Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Net Actuarial (Losses) and Prior Service (Costs) and Credits Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Other Corporate, Non-Segment [Member] Total Abbott Shareholders’ Investment Beginning of the period End of the period Stockholders' Equity Attributable to Parent Financial Instruments, Derivatives and Fair Value Measures Derivative Instruments and Hedging Activities Disclosure [Text Block] Corporate functions and benefit plan costs Corporate and Benefit Plan Costs The reconciling item from aggregate segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to corporate functions and benefit plan costs. Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table] Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Accumulated amortization of intangible assets Finite-Lived Intangible Assets, Accumulated Amortization Restricted Stock Awards Restricted stock awards [Member] Restricted stock awards. Deferred income taxes and other assets Deferred income taxes and other assets [Member] The Deferred Income Taxes and Other Assets line item in the statement of financial position in which the amounts are included. Estimated annual amortization expense, intangible assets, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Retained Earnings Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Cash dividends declared on common shares Dividends, Common Stock, Cash Condensed Cash Flow Statements, Captions [Line Items] Condensed Cash Flow Statements, Captions [Line Items] Common Stock Common Stock [Member] Other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Share-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Number of reportable segments Number of Reportable Segments Purchases of common shares Payments for Repurchase of Common Stock Contingent consideration related to business combinations Business Combination, Contingent Consideration, Liability Incentive stock program, shares reserved for future grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Statement [Table] Statement [Table] Diagnostic Products Diagnostic Products [Member] The diagnostics products segment of the entity. Document Quarterly Report Document Quarterly Report Current Assets: Assets, Current [Abstract] Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $11 and $36 in 2022 and $18 and $54 in 2021 Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Statistical Measurement [Axis] Statistical Measurement [Axis] Purchased (in shares) Treasury Stock, Shares, Acquired Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Indefinite-lived intangible assets related to in-process R&D acquired in a business combination Indefinite-Lived Intangible Assets (Excluding Goodwill) Earnings employed in the business Retained Earnings (Accumulated Deficit) Trade receivables, less allowances of $520 in 2022 and $519 in 2021 Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Fair Value, Recurring Fair Value, Recurring [Member] Exercisable options, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Document Fiscal Year Focus Document Fiscal Year Focus Cash Flow From (Used in) Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement Statement [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax: Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Gross amount of amortizable intangible assets Finite-Lived Intangible Assets, Gross Selling, general and administrative Selling, General and Administrative Expense Loss Contingencies [Table] Loss Contingencies [Table] AOCI Attributable to Parent AOCI Attributable to Parent [Member] Changes in Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold Minimum Length Of Time Hedged In Cash Flow Hedge Minimum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Schedule of stock options outstanding and exercisable Share-Based Payment Arrangement, Option, Activity [Table Text Block] Operating earnings Operating Earnings Operating Income (Loss) Inventories Increase (Decrease) in Inventories Equity investment without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Amount Document Information [Table] Document Information [Table] Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Goodwill Goodwill Post-employment obligations, deferred income taxes and other long-term liabilities Postemployment Obligations Deferred Income Taxes And Other Long Term Liabilities [Member] Postemployment Obligations Deferred Income Taxes And Other Long Term Liabilities Total Liabilities Liabilities, Fair Value Disclosure Foreign currency forward exchange contracts, (payable) position Foreign currency forward exchange contracts Foreign Currency Cash Flow Hedge Liability at Fair Value Adjustments to reconcile net earnings to net cash from operating activities — Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Taxes on earnings Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Preferred shares, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Medical Devices Medical Devices [Member] The medical devices segment of the entity. Income Statement [Abstract] Income Statement [Abstract] Hedging Relationship [Axis] Hedging Relationship [Axis] Stock options granted during the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Cost of products sold, excluding amortization of intangible assets Cost of Goods and Services Sold Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) Weighted Average Number of Shares Outstanding, Diluted Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Other, net Other Cost and Expense, Operating and Nonoperating The reconciling item from segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to net other income or expenses. Fair Value - Liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset Loss Contingencies [Line Items] Loss Contingencies [Line Items] Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2022: 1,985,919,440; 2021: 1,985,273,421 Common Stock, Value, Issued Carrying Value Reported Value Measurement [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Excess tax benefits associated with share-based compensation Excess Tax Benefit from Share-based Compensation Amount of tax benefits related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes. Schedule of assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Operating Segments Operating Segments [Member] Aggregate intrinsic value of options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Preferred shares, authorized (in shares) Preferred Stock, Shares Authorized Decrease reasonably possible in gross unrecognized tax benefits Decrease in Unrecognized Tax Benefits is Reasonably Possible Cash and Cash Equivalents, Beginning of Year Cash and Cash Equivalents, End of Period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Unearned revenue from cash received during the period Contract With Customer Liability, Change In Unearned Revenue From Cash Received Recognized Amount of revenue recognized arising from contract liability from change in cash received to be satisfied. Litigation and Environmental Matters Commitments and Contingencies Disclosure [Text Block] Current Liabilities: Liabilities, Current [Abstract] Foreign Exchange Forward Foreign Exchange Forward [Member] Net earnings allocated to common shares Net Income (Loss) Available to Common Stockholders, Basic Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Proceeds from stock options exercised Proceeds from Stock Options Exercised Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt Common shares, issued (in shares) Common Stock, Shares, Issued Equity method investments carrying value Equity Method Investments Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Net foreign exchange (gain) loss Foreign Currency Transaction Gain (Loss), before Tax Retirement Plan Type [Domain] Retirement Plan Type [Domain] Income Statement Location [Domain] Income Statement Location [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Decrease in intangible assets due to foreign currency translation adjustments Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Net Cash From (Used in) Investing Activities Net Cash Provided by (Used in) Investing Activities Fair Value Hedging Fair Value Hedging [Member] Deferred income taxes and other assets Deferred Income Taxes and Other Assets, Noncurrent Investment Type [Axis] Investment Type [Axis] Comprehensive Income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of segment information - net sales and operating earnings Schedule of Segment Reporting Information, by Segment [Table Text Block] Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Entity Current Reporting Status Entity Current Reporting Status Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Payments Payments for Restructuring Exercisable options, number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Derivative [Table] Derivative [Table] Stock options outstanding, number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Net property and equipment Property, Plant and Equipment, Net Repayments of long-term debt Repayments of Long-Term Debt Share-based Payment Arrangement, Option Share-Based Payment Arrangement, Option [Member] Foreign currency forward exchange contracts, receivable position Foreign currency forward exchange contracts Foreign Currency Cash Flow Hedge Asset at Fair Value Postemployment Benefits [Abstract] Postemployment Benefits [Abstract] Long-term debt Long-Term Debt [Member] Trade receivables, allowances Accounts Receivable, Allowance for Credit Loss, Current Long-term debt Long-Term Debt Other (income) expense, net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Restructuring Plans Restructuring and Related Activities Disclosure [Text Block] Common shares, authorized (in shares) Common Stock, Shares Authorized Gain (loss) recognized related to derivatives not designated as hedge Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Income taxes payable Accrued Income Taxes, Current Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Accumulated other comprehensive income (loss) Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Condensed Cash Flow Statement [Table] Condensed Cash Flow Statement [Table] Total Current Assets Assets, Current Designated as Hedging Instrument Designated as Hedging Instrument [Member] Revenue recognized related to contract liability balance Contract with Customer, Liability, Revenue Recognized Entity Small Business Entity Small Business Measurement Basis [Axis] Measurement Basis [Axis] Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $50 and $96 in 2022 and $50 and $98 in 2021 Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Measurement Frequency [Domain] Measurement Frequency [Domain] Schedule of components of the net periodic benefit cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans Schedule of Net Benefit Costs [Table Text Block] Cash dividends declared on common shares (in dollars per share) Common Stock, Dividends, Per Share, Declared Expected timing of satisfaction period (in months) Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Other Exit Costs Other exit costs [Member] Represents the information pertaining to fixed asset other exit cost . Total unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Core Laboratory Core Laboratory [Member] It represents the core laboratory, segment of the entity. Allowance for Doubtful Accounts: SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Percentage of remaining performance obligation expected to be recognized in period Revenue Remaining Performance Obligation Expected Timing Percentage Represents the percentage of revenue recognized for remaining performance obligations. Prepaid expenses and other receivables Prepaid expenses and other receivables [Member] Prepaid expenses and other receivables. COVID-19 Test Manufacturing Network Restructuring Plan COVID-19 Test Manufacturing Network Restructuring Plan [Member] Restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with recent changes in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and recent U.S. health authority guidance on testing for fully vaccinated individuals. Aggregate intrinsic value of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Trade receivables Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Schedule of long-term investments Schedule of Long Term Investments [Table Text Block] Tabular disclosure of the investments which are intended to be held for an extended period of time (longer than one operating cycle). Established Pharmaceutical Products Established Pharmaceutical Products [Member] Represents Established Pharmaceutical Products, segment of the entity. Short-term investments Short-Term Investments Fixed Asset Write-Downs Fixed asset write-downs [Member] Represents the information pertaining to fixed asset write-downs cost . Total operating cost and expenses Costs and Expenses Debt Instrument [Line Items] Debt Instrument [Line Items] Schedule of Goodwill and Intangible Assets [Table] Schedule of Goodwill and Intangible Assets [Table] Schedule of Goodwill and Intangible Assets Segment Information Segment Reporting Disclosure [Text Block] Selling, General and Administrative Expense Selling, General and Administrative Expenses [Member] Estimated annual amortization expense, intangible assets, 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Tax expense from prior year tax positions Tax Adjustments, Settlements, and Unusual Provisions 2.55% Long-term Notes Due 2022 2.55% Long-term Notes Due 2022 [Member] 2.55% Long-term Notes Due 2022 Liabilities and Shareholders’ Investment Liabilities and Equity [Abstract] Fair Value Estimate of Fair Value Measurement [Member] Foreign currency translation gain (loss) adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Subsegments [Domain] Subsegments [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Total inventories Inventory, Net Restructuring charges Restructuring charges recorded in 2021 Restructuring Charges Hedging Relationship [Domain] Hedging Relationship [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Nutritional Products Nutritional Products [Member] The nutritional products segment of the entity. Proceeds from business dispositions Proceeds from Sales of Business, Affiliate and Productive Assets Payments and other adjustments Restructuring Reserve Period Cash Settled and Other Adjustments The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period. Entity Filer Category Entity Filer Category Shareholders’ Investment: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) Weighted Average Number of Shares Outstanding, Basic United States UNITED STATES Recorded accrual balance for legal proceedings and exposures Loss Contingency Accrual Securities in mutual funds held in a rabbi trust Common Stock, Shares Held in Employee Trust Share-based compensation Share-Based Payment Arrangement, Expense Rapid Diagnostics Rapid Diagnostics [Member] It represents the rapid diagnostics, segment of the entity. CHICAGO STOCK EXCHANGE, INC NYSE CHICAGO, INC. [Member] Commitments and Contingencies Commitments and Contingencies Security Exchange Name Security Exchange Name Stock options outstanding, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Interest rate swap derivative financial instruments Interest Rate Derivative Liabilities, at Fair Value Derivative, notional amount Derivative, Notional Amount Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued Preferred Stock, Value, Issued Segment Reconciling Items Segment Reconciling Items [Member] Net sales Net Sales to External Customers Revenue from Contract with Customer, Excluding Assessed Tax Service cost - benefits earned during the period Defined Benefit Plan, Service Cost Interest rate swap derivative financial instruments Interest Rate Derivative Assets, at Fair Value Cover [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Significant Unobservable Inputs Fair Value, Inputs, Level 3 [Member] Amount of reductions of goodwill relating to impairments Goodwill, Impairment Loss Vascular Vascular [Member] It represents the vascular products, segment of the entity. Incentive Stock Program Share-Based Payment Arrangement [Text Block] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Beginning balance Ending balance Accounts Receivable, Allowance for Credit Loss Work in process Inventory, Work in Process, Net of Reserves Revenue Revenue from Contract with Customer [Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Contract Liabilities: Contract Liabilities [Roll Forward] Contract Liabilities Investments [Domain] Investments [Domain] Noncontrolling Interest Noncontrolling Interest [Member] Electrophysiology Electrophysiology [Member] It represents the electrophysiology, segment of the entity. Net interest expense Interest Income (Expense), Net Actuarial loss, net Defined Benefit Plan, Amortization of Gain (Loss) Total Liabilities and Shareholders' Investment Liabilities and Equity Debt instrument, term Debt Instrument, Term Net amortization of: Defined Benefit Plan Net Amortization Costs [Abstract] No definition available. Dilutive Common Stock Options (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Walk Vascular Walk Vascular, LLC [Member] It represents information pertaining to its Walk vascular llc. International Non-US [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Changes in accumulated other comprehensive income (loss), net of income taxes AOCI Attributable to Parent, Net of Tax [Roll Forward] Significant Other Observable Inputs Fair Value, Inputs, Level 2 [Member] Annual share-based awards recognized in first quarter (as a percent) Annual Share Based Awards Recognized in First Quarter Percent Percentage of the annual cost of share-based awards which will typically be recognized in the first quarter. Current Fiscal Year End Date Current Fiscal Year End Date Intangible assets, net of amortization Intangible Assets, Net (Excluding Goodwill) Diluted Earnings Per Common Share (in dollars per share) Earnings Per Share, Diluted Maximum expected cleanup exposure in aggregate Loss Contingency Range of Possible Loss, Maximum Aggregate Sites The estimated maximum loss, for all sites, from the contingency related to the environmental clean up in the United States and Puerto Rico. Consolidation Items [Axis] Consolidation Items [Axis] Total Current Liabilities Liabilities, Current Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Equity securities Equity Securities [Member] Remaining performance obligations Revenue, Remaining Performance Obligation, Amount Summary of activity of allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss [Table Text Block] Fair Value - Assets Derivative Asset, Subject to Master Netting Arrangement, before Offset Legal proceedings and environmental exposures Legal proceedings and environmental exposures [Member] Loss contingencies related to legal proceedings and environmental exposures. Entity Address, Address Line One Entity Address, Address Line One Beginning balance Ending balance Contract with Customer, Liability Impairment of indefinite-lived intangible assets Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Net borrowings (repayments) of short-term debt and other Proceeds from (Repayments of) Short-Term Debt Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Interest expense Interest Expense Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Interest rate hedge contracts, receivable position Interest Rate Fair Value Hedge Asset at Fair Value Exchange [Domain] Exchange [Domain] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Entity Tax Identification Number Entity Tax Identification Number Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Other Other Security Investments [Member] Adult Nutritionals Adult Nutritionals [Member] It represents the adult nutritionals, segment of the entity. Fair value of hedged long-term debt Hedged Liability, Fair Value Hedge Schedule of reportable segment included under sales category Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Estimated annual amortization expense, intangible assets, 2022 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Maximum expected cleanup exposure for individual site Loss Contingency Range of Possible Loss, Maximum Individual Site The estimated maximum loss, per individual site, from the contingency related to the environmental clean up in the United States and Puerto Rico. Dividends payable Dividends Payable, Current Net Increase (Decrease) in Cash and Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Other accrued liabilities Accrued Liabilities [Member] Schedule of restructuring reserve and related cost Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Summary of restructuring activity Restructuring and Related Costs [Table Text Block] Entity Central Index Key Entity Central Index Key Interest (income) Investment Income, Interest Measurement Frequency [Axis] Measurement Frequency [Axis] Goodwill and Intangible Assets [Line Items] Goodwill and Intangible Assets [Line Items] Goodwill and Intangible Assets Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Other accrued liabilities Other Accrued Liabilities, Current Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Post-employment obligations, deferred income taxes and other long-term liabilities Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities Amount of Post-employment obligations and amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer. City Area Code City Area Code Assets Assets [Abstract] Other Emerging Markets Other Emerging Markets [Member] Other Emerging Markets Other, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Sales (purchases) of other investment securities, net Payments for (Proceeds from) Investments Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Debt Debt [Member] Cash Flow From (Used in) Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Inventory recall expense Inventory Recall Expense Share-based compensation Share-Based Payment Arrangement, Noncash Expense Acquisitions of property and equipment Payments to Acquire Property, Plant, and Equipment Research and Development Research and Development Expense [Member] Estimated annual amortization expense, intangible assets, 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Cost of products sold Cost of Sales [Member] Medical and Dental Plans Other Postretirement Benefits Plan [Member] EX-101.PRE 10 abt-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
 9 Months Ended
Sep. 30, 2022
shares
Document and Entity Information  
Document Type 10-Q
Document Quarterly Report true
Document Period End Date Sep. 30, 2022
Document Transition Report false
Entity File Number 1-2189
Entity Registrant Name ABBOTT LABORATORIES
Entity Incorporation, State or Country Code IL
Entity Tax Identification Number 36-0698440
Entity Address, Address Line One 100 Abbott Park Road
Entity Address, City or Town Abbott Park
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 224
Local Phone Number 667-6100
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Large Accelerated Filer
Entity Small Business false
Entity Emerging Growth Company false
Entity Shell Company false
Entity Common Stock, Shares Outstanding 1,743,573,777
Entity Central Index Key 0000001800
Current Fiscal Year End Date --12-31
Document Fiscal Year Focus 2022
Document Fiscal Period Focus Q3
Amendment Flag false
NEW YORK STOCK EXCHANGE, INC.  
Document and Entity Information  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name NYSE
CHICAGO STOCK EXCHANGE, INC  
Document and Entity Information  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name CHX
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statement of Earnings (Unaudited) - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Net sales $ 10,410 $ 10,928 $ 33,562 $ 31,607
Cost of products sold, excluding amortization of intangible assets 4,629 4,423 14,549 13,771
Amortization of intangible assets 498 520 1,517 1,533
Research and development 782 672 2,163 1,980
Selling, general and administrative 2,731 2,767 8,275 8,276
Total operating cost and expenses 8,640 8,382 26,504 25,560
Operating earnings 1,770 2,546 7,058 6,047
Interest expense 141 133 404 402
Interest (income) (55) (10) (95) (32)
Net foreign exchange (gain) loss 19 4 16 7
Other (income) expense, net (93) (74) (253) (214)
Earnings before taxes 1,758 2,493 6,986 5,884
Taxes on earnings 323 393 1,086 802
Net Earnings $ 1,435 $ 2,100 $ 5,900 $ 5,082
Basic Earnings Per Common Share (in dollars per share) $ 0.82 $ 1.18 $ 3.35 $ 2.85
Diluted Earnings Per Common Share (in dollars per share) $ 0.81 $ 1.17 $ 3.32 $ 2.83
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) 1,752,968 1,774,516 1,756,209 1,776,870
Dilutive Common Stock Options (in shares) 10,685 14,483 11,638 14,407
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) 1,763,653 1,788,999 1,767,847 1,791,277
Outstanding Common Stock Options Having No Dilutive Effect (in shares) 5,445 2,740 2,655 2,694
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statement of Comprehensive Income (Unaudited) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Statement of Comprehensive Income [Abstract]          
Net earnings $ 1,435 $ 2,100 $ 5,900 $ 5,082  
Foreign currency translation gain (loss) adjustments (1,008) (391) (1,429) (762)  
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $11 and $36 in 2022 and $18 and $54 in 2021 56 78 172 211  
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $50 and $96 in 2022 and $50 and $98 in 2021 213 139 186 257  
Other comprehensive income (loss) (739) (174) (1,071) (294)  
Comprehensive Income 696 $ 1,926 4,829 $ 4,788  
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:          
Cumulative foreign currency translation (loss) adjustments (7,268)   (7,268)   $ (5,839)
Net actuarial (losses) and prior service (costs) and credits (2,498)   (2,498)   (2,670)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other 321   321   135
Accumulated other comprehensive income (loss) $ (9,445)   $ (9,445)   $ (8,374)
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax $ 11 $ 18 $ 36 $ 54
Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax $ 50 $ 50 $ 96 $ 98
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheet (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current Assets:    
Cash and cash equivalents $ 9,594 $ 9,799
Short-term investments 313 450
Trade receivables, less allowances of $520 in 2022 and $519 in 2021 6,408 6,487
Inventories:    
Finished products 3,407 3,081
Work in process 726 694
Materials 1,601 1,382
Total inventories 5,734 5,157
Prepaid expenses and other receivables 2,796 2,346
Total Current Assets 24,845 24,239
Investments 764 816
Property and equipment, at cost 19,306 19,364
Less: accumulated depreciation and amortization 10,617 10,405
Net property and equipment 8,689 8,959
Intangible assets, net of amortization 10,850 12,739
Goodwill 22,284 23,231
Deferred income taxes and other assets 5,369 5,212
Total Assets 72,801 75,196
Current Liabilities:    
Trade accounts payable 4,133 4,408
Salaries, wages and commissions 1,426 1,625
Other accrued liabilities 5,475 5,181
Dividends payable 820 831
Income taxes payable 394 306
Current portion of long-term debt 1,117 754
Total Current Liabilities 13,365 13,105
Long-term debt 15,297 17,296
Post-employment obligations, deferred income taxes and other long-term liabilities 8,255 8,771
Commitments and Contingencies
Shareholders’ Investment:    
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued 0 0
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2022: 1,985,919,440; 2021: 1,985,273,421 24,560 24,470
Common shares held in treasury, at cost — Shares: 2022: 242,345,663; 2021: 221,191,228 (14,555) (11,822)
Earnings employed in the business 35,115 31,528
Accumulated other comprehensive income (loss) (9,445) (8,374)
Total Abbott Shareholders’ Investment 35,675 35,802
Noncontrolling Interests in Subsidiaries 209 222
Total Shareholders’ Investment 35,884 36,024
Total Liabilities and Shareholders' Investment $ 72,801 $ 75,196
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Trade receivables, allowances $ 520 $ 519
Preferred shares, par value (in dollars per share) $ 1 $ 1
Preferred shares, authorized (in shares) 1,000,000 1,000,000
Preferred shares, issued (in shares) 0 0
Common shares, authorized (in shares) 2,400,000,000 2,400,000,000
Common shares, issued (in shares) 1,985,919,440 1,985,273,421
Common shares held in treasury (in shares) 242,345,663 221,191,228
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statement of Shareholders' Investment (Unaudited) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Increase (Decrease) in Shareholders' Investment        
Beginning balance     $ 36,024  
Net earnings $ 1,435 $ 2,100 5,900 $ 5,082
Other comprehensive income (loss) (739) (174) (1,071) (294)
Ending balance 35,884   35,884  
Common Stock        
Increase (Decrease) in Shareholders' Investment        
Beginning balance 24,429 24,153 24,470 24,145
Issued under incentive stock programs 12 26 36 91
Share-based compensation 123 113 572 536
Issuance of restricted stock awards (4) (7) (518) (487)
Ending balance 24,560 24,285 24,560 24,285
Treasury Stock, Common        
Increase (Decrease) in Shareholders' Investment        
Beginning balance (13,720) (10,340) (11,822) (10,042)
Issued under incentive stock programs 31 26 261 265
Purchased (866) (685) (2,994) (1,222)
Ending balance (14,555) (10,999) (14,555) (10,999)
Retained Earnings        
Increase (Decrease) in Shareholders' Investment        
Beginning balance 34,487 29,053 31,528 27,627
Net earnings 1,435 2,100 5,900 5,082
Cash dividends declared on common shares (822) (799) (2,475) (2,403)
Effect of common and treasury share transactions 15 22 162 70
Ending balance 35,115 30,376 35,115 30,376
AOCI Attributable to Parent        
Increase (Decrease) in Shareholders' Investment        
Beginning balance (8,706) (9,066) (8,374) (8,946)
Other comprehensive income (loss) (739) (174) (1,071) (294)
Ending balance (9,445) (9,240) (9,445) (9,240)
Noncontrolling Interest        
Increase (Decrease) in Shareholders' Investment        
Beginning balance 226 229 222 219
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases (17) (13) (13) (3)
Ending balance $ 209 $ 216 $ 209 $ 216
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) - $ / shares
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Increase (Decrease) in Shareholders' Investment        
Beginning balance, treasury stock, common (in shares)     221,191,228  
Ending balance, treasury stock, common (in shares) 242,345,663   242,345,663  
Common Stock        
Increase (Decrease) in Shareholders' Investment        
Beginning balance (in shares) 1,985,676,735 1,982,553,488 1,985,273,421 1,981,156,896
Issued under incentive stock programs (in shares) 242,705 550,366 646,019 1,946,958
Ending balance (in shares) 1,985,919,440 1,983,103,854 1,985,919,440 1,983,103,854
Treasury Stock, Common        
Increase (Decrease) in Shareholders' Investment        
Beginning balance, treasury stock, common (in shares) 234,456,992 209,736,139 221,191,228 209,926,622
Issued under incentive stock programs (in shares) 528,436 545,860 4,808,575 5,524,291
Purchased (in shares) 8,417,107 5,626,606 25,963,010 10,414,554
Ending balance, treasury stock, common (in shares) 242,345,663 214,816,885 242,345,663 214,816,885
Retained Earnings        
Increase (Decrease) in Shareholders' Investment        
Cash dividends declared on common shares (in dollars per share) $ 0.47 $ 0.45 $ 1.41 $ 1.35
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash Flow From (Used in) Operating Activities:    
Net earnings $ 5,900 $ 5,082
Adjustments to reconcile net earnings to net cash from operating activities —    
Depreciation 943 1,122
Amortization of intangible assets 1,517 1,533
Share-based compensation 570 534
Trade receivables (409) (194)
Inventories (1,224) (471)
Other, net (42) (140)
Net Cash From Operating Activities 7,255 7,466
Cash Flow From (Used in) Investing Activities:    
Acquisitions of property and equipment (1,167) (1,271)
Acquisitions of businesses and technologies, net of cash acquired 0 (187)
Proceeds from business dispositions 48 134
Sales (purchases) of other investment securities, net (3) (27)
Other 14 14
Net Cash From (Used in) Investing Activities (1,108) (1,337)
Cash Flow From (Used in) Financing Activities:    
Net borrowings (repayments) of short-term debt and other 37 (7)
Proceeds from issuance of long-term debt 7 0
Repayments of long-term debt (753) (45)
Purchases of common shares (3,110) (1,325)
Proceeds from stock options exercised 126 173
Dividends paid (2,486) (2,404)
Net Cash From (Used in) Financing Activities (6,179) (3,608)
Effect of exchange rate changes on cash and cash equivalents (173) (57)
Net Increase (Decrease) in Cash and Cash Equivalents (205) 2,464
Cash and Cash Equivalents, Beginning of Year 9,799 6,838
Cash and Cash Equivalents, End of Period $ 9,594 $ 9,302
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2021. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenue
Note 2 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The following tables provide detail by sales category:

Three Months Ended September 30, 2022Three Months Ended September 30, 2021
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $993 $993 $— $936 $936 
Other— 333 333 — 329 329 
Total— 1,326 1,326 — 1,265 1,265 
Nutritionals —    
Pediatric Nutritionals357 470 827 586 514 1,100 
Adult Nutritionals329 639 968 333 675 1,008 
Total686 1,109 1,795 919 1,189 2,108 
Diagnostics —     
Core Laboratory281 938 1,219 291 1,001 1,292 
Molecular65 118 183 162 183 345 
Point of Care92 35 127 100 35 135 
Rapid Diagnostics1,303 839 2,142 1,394 746 2,140 
Total1,741 1,930 3,671 1,947 1,965 3,912 
Medical Devices —    
Rhythm Management263 270 533 266 305 571 
Electrophysiology225 244 469 192 293 485 
Heart Failure177 51 228 170 59 229 
Vascular213 393 606 219 425 644 
Structural Heart207 213 420 177 215 392 
Neuromodulation156 36 192 149 41 190 
Diabetes Care 423 744 1,167 323 798 1,121 
Total1,664 1,951 3,615 1,496 2,136 3,632 
Other3 — 3 6 5 11 
Total$4,094 $6,316 $10,410 $4,368 $6,560 $10,928 
Nine Months Ended September 30, 2022Nine Months Ended September 30, 2021
(in millions)U.S.Int’lTotal U.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $2,826 $2,826 $— $2,672 $2,672 
Other— 870 870 — 843 843 
Total— 3,696 3,696 — 3,515 3,515 
Nutritionals —    
Pediatric Nutritionals1,108 1,491 2,599 1,622 1,637 3,259 
Adult Nutritionals1,016 2,027 3,043 1,006 1,987 2,993 
Total2,124 3,518 5,642 2,628 3,624 6,252 
Diagnostics —
Core Laboratory836 2,788 3,624 845 2,935 3,780 
Molecular308 507 815 431 651 1,082 
Point of Care284 110 394 289 112 401 
Rapid Diagnostics5,523 2,923 8,446 3,178 2,732 5,910 
Total6,951 6,328 13,279 4,743 6,430 11,173 
Medical Devices —
Rhythm Management775 830 1,605 776 881 1,657 
Electrophysiology667 773 1,440 580 823 1,403 
Heart Failure523 167 690 483 167 650 
Vascular650 1,228 1,878 684 1,292 1,976 
Structural Heart604 667 1,271 537 654 1,191 
Neuromodulation456 112 568 460 124 584 
Diabetes Care1,165 2,320 3,485 865 2,292 3,157 
Total4,840 6,097 10,937 4,385 6,233 10,618 
Other8 — 8 31 18 49 
Total$13,923 $19,639 $33,562 $11,787 $19,820 $31,607 

Remaining Performance Obligations

As of September 30, 2022, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $3.9 billion in the Diagnostics segment and approximately $433 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 60 percent of these remaining performance obligations over the next 24 months, approximately 16 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.
Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2021$520 
Unearned revenue from cash received during the period466 
Revenue recognized related to contract liability balance(508)
Balance at September 30, 2022$478 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Supplemental Financial Information
 9 Months Ended
Sep. 30, 2022
Disclosure Text Block Supplement [Abstract]  
Supplemental Financial Information
Note 3 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended September 30, 2022 and 2021 were $1.429 billion and $2.092 billion, respectively, and for the nine months ended September 30, 2022 and 2021 were $5.876 billion and $5.061 billion, respectively.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2022 includes $362 million of pension contributions and the payment of cash taxes of approximately $987 million. The first nine months of 2021 includes $366 million of pension contributions and the payment of cash taxes of approximately $990 million.

The following summarizes the activity for the first nine months of 2022 related to the allowance for doubtful accounts as of September 30, 2022:

(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2021$313 
Provisions/charges to income10 
Amounts charged off and other deductions(49)
Balance at September 30, 2022$274 

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.
The components of long-term investments as of September 30, 2022 and December 31, 2021 are as follows:

(in millions)September 30,
2022		December 31,
2021
Long-term Investments:
Equity securities$604 $748 
Other160 68 
Total$764 $816 

The decrease in Abbott’s long-term investments as of September 30, 2022 versus the balance as of December 31, 2021 primarily relates to a decrease in the value of investments held in a rabbi trust and the impact of equity method investment losses partially offset by an investment in long-term time deposits.

Abbott’s equity securities as of September 30, 2022, include $285 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott also holds certain investments as of September 30, 2022 with a carrying value of $228 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $83 million that do not have a readily determinable fair value.

In September 2021, Abbott acquired 100 percent of Walk Vascular, LLC (Walk Vascular), a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots. The purchase price, the allocation of acquired assets and liabilities, and the revenue and net income contributed by Walk Vascular since the date of acquisition are not material to Abbott’s condensed consolidated financial statements.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Changes in Accumulated Other Comprehensive Income (Loss)
 9 Months Ended
Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Changes in Accumulated Other Comprehensive Income (Loss)
Note 4 — Changes In Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)202220212022202120222021
Balance at June 30$(6,260)$(5,230)$(2,554)$(3,738)$108 $(98)
Other comprehensive income (loss) before reclassifications(1,008)(391)15 16 278 70 
Amounts reclassified from accumulated other comprehensive income— — 41 62 (65)69 
Net current period comprehensive income (loss)(1,008)(391)56 78 213 139 
Balance at September 30$(7,268)$(5,621)$(2,498)$(3,660)$321 $41 
Nine Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)20222021202220212022 2021
Balance at January 1$(5,839)$(4,859)$(2,670)$(3,871)$135 $(216)
Other comprehensive income (loss) before reclassifications(1,429)(762)45 26 289 138 
Amounts reclassified from accumulated other comprehensive income — — 127 185 (103)119 
Net current period comprehensive income (loss)(1,429)(762)172 211 186 257 
Balance at September 30$(7,268)$(5,621)$(2,498)$(3,660)$321 $41 

Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 11 for additional details.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Intangible Assets
 9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets
Note 5 — Goodwill and Intangible Assets

The total amount of goodwill reported was $22.3 billion at September 30, 2022 and $23.2 billion at December 31, 2021. Foreign currency translation adjustments decreased goodwill by approximately $946 million in the first nine months of 2022. The amount of goodwill related to reportable segments at September 30, 2022 was $2.6 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $15.9 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first nine months of 2022.

The gross amount of amortizable intangible assets, primarily product rights and technology, was $26.9 billion and $27.7 billion as of September 30, 2022 and December 31, 2021, respectively. Accumulated amortization was $16.9 billion and $15.9 billion as of September 30, 2022 and December 31, 2021, respectively. Foreign currency translation adjustments decreased intangible assets by $250 million in the first nine months of 2022. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.1 billion in 2022, $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025 and $1.6 billion in 2026.

Indefinite-lived intangible assets, which relate to in-process R&D (IPR&D) acquired in a business combination, were approximately $807 million as of September 30, 2022 and $919 million as of December 31, 2021. In the third quarter of 2022, $111 million of impairment charges were recorded on the Research and development line of the Condensed Consolidated Statement of Earnings related to certain IPR&D intangible assets associated with the Medical Devices business segment.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring Plans
 9 Months Ended
Sep. 30, 2022
Restructuring and Related Activities [Abstract]  
Restructuring Plans
Note 6 — Restructuring Plans

On May 27, 2021, Abbott management approved a restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with changes in the second quarter in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and the U.S. health authority’s updated guidance on testing for fully vaccinated individuals. In the second quarter of 2021, Abbott recorded charges of $499 million under this plan in Cost of products sold. The charge recognized in the second quarter of 2021 included fixed asset write-downs of $80 million, inventory-related charges of $248 million, and other exit costs, which included contract cancellations and employee-related costs of $171 million.
In the second half of 2021, as the Delta and Omicron variants of COVID-19 spread and the number of new COVID-19 cases increased significantly, particularly in the U.S., demand for rapid COVID-19 tests increased significantly. As a result, in the second half of 2021, Abbott sold approximately $181 million of inventory that was previously estimated to have no net realizable value under the second quarter of 2021 restructuring action. In addition, the estimate of other exit costs was reduced by a net $58 million as Abbott fulfilled its purchase obligations under certain contracts for which a liability was recorded in the second quarter of 2021 or Abbott settled with the counterparty in the second half of 2021.

The following summarizes the activity related to this restructuring action and the status of the related accruals as of September 30, 2022:

(in millions)Inventory-
Related
Charges		Fixed Asset
Write-Downs		Other Exit
Costs		Total
Restructuring charges recorded in 2021$248 $80 $113 $441 
Payments— — (90)(90)
Other non-cash(248)(80)— (328)
Accrued balance at December 31, 2021— — 23 23 
Payments and other adjustments— — (10)(10)
Accrued balance at September 30, 2022$— $— $13 $13 

In 2021, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in Abbott’s diagnostic, established pharmaceutical, and nutritional businesses. In 2022 and 2021, Abbott management approved plans to streamline operations in its medical devices segment. Abbott recorded employees-related severance and other charges of approximately $12 million in the first nine months of 2022 of which approximately $5 million was recorded in Cost of products sold, approximately $2 million was recorded in Research and development, and approximately $5 million was recorded in Selling, general and administrative expense.

The following summarizes the activity for these restructurings:

(in millions)
Restructuring charges recorded in 2021$68 
Payments and other adjustments(7)
Accrued balance at December 31, 202161 
Restructuring charges recorded in 202212 
Payments and other adjustments(39)
Accrued balance at September 30, 2022$34 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Incentive Stock Program
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Incentive Stock Program
Note 7 — Incentive Stock Program

In the first nine months of 2022, Abbott granted 2,634,647 stock options, 514,205 restricted stock awards and 5,427,697 restricted stock units under its incentive stock program. At September 30, 2022, approximately 87 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at September 30, 2022 is as follows:

OutstandingExercisable
Number of shares 29,048,449 23,310,464 
Weighted average remaining life (years)
5.44.6
Weighted average exercise price $70.22 $59.69 
Aggregate intrinsic value (in millions)
$901 $890 

The total unrecognized share-based compensation cost at September 30, 2022 amounted to approximately $600 million which is expected to be recognized over the next three years.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt and Lines of Credit
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Debt and Lines of Credit
Note 8 — Debt and Lines of Credit

On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments, Derivatives and Fair Value Measures
 9 Months Ended
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments, Derivatives and Fair Value Measures
Note 9 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.9 billion at September 30, 2022 and $8.6 billion at December 31, 2021, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September 30, 2022 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At September 30, 2022 and December 31, 2021, Abbott held the gross notional amounts of $10.3 billion and $12.2 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan of approximately $413 million and $521 million as of September 30, 2022 and December 31, 2021, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts with notional values totaling approximately $2.9 billion at September 30, 2022 and December 31, 2021 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.
The following table summarizes the amounts and location of certain derivative financial instruments as of September 30, 2022 and December 31, 2021:

Fair Value - AssetsFair Value - Liabilities
(in millions)September 30,
2022		Dec. 31,
2021		Balance Sheet CaptionSeptember 30,
2022		Dec. 31,
2021		Balance Sheet Caption
Interest rate swaps designated as fair value hedges$— $87 Deferred income taxes and other assets$166 $— Post-employment obligations, deferred income taxes and other long-term liabilities
Foreign currency forward exchange contracts:
Hedging instruments760 222 Prepaid expenses and other receivables66 65 Other accrued liabilities
Others not designated as hedges148 70 Prepaid expenses and other receivables141 32 Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary— — n/a413 521 Long-term debt
$908 $379 $786 $618 

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September 30, 2022 and 2021.

Gain (loss) Recognized in Other
Comprehensive Income (loss)		Income (expense) and Gain (loss)
Reclassified into Income
Three Months
Ended September 30		Nine Months
Ended September 30		Three Months
Ended September 30		Nine Months
Ended September 30
(in millions)20222021202220212022202120222021Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges$350 $96 $442 $142 $79 $(92)$149 $(207)Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary24 4 108 41 — — — — n/a
Interest rate swaps designated as fair value hedgesn/an/an/an/a(85)(14)(253)(81)Interest expense
Losses of $27 million and $18 million were recognized in the three months ended September 30, 2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Gains of $225 million and $15 million were recognized in the nine months ended September 30, 2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

The carrying values and fair values of certain financial instruments as of September 30, 2022 and December 31, 2021 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

September 30, 2022December 31, 2021
(in millions)Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Long-term Investment Securities:
Equity securities$604 $604 $748 $748 
Other160 160 68 68 
Total Long-term Debt(16,414)(15,821)(18,050)(21,152)
Foreign Currency Forward Exchange Contracts:   
Receivable position908 908 292 292 
(Payable) position(207)(207)(97)(97)
Interest Rate Hedge Contracts:    
Receivable position— — 87 87 
(Payable) position(166)(166)— — 

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement
(in millions)Outstanding
Balances		Quoted
Prices in
Active
Markets		Significant
Other
Observable
Inputs		Significant
Unobservable
Inputs
September 30, 2022:
Equity securities$293 $293 $— $— 
Foreign currency forward exchange contracts908 — 908 — 
Total Assets$1,201 $293 $908 $— 
Fair value of hedged long-term debt$2,685 $— $2,685 $— 
Interest rate swap derivative financial instruments166 — 166 — 
Foreign currency forward exchange contracts207 — 207 — 
Contingent consideration related to business combinations138 — — 138 
Total Liabilities$3,196 $— $3,058 $138 
December 31, 2021:
Equity securities$402 $402 $— $— 
Interest rate swap derivative financial instruments 87 — 87 — 
Foreign currency forward exchange contracts292 — 292 — 
Total Assets$781 $402 $379 $— 
Fair value of hedged long-term debt$2,926 $— $2,926 $— 
Foreign currency forward exchange contracts97 — 97 — 
Contingent consideration related to business combinations130 — — 130 
Total Liabilities$3,153 $— $3,023 $130 

The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Litigation and Environmental Matters
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Litigation and Environmental Matters
Note 10 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.
Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $40 million to $50 million. The recorded accrual balance at September 30, 2022 for these proceedings and exposures was approximately $45 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Post-Employment Benefits
 9 Months Ended
Sep. 30, 2022
Postemployment Benefits [Abstract]  
Post-Employment Benefits
Note 11 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three and nine months ended September 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:

Defined Benefit PlansMedical and Dental Plans
Three Months
Ended Sept. 30		Nine Months
Ended Sept. 30		Three Months
Ended Sept. 30		Nine Months
Ended Sept. 30
(in millions)20222021202220212022202120222021
Service cost - benefits earned during the period$92 $98 $282 $294 $13 $14 $38 $42 
Interest cost on projected benefit obligations74 62 225 186 9 8 27 25 
Expected return on plan assets(231)(211)(701)(633)(8)(6)(23)(20)
Net amortization of:
Actuarial loss, net58 79 174 238 2 7 8 21 
Prior service cost (credit)— — 1 1 (6)(7)(18)(21)
Net cost (credit)$(7)$28 $(19)$86 $10 $16 $32 $47 
Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first nine months of 2022 and 2021, $362 million and $366 million, respectively, were contributed to defined benefit plans. In the first nine months of 2022 and 2021, $28 million and $26 million, respectively, were contributed to the post-employment medical and dental plans.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Taxes on Earnings
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Taxes on Earnings
Note 12 — Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2022 and 2021, taxes on earnings include approximately $36 million and $97 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2022, taxes on earnings also include approximately $20 million of tax expense as the result of the resolution of various tax positions related to prior years.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $75 million to $100 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Segment Information
Note 13 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

 Net Sales to External CustomersOperating Earnings
Three Months
Ended Sept. 30		Nine Months
Ended Sept. 30		Three Months
Ended Sept. 30		Nine Months
Ended Sept. 30
(in millions)20222021202220212022 2021 2022 2021
Established Pharmaceutical Products$1,326 $1,265 $3,696 $3,515 $331 $293 $831 $682 
Nutritional Products1,795 2,108 5,642 6,252 69 431 550 1,388 
Diagnostic Products3,671 3,912 13,279 11,173 1,352 1,652 5,631 4,429 
Medical Devices3,615 3,632 10,937 10,618 1,039 1,160 3,272 3,375 
Total Reportable Segments10,407 10,917 33,554 31,558 2,791 3,536 10,284 9,874 
Other 3 11 8 49 
Net sales$10,410 $10,928 $33,562 $31,607 
Corporate functions and benefit plan costs(115)(204)(352)(450)
Net interest expense (86)(123)(309)(370)
Share-based compensation (a) (123)(114)(570)(534)
Amortization of intangible assets(498)(520)(1,517)(1,533)
Other, net (b)(211)(82)(550)(1,103)
Earnings before taxes$1,758 $2,493 $6,986 $5,884 
______________________________________
(a)
Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)
Other, net for the three and nine months ended September 30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment and $111 million of charges related to the impairment of IPR&D intangible assets. Other, net for the three and nine months ended September 30, 2022 and 2021 also includes integration costs associated with the acquisition of Alere and restructuring charges. Restructuring charges in 2021 include Abbott’s restructuring plan for its COVID-19 test manufacturing network. Other, net for the nine months ended September 30, 2021 also includes costs related to certain litigation.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue (Tables)
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of reportable segment included under sales category
The following tables provide detail by sales category:

Three Months Ended September 30, 2022Three Months Ended September 30, 2021
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $993 $993 $— $936 $936 
Other— 333 333 — 329 329 
Total— 1,326 1,326 — 1,265 1,265 
Nutritionals —    
Pediatric Nutritionals357 470 827 586 514 1,100 
Adult Nutritionals329 639 968 333 675 1,008 
Total686 1,109 1,795 919 1,189 2,108 
Diagnostics —     
Core Laboratory281 938 1,219 291 1,001 1,292 
Molecular65 118 183 162 183 345 
Point of Care92 35 127 100 35 135 
Rapid Diagnostics1,303 839 2,142 1,394 746 2,140 
Total1,741 1,930 3,671 1,947 1,965 3,912 
Medical Devices —    
Rhythm Management263 270 533 266 305 571 
Electrophysiology225 244 469 192 293 485 
Heart Failure177 51 228 170 59 229 
Vascular213 393 606 219 425 644 
Structural Heart207 213 420 177 215 392 
Neuromodulation156 36 192 149 41 190 
Diabetes Care 423 744 1,167 323 798 1,121 
Total1,664 1,951 3,615 1,496 2,136 3,632 
Other3 — 3 6 5 11 
Total$4,094 $6,316 $10,410 $4,368 $6,560 $10,928 
Nine Months Ended September 30, 2022Nine Months Ended September 30, 2021
(in millions)U.S.Int’lTotal U.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $2,826 $2,826 $— $2,672 $2,672 
Other— 870 870 — 843 843 
Total— 3,696 3,696 — 3,515 3,515 
Nutritionals —    
Pediatric Nutritionals1,108 1,491 2,599 1,622 1,637 3,259 
Adult Nutritionals1,016 2,027 3,043 1,006 1,987 2,993 
Total2,124 3,518 5,642 2,628 3,624 6,252 
Diagnostics —
Core Laboratory836 2,788 3,624 845 2,935 3,780 
Molecular308 507 815 431 651 1,082 
Point of Care284 110 394 289 112 401 
Rapid Diagnostics5,523 2,923 8,446 3,178 2,732 5,910 
Total6,951 6,328 13,279 4,743 6,430 11,173 
Medical Devices —
Rhythm Management775 830 1,605 776 881 1,657 
Electrophysiology667 773 1,440 580 823 1,403 
Heart Failure523 167 690 483 167 650 
Vascular650 1,228 1,878 684 1,292 1,976 
Structural Heart604 667 1,271 537 654 1,191 
Neuromodulation456 112 568 460 124 584 
Diabetes Care1,165 2,320 3,485 865 2,292 3,157 
Total4,840 6,097 10,937 4,385 6,233 10,618 
Other8 — 8 31 18 49 
Total$13,923 $19,639 $33,562 $11,787 $19,820 $31,607 
Schedule of changes in contract liabilities
Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2021$520 
Unearned revenue from cash received during the period466 
Revenue recognized related to contract liability balance(508)
Balance at September 30, 2022$478 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Supplemental Financial Information (Tables)
 9 Months Ended
Sep. 30, 2022
Disclosure Text Block Supplement [Abstract]  
Summary of activity of allowance for doubtful accounts
The following summarizes the activity for the first nine months of 2022 related to the allowance for doubtful accounts as of September 30, 2022:

(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2021$313 
Provisions/charges to income10 
Amounts charged off and other deductions(49)
Balance at September 30, 2022$274 
Schedule of long-term investments
The components of long-term investments as of September 30, 2022 and December 31, 2021 are as follows:

(in millions)September 30,
2022		December 31,
2021
Long-term Investments:
Equity securities$604 $748 
Other160 68 
Total$764 $816 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Changes in Accumulated Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Schedule of accumulated other comprehensive income (loss), net of taxes
The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)202220212022202120222021
Balance at June 30$(6,260)$(5,230)$(2,554)$(3,738)$108 $(98)
Other comprehensive income (loss) before reclassifications(1,008)(391)15 16 278 70 
Amounts reclassified from accumulated other comprehensive income— — 41 62 (65)69 
Net current period comprehensive income (loss)(1,008)(391)56 78 213 139 
Balance at September 30$(7,268)$(5,621)$(2,498)$(3,660)$321 $41 
Nine Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments		Net Actuarial (Losses) and
Prior Service (Costs) and
Credits		Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions)20222021202220212022 2021
Balance at January 1$(5,839)$(4,859)$(2,670)$(3,871)$135 $(216)
Other comprehensive income (loss) before reclassifications(1,429)(762)45 26 289 138 
Amounts reclassified from accumulated other comprehensive income — — 127 185 (103)119 
Net current period comprehensive income (loss)(1,429)(762)172 211 186 257 
Balance at September 30$(7,268)$(5,621)$(2,498)$(3,660)$321 $41 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring Plans (Tables)
 9 Months Ended
Sep. 30, 2022
Restructuring and Related Activities [Abstract]  
Schedule of restructuring reserve and related cost
The following summarizes the activity related to this restructuring action and the status of the related accruals as of September 30, 2022:

(in millions)Inventory-
Related
Charges		Fixed Asset
Write-Downs		Other Exit
Costs		Total
Restructuring charges recorded in 2021$248 $80 $113 $441 
Payments— — (90)(90)
Other non-cash(248)(80)— (328)
Accrued balance at December 31, 2021— — 23 23 
Payments and other adjustments— — (10)(10)
Accrued balance at September 30, 2022$— $— $13 $13 
Summary of restructuring activity
The following summarizes the activity for these restructurings:

(in millions)
Restructuring charges recorded in 2021$68 
Payments and other adjustments(7)
Accrued balance at December 31, 202161 
Restructuring charges recorded in 202212 
Payments and other adjustments(39)
Accrued balance at September 30, 2022$34 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Incentive Stock Program (Tables)
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of stock options outstanding and exercisable Information regarding the number of options outstanding and exercisable at September 30, 2022 is as follows:
OutstandingExercisable
Number of shares 29,048,449 23,310,464 
Weighted average remaining life (years)
5.44.6
Weighted average exercise price $70.22 $59.69 
Aggregate intrinsic value (in millions)
$901 $890 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments, Derivatives and Fair Value Measures (Tables)
 9 Months Ended
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Summary of the amounts and location of certain derivative financial instruments
The following table summarizes the amounts and location of certain derivative financial instruments as of September 30, 2022 and December 31, 2021:

Fair Value - AssetsFair Value - Liabilities
(in millions)September 30,
2022		Dec. 31,
2021		Balance Sheet CaptionSeptember 30,
2022		Dec. 31,
2021		Balance Sheet Caption
Interest rate swaps designated as fair value hedges$— $87 Deferred income taxes and other assets$166 $— Post-employment obligations, deferred income taxes and other long-term liabilities
Foreign currency forward exchange contracts:
Hedging instruments760 222 Prepaid expenses and other receivables66 65 Other accrued liabilities
Others not designated as hedges148 70 Prepaid expenses and other receivables141 32 Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary— — n/a413 521 Long-term debt
$908 $379 $786 $618 
Schedule of derivatives gain (loss) in OCI and earnings
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September 30, 2022 and 2021.

Gain (loss) Recognized in Other
Comprehensive Income (loss)		Income (expense) and Gain (loss)
Reclassified into Income
Three Months
Ended September 30		Nine Months
Ended September 30		Three Months
Ended September 30		Nine Months
Ended September 30
(in millions)20222021202220212022202120222021Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges$350 $96 $442 $142 $79 $(92)$149 $(207)Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary24 4 108 41 — — — — n/a
Interest rate swaps designated as fair value hedgesn/an/an/an/a(85)(14)(253)(81)Interest expense
Schedule of carrying values and fair values of certain financial instruments
The carrying values and fair values of certain financial instruments as of September 30, 2022 and December 31, 2021 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

September 30, 2022December 31, 2021
(in millions)Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Long-term Investment Securities:
Equity securities$604 $604 $748 $748 
Other160 160 68 68 
Total Long-term Debt(16,414)(15,821)(18,050)(21,152)
Foreign Currency Forward Exchange Contracts:   
Receivable position908 908 292 292 
(Payable) position(207)(207)(97)(97)
Interest Rate Hedge Contracts:    
Receivable position— — 87 87 
(Payable) position(166)(166)— — 
Schedule of assets and liabilities measured at fair value on a recurring basis
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement
(in millions)Outstanding
Balances		Quoted
Prices in
Active
Markets		Significant
Other
Observable
Inputs		Significant
Unobservable
Inputs
September 30, 2022:
Equity securities$293 $293 $— $— 
Foreign currency forward exchange contracts908 — 908 — 
Total Assets$1,201 $293 $908 $— 
Fair value of hedged long-term debt$2,685 $— $2,685 $— 
Interest rate swap derivative financial instruments166 — 166 — 
Foreign currency forward exchange contracts207 — 207 — 
Contingent consideration related to business combinations138 — — 138 
Total Liabilities$3,196 $— $3,058 $138 
December 31, 2021:
Equity securities$402 $402 $— $— 
Interest rate swap derivative financial instruments 87 — 87 — 
Foreign currency forward exchange contracts292 — 292 — 
Total Assets$781 $402 $379 $— 
Fair value of hedged long-term debt$2,926 $— $2,926 $— 
Foreign currency forward exchange contracts97 — 97 — 
Contingent consideration related to business combinations130 — — 130 
Total Liabilities$3,153 $— $3,023 $130 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Post-Employment Benefits (Tables)
 9 Months Ended
Sep. 30, 2022
Postemployment Benefits [Abstract]  
Schedule of components of the net periodic benefit cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans Net cost recognized for the three and nine months ended September 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:
Defined Benefit PlansMedical and Dental Plans
Three Months
Ended Sept. 30		Nine Months
Ended Sept. 30		Three Months
Ended Sept. 30		Nine Months
Ended Sept. 30
(in millions)20222021202220212022202120222021
Service cost - benefits earned during the period$92 $98 $282 $294 $13 $14 $38 $42 
Interest cost on projected benefit obligations74 62 225 186 9 8 27 25 
Expected return on plan assets(231)(211)(701)(633)(8)(6)(23)(20)
Net amortization of:
Actuarial loss, net58 79 174 238 2 7 8 21 
Prior service cost (credit)— — 1 1 (6)(7)(18)(21)
Net cost (credit)$(7)$28 $(19)$86 $10 $16 $32 $47 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Schedule of segment information - net sales and operating earnings
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

 Net Sales to External CustomersOperating Earnings
Three Months
Ended Sept. 30		Nine Months
Ended Sept. 30		Three Months
Ended Sept. 30		Nine Months
Ended Sept. 30
(in millions)20222021202220212022 2021 2022 2021
Established Pharmaceutical Products$1,326 $1,265 $3,696 $3,515 $331 $293 $831 $682 
Nutritional Products1,795 2,108 5,642 6,252 69 431 550 1,388 
Diagnostic Products3,671 3,912 13,279 11,173 1,352 1,652 5,631 4,429 
Medical Devices3,615 3,632 10,937 10,618 1,039 1,160 3,272 3,375 
Total Reportable Segments10,407 10,917 33,554 31,558 2,791 3,536 10,284 9,874 
Other 3 11 8 49 
Net sales$10,410 $10,928 $33,562 $31,607 
Corporate functions and benefit plan costs(115)(204)(352)(450)
Net interest expense (86)(123)(309)(370)
Share-based compensation (a) (123)(114)(570)(534)
Amortization of intangible assets(498)(520)(1,517)(1,533)
Other, net (b)(211)(82)(550)(1,103)
Earnings before taxes$1,758 $2,493 $6,986 $5,884 
______________________________________
(a)
Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)
Other, net for the three and nine months ended September 30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment and $111 million of charges related to the impairment of IPR&D intangible assets. Other, net for the three and nine months ended September 30, 2022 and 2021 also includes integration costs associated with the acquisition of Alere and restructuring charges. Restructuring charges in 2021 include Abbott’s restructuring plan for its COVID-19 test manufacturing network. Other, net for the nine months ended September 30, 2021 also includes costs related to certain litigation.
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue - Narrative (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
segment
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
segment
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Number of reportable segments | segment 4 4 4 4
Diagnostic Products        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Remaining performance obligations $ 3,900   $ 3,900  
Medical Devices        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Remaining performance obligations $ 433   $ 433  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Percentage of remaining performance obligation expected to be recognized in period     60.00%  
Expected timing of satisfaction period (in months) 24 months   24 months  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]        
Percentage of remaining performance obligation expected to be recognized in period     16.00%  
Expected timing of satisfaction period (in months) 12 months   12 months  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue - Segments (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting Information [Line Items]        
Net sales $ 10,410 $ 10,928 $ 33,562 $ 31,607
Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 10,407 10,917 33,554 31,558
Other        
Segment Reporting Information [Line Items]        
Net sales 3 11 8 49
United States        
Segment Reporting Information [Line Items]        
Net sales 4,094 4,368 13,923 11,787
United States | Other        
Segment Reporting Information [Line Items]        
Net sales 3 6 8 31
International        
Segment Reporting Information [Line Items]        
Net sales 6,316 6,560 19,639 19,820
International | Other        
Segment Reporting Information [Line Items]        
Net sales 0 5 0 18
Established Pharmaceutical Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,326 1,265 3,696 3,515
Established Pharmaceutical Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 0 0 0 0
Established Pharmaceutical Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,326 1,265 3,696 3,515
Nutritional Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,795 2,108 5,642 6,252
Nutritional Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 686 919 2,124 2,628
Nutritional Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,109 1,189 3,518 3,624
Diagnostic Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 3,671 3,912 13,279 11,173
Diagnostic Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,741 1,947 6,951 4,743
Diagnostic Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,930 1,965 6,328 6,430
Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 3,615 3,632 10,937 10,618
Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,664 1,496 4,840 4,385
Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,951 2,136 6,097 6,233
Key Emerging Markets | Established Pharmaceutical Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 993 936 2,826 2,672
Key Emerging Markets | Established Pharmaceutical Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 0 0 0 0
Key Emerging Markets | Established Pharmaceutical Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 993 936 2,826 2,672
Other Emerging Markets | Established Pharmaceutical Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 333 329 870 843
Other Emerging Markets | Established Pharmaceutical Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 0 0 0 0
Other Emerging Markets | Established Pharmaceutical Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 333 329 870 843
Pediatric Nutritionals | Nutritional Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 827 1,100 2,599 3,259
Pediatric Nutritionals | Nutritional Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 357 586 1,108 1,622
Pediatric Nutritionals | Nutritional Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 470 514 1,491 1,637
Adult Nutritionals | Nutritional Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 968 1,008 3,043 2,993
Adult Nutritionals | Nutritional Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 329 333 1,016 1,006
Adult Nutritionals | Nutritional Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 639 675 2,027 1,987
Core Laboratory | Diagnostic Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,219 1,292 3,624 3,780
Core Laboratory | Diagnostic Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 281 291 836 845
Core Laboratory | Diagnostic Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 938 1,001 2,788 2,935
Molecular | Diagnostic Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 183 345 815 1,082
Molecular | Diagnostic Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 65 162 308 431
Molecular | Diagnostic Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 118 183 507 651
Point of Care | Diagnostic Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 127 135 394 401
Point of Care | Diagnostic Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 92 100 284 289
Point of Care | Diagnostic Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 35 35 110 112
Rapid Diagnostics | Diagnostic Products | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 2,142 2,140 8,446 5,910
Rapid Diagnostics | Diagnostic Products | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,303 1,394 5,523 3,178
Rapid Diagnostics | Diagnostic Products | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 839 746 2,923 2,732
Rhythm Management | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 533 571 1,605 1,657
Rhythm Management | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 263 266 775 776
Rhythm Management | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 270 305 830 881
Electrophysiology | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 469 485 1,440 1,403
Electrophysiology | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 225 192 667 580
Electrophysiology | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 244 293 773 823
Heart Failure | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 228 229 690 650
Heart Failure | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 177 170 523 483
Heart Failure | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 51 59 167 167
Vascular | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 606 644 1,878 1,976
Vascular | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 213 219 650 684
Vascular | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 393 425 1,228 1,292
Structural Heart | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 420 392 1,271 1,191
Structural Heart | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 207 177 604 537
Structural Heart | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 213 215 667 654
Neuromodulation | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 192 190 568 584
Neuromodulation | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 156 149 456 460
Neuromodulation | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 36 41 112 124
Diabetes Care | Medical Devices | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 1,167 1,121 3,485 3,157
Diabetes Care | Medical Devices | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 423 323 1,165 865
Diabetes Care | Medical Devices | International | Operating Segments        
Segment Reporting Information [Line Items]        
Net sales $ 744 $ 798 $ 2,320 $ 2,292
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue - Other Contract Assets and Liabilities (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2022
USD ($)
Contract Liabilities:  
Beginning balance $ 520
Unearned revenue from cash received during the period 466
Revenue recognized related to contract liability balance (508)
Ending balance $ 478
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Supplemental Financial Information - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Condensed Cash Flow Statements, Captions [Line Items]        
Net earnings allocated to common shares $ 1,429 $ 2,092 $ 5,876 $ 5,061
Payment of cash taxes     987 $ 990
Equity method investments carrying value 228   228  
Equity investment without readily determinable fair value 83   83  
St. Jude Medical | Equity securities        
Condensed Cash Flow Statements, Captions [Line Items]        
Securities in mutual funds held in a rabbi trust $ 285   285  
Walk Vascular        
Condensed Cash Flow Statements, Captions [Line Items]        
Business acquisition, percentage acquired   100.00%   100.00%
Defined Benefit Plans        
Condensed Cash Flow Statements, Captions [Line Items]        
Pension contributions     $ 362 $ 366
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Supplemental Financial Information - Allowance for Doubtful Accounts (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2022
USD ($)
Allowance for Doubtful Accounts:  
Beginning balance $ 313
Provisions/charges to income 10
Amounts charged off and other deductions (49)
Ending balance $ 274
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Supplemental Financial Information - Investments (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Summary of Investment Holdings [Line Items]    
Investments $ 764 $ 816
Equity securities    
Summary of Investment Holdings [Line Items]    
Investments 604 748
Other    
Summary of Investment Holdings [Line Items]    
Investments $ 160 $ 68
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Changes in accumulated other comprehensive income (loss), net of income taxes        
Beginning of the period     $ 35,802  
Other comprehensive income (loss) $ (739) $ (174) (1,071) $ (294)
End of the period 35,675   35,675  
Cumulative Foreign Currency Translation (Loss) Adjustments        
Changes in accumulated other comprehensive income (loss), net of income taxes        
Beginning of the period (6,260) (5,230) (5,839) (4,859)
Other comprehensive income (loss) before reclassifications (1,008) (391) (1,429) (762)
Amounts reclassified from accumulated other comprehensive income 0 0 0 0
Other comprehensive income (loss) (1,008) (391) (1,429) (762)
End of the period (7,268) (5,621) (7,268) (5,621)
Net Actuarial (Losses) and Prior Service (Costs) and Credits        
Changes in accumulated other comprehensive income (loss), net of income taxes        
Beginning of the period (2,554) (3,738) (2,670) (3,871)
Other comprehensive income (loss) before reclassifications 15 16 45 26
Amounts reclassified from accumulated other comprehensive income 41 62 127 185
Other comprehensive income (loss) 56 78 172 211
End of the period (2,498) (3,660) (2,498) (3,660)
Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other        
Changes in accumulated other comprehensive income (loss), net of income taxes        
Beginning of the period 108 (98) 135 (216)
Other comprehensive income (loss) before reclassifications 278 70 289 138
Amounts reclassified from accumulated other comprehensive income (65) 69 (103) 119
Other comprehensive income (loss) 213 139 186 257
End of the period $ 321 $ 41 $ 321 $ 41
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Intangible Assets (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2022
Dec. 31, 2021
Goodwill and Intangible Assets [Line Items]      
Goodwill $ 22,284 $ 22,284 $ 23,231
Decrease in goodwill due to foreign currency translation adjustments   946  
Amount of reductions of goodwill relating to impairments   0  
Gross amount of amortizable intangible assets 26,900 26,900 27,700
Accumulated amortization of intangible assets 16,900 16,900 15,900
Decrease in intangible assets due to foreign currency translation adjustments   250  
Estimated annual amortization expense, intangible assets, 2022 2,100 2,100  
Estimated annual amortization expense, intangible assets, 2023 2,000 2,000  
Estimated annual amortization expense, intangible assets, 2024 1,900 1,900  
Estimated annual amortization expense, intangible assets, 2025 1,700 1,700  
Estimated annual amortization expense, intangible assets, 2026 1,600 1,600  
Indefinite-lived intangible assets related to in-process R&D acquired in a business combination 807 807 $ 919
Established Pharmaceutical Products      
Goodwill and Intangible Assets [Line Items]      
Goodwill 2,600 2,600  
Nutritional Products      
Goodwill and Intangible Assets [Line Items]      
Goodwill 286 286  
Diagnostic Products      
Goodwill and Intangible Assets [Line Items]      
Goodwill 3,500 3,500  
Medical Devices      
Goodwill and Intangible Assets [Line Items]      
Goodwill 15,900 15,900  
Impairment of indefinite-lived intangible assets $ 111 $ 111  
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring Plans - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2021
Dec. 31, 2021
Sep. 30, 2022
Dec. 31, 2021
COVID-19 Test Manufacturing Network Restructuring Plan        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges $ 499     $ 441
Inventory sold that was previously estimated to have no net realizable value   $ 181    
COVID-19 Test Manufacturing Network Restructuring Plan | Fixed Asset Write-Downs        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 80     80
COVID-19 Test Manufacturing Network Restructuring Plan | Inventory- Related Charges        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 248     248
COVID-19 Test Manufacturing Network Restructuring Plan | Other Exit Costs        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges $ 171     113
Reduction of restructuring estimate   $ 58    
Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges     $ 12 $ 68
Severance costs     12  
Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies | Cost of Products Sold        
Restructuring Cost and Reserve [Line Items]        
Severance costs     5  
Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies | Research and Development        
Restructuring Cost and Reserve [Line Items]        
Severance costs     2  
Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies | Selling, General and Administrative Expense        
Restructuring Cost and Reserve [Line Items]        
Severance costs     $ 5  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring Plans - Streamline of Operations and Improve Efficiencies (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2021
Sep. 30, 2022
Dec. 31, 2021
COVID-19 Test Manufacturing Network Restructuring Plan      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges recorded in 2021 $ 499   $ 441
Payments     (90)
Other non-cash     (328)
Restructuring Reserve [Roll Forward]      
Accrued balance at beginning of the period   $ 23  
Payments and other adjustments   (10)  
Accrued balance at end of the period   13 23
COVID-19 Test Manufacturing Network Restructuring Plan | Inventory- Related Charges      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges recorded in 2021 248   248
Payments     0
Other non-cash     (248)
Restructuring Reserve [Roll Forward]      
Accrued balance at beginning of the period   0  
Payments and other adjustments   0  
Accrued balance at end of the period   0 0
COVID-19 Test Manufacturing Network Restructuring Plan | Fixed Asset Write-Downs      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges recorded in 2021 80   80
Payments     0
Other non-cash     (80)
Restructuring Reserve [Roll Forward]      
Accrued balance at beginning of the period   0  
Payments and other adjustments   0  
Accrued balance at end of the period   0 0
COVID-19 Test Manufacturing Network Restructuring Plan | Other Exit Costs      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges recorded in 2021 $ 171   113
Payments     (90)
Other non-cash     0
Restructuring Reserve [Roll Forward]      
Accrued balance at beginning of the period   23  
Payments and other adjustments   (10)  
Accrued balance at end of the period   13 23
Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies      
Restructuring Cost and Reserve [Line Items]      
Restructuring charges recorded in 2021   12 68
Restructuring Reserve [Roll Forward]      
Accrued balance at beginning of the period   61  
Payments and other adjustments   (39) (7)
Accrued balance at end of the period   $ 34 $ 61
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Incentive Stock Program - Narrative (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2022
USD ($)
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Incentive stock program, shares reserved for future grants (in shares) 87,000,000
Total unrecognized compensation cost | $ $ 600
Total unrecognized compensation cost, recognition period 3 years
Share-based Payment Arrangement, Option  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Stock options granted during the period (in shares) 2,634,647
Restricted Stock Awards  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Restricted stock awards granted during the period (in shares) 514,205
Restricted Stock Units (RSUs)  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Restricted stock units granted during period (in shares) 5,427,697
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Incentive Stock Program - Options (Details) - Share-based Payment Arrangement, Option
$ / shares in Units, $ in Millions
 9 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Stock options outstanding, number of shares | shares 29,048,449
Exercisable options, number of shares | shares 23,310,464
Stock options outstanding, weighted-average remaining life 5 years 4 months 24 days
Exercisable options, weighted-average remaining life 4 years 7 months 6 days
Stock options outstanding, weighted-average exercise price (in dollars per share) | $ / shares $ 70.22
Exercisable options, weighted-average exercise price (in dollars per share) | $ / shares $ 59.69
Aggregate intrinsic value of options outstanding | $ $ 901
Aggregate intrinsic value of options exercisable | $ $ 890
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt and Lines of Credit (Details) - 2.55% Long-term Notes Due 2022
$ in Millions
Mar. 15, 2022
USD ($)
Debt Instrument [Line Items]  
Repayments of debt $ 750
Interest rate percentage 2.55%
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Net Investment Hedging | Designated as Hedging Instrument | Yen-denominated long-term debt          
Derivatives, Fair Value [Line Items]          
Debt instrument, term     5 years   5 years
Long-term debt $ 413   $ 413   $ 521
Foreign Exchange Forward          
Derivatives, Fair Value [Line Items]          
Gain (loss) recognized related to derivatives not designated as hedge (27) $ (18) 225 $ 15  
Foreign Exchange Forward | Not Designated as Hedging Instrument          
Derivatives, Fair Value [Line Items]          
Derivative, notional amount 10,300   10,300   12,200
Foreign Exchange Forward | Cash Flow Hedging | Designated as Hedging Instrument          
Derivatives, Fair Value [Line Items]          
Derivative, notional amount 7,900   $ 7,900   8,600
Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold     12 months    
Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold     18 months    
Interest Rate Swap | Fair Value Hedging | Designated as Hedging Instrument          
Derivatives, Fair Value [Line Items]          
Derivative, notional amount $ 2,900   $ 2,900   $ 2,900
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Derivatives, Fair Value [Line Items]    
Fair Value - Assets $ 908 $ 379
Fair Value - Liabilities 786 618
Designated as Hedging Instrument | Interest Rate Swap | Deferred income taxes and other assets | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 0 87
Designated as Hedging Instrument | Interest Rate Swap | Post-employment obligations, deferred income taxes and other long-term liabilities | Fair Value Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 166 0
Designated as Hedging Instrument | Foreign Exchange Forward | Prepaid expenses and other receivables    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 760 222
Designated as Hedging Instrument | Foreign Exchange Forward | Other accrued liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 66 65
Designated as Hedging Instrument | Debt | Long-term debt | Net Investment Hedging    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities 413 521
Not Designated as Hedging Instrument | Foreign Exchange Forward | Prepaid expenses and other receivables    
Derivatives, Fair Value [Line Items]    
Fair Value - Assets 148 70
Not Designated as Hedging Instrument | Foreign Exchange Forward | Other accrued liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value - Liabilities $ 141 $ 32
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details) - Designated as Hedging Instrument - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Foreign Exchange Forward | Cash Flow Hedging | Cost of products sold        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) Recognized in Other Comprehensive Income (loss) $ 350 $ 96 $ 442 $ 142
Income (expense) and Gain (loss) Reclassified into Income 79 (92) 149 (207)
Debt | Net Investment Hedging        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) Recognized in Other Comprehensive Income (loss) 24 4 108 41
Interest Rate Swap | Fair Value Hedging | Interest expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Income (expense) and Gain (loss) Reclassified into Income $ (85) $ (14) $ (253) $ (81)
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term Investment Securities: $ 764 $ 816
Equity securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term Investment Securities: 604 748
Carrying Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total Long-term Debt (16,414) (18,050)
Foreign currency forward exchange contracts, receivable position 908 292
Foreign currency forward exchange contracts, (payable) position (207) (97)
Interest rate hedge contracts, receivable position 0 87
Interest rate hedge contracts, (payable) position (166) 0
Carrying Value | Equity securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term Investment Securities: 604 748
Carrying Value | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term Investment Securities: 160 68
Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total Long-term Debt (15,821) (21,152)
Foreign currency forward exchange contracts, receivable position 908 292
Foreign currency forward exchange contracts, (payable) position (207) (97)
Interest rate hedge contracts, receivable position 0 87
Interest rate hedge contracts, (payable) position (166) 0
Fair Value | Equity securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term Investment Securities: 604 748
Fair Value | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term Investment Securities: $ 160 $ 68
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) - Fair Value, Recurring - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities $ 293 $ 402
Interest rate swap derivative financial instruments   87
Foreign currency forward exchange contracts 908 292
Total Assets 1,201 781
Fair value of hedged long-term debt 2,685 2,926
Interest rate swap derivative financial instruments 166  
Foreign currency forward exchange contracts 207 97
Contingent consideration related to business combinations 138 130
Total Liabilities 3,196 3,153
Quoted Prices in Active Markets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 293 402
Interest rate swap derivative financial instruments   0
Foreign currency forward exchange contracts 0 0
Total Assets 293 402
Fair value of hedged long-term debt 0 0
Interest rate swap derivative financial instruments 0  
Foreign currency forward exchange contracts 0 0
Contingent consideration related to business combinations 0 0
Total Liabilities 0 0
Significant Other Observable Inputs    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 0 0
Interest rate swap derivative financial instruments   87
Foreign currency forward exchange contracts 908 292
Total Assets 908 379
Fair value of hedged long-term debt 2,685 2,926
Interest rate swap derivative financial instruments 166  
Foreign currency forward exchange contracts 207 97
Contingent consideration related to business combinations 0 0
Total Liabilities 3,058 3,023
Significant Unobservable Inputs    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities 0 0
Interest rate swap derivative financial instruments   0
Foreign currency forward exchange contracts 0 0
Total Assets 0 0
Fair value of hedged long-term debt 0 0
Interest rate swap derivative financial instruments 0  
Foreign currency forward exchange contracts 0 0
Contingent consideration related to business combinations 138 130
Total Liabilities $ 138 $ 130
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Litigation and Environmental Matters (Details)
$ in Millions
Sep. 30, 2022
USD ($)
Loss Contingencies [Line Items]  
Maximum expected cleanup exposure for individual site $ 4
Maximum expected cleanup exposure in aggregate 10
Legal proceedings and environmental exposures  
Loss Contingencies [Line Items]  
Recorded accrual balance for legal proceedings and exposures 45
Legal proceedings and environmental exposures | Minimum  
Loss Contingencies [Line Items]  
Estimation of possible loss 40
Legal proceedings and environmental exposures | Maximum  
Loss Contingencies [Line Items]  
Estimation of possible loss $ 50
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Post-Employment Benefits (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Defined Benefit Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost - benefits earned during the period $ 92 $ 98 $ 282 $ 294
Interest cost on projected benefit obligations 74 62 225 186
Expected return on plan assets (231) (211) (701) (633)
Net amortization of:        
Actuarial loss, net 58 79 174 238
Prior service cost (credit) 0 0 1 1
Net cost (credit) (7) 28 (19) 86
Medical and Dental Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost - benefits earned during the period 13 14 38 42
Interest cost on projected benefit obligations 9 8 27 25
Expected return on plan assets (8) (6) (23) (20)
Net amortization of:        
Actuarial loss, net 2 7 8 21
Prior service cost (credit) (6) (7) (18) (21)
Net cost (credit) $ 10 $ 16 $ 32 $ 47
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Post-Employment Benefits - Narrative (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Defined Benefit Plans    
Defined Benefit Plan Disclosure [Line Items]    
Company contributions $ 362 $ 366
Medical and Dental Plans    
Defined Benefit Plan Disclosure [Line Items]    
Company contributions $ 28 $ 26
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Taxes on Earnings (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]    
Excess tax benefits associated with share-based compensation $ 36 $ 97
Tax expense from prior year tax positions 20  
Minimum    
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]    
Decrease reasonably possible in gross unrecognized tax benefits 75  
Maximum    
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]    
Decrease reasonably possible in gross unrecognized tax benefits $ 100  
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting Information [Line Items]        
Net Sales to External Customers $ 10,410 $ 10,928 $ 33,562 $ 31,607
Operating Earnings 1,770 2,546 7,058 6,047
Amortization of intangible assets (498) (520) (1,517) (1,533)
Earnings before taxes $ 1,758 $ 2,493 $ 6,986 $ 5,884
Annual share-based awards recognized in first quarter (as a percent) 45.00% 45.00% 45.00% 45.00%
Nutritional Products        
Segment Reporting Information [Line Items]        
Inventory recall expense $ 10   $ 172  
Medical Devices        
Segment Reporting Information [Line Items]        
Impairment of indefinite-lived intangible assets 111   111  
Operating Segments        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 10,407 $ 10,917 33,554 $ 31,558
Operating Earnings 2,791 3,536 10,284 9,874
Operating Segments | Established Pharmaceutical Products        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 1,326 1,265 3,696 3,515
Operating Earnings 331 293 831 682
Operating Segments | Nutritional Products        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 1,795 2,108 5,642 6,252
Operating Earnings 69 431 550 1,388
Operating Segments | Diagnostic Products        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 3,671 3,912 13,279 11,173
Operating Earnings 1,352 1,652 5,631 4,429
Operating Segments | Medical Devices        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 3,615 3,632 10,937 10,618
Operating Earnings 1,039 1,160 3,272 3,375
Other        
Segment Reporting Information [Line Items]        
Net Sales to External Customers 3 11 8 49
Segment Reconciling Items        
Segment Reporting Information [Line Items]        
Corporate functions and benefit plan costs (115) (204) (352) (450)
Net interest expense (86) (123) (309) (370)
Share-based compensation (123) (114) (570) (534)
Amortization of intangible assets (498) (520) (1,517) (1,533)
Other, net $ (211) $ (82) $ (550) $ (1,103)
XML 64 abt-20220930_htm.xml IDEA: XBRL DOCUMENT 0000001800 2022-01-01 2022-09-30 0000001800 exch:XCHI 2022-01-01 2022-09-30 0000001800 exch:XNYS 2022-01-01 2022-09-30 0000001800 2022-09-30 0000001800 2022-07-01 2022-09-30 0000001800 2021-07-01 2021-09-30 0000001800 2021-01-01 2021-09-30 0000001800 2021-12-31 0000001800 us-gaap:CommonStockMember 2022-06-30 0000001800 us-gaap:CommonStockMember 2021-06-30 0000001800 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000001800 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000001800 us-gaap:CommonStockMember 2022-09-30 0000001800 us-gaap:CommonStockMember 2021-09-30 0000001800 us-gaap:TreasuryStockCommonMember 2022-06-30 0000001800 us-gaap:TreasuryStockCommonMember 2021-06-30 0000001800 us-gaap:TreasuryStockCommonMember 2022-07-01 2022-09-30 0000001800 us-gaap:TreasuryStockCommonMember 2021-07-01 2021-09-30 0000001800 us-gaap:TreasuryStockCommonMember 2022-09-30 0000001800 us-gaap:TreasuryStockCommonMember 2021-09-30 0000001800 us-gaap:RetainedEarningsMember 2022-06-30 0000001800 us-gaap:RetainedEarningsMember 2021-06-30 0000001800 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000001800 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000001800 us-gaap:RetainedEarningsMember 2022-09-30 0000001800 us-gaap:RetainedEarningsMember 2021-09-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000001800 us-gaap:NoncontrollingInterestMember 2022-06-30 0000001800 us-gaap:NoncontrollingInterestMember 2021-06-30 0000001800 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0000001800 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0000001800 us-gaap:NoncontrollingInterestMember 2022-09-30 0000001800 us-gaap:NoncontrollingInterestMember 2021-09-30 0000001800 us-gaap:CommonStockMember 2021-12-31 0000001800 us-gaap:CommonStockMember 2020-12-31 0000001800 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000001800 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000001800 us-gaap:TreasuryStockCommonMember 2021-12-31 0000001800 us-gaap:TreasuryStockCommonMember 2020-12-31 0000001800 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-09-30 0000001800 us-gaap:TreasuryStockCommonMember 2021-01-01 2021-09-30 0000001800 us-gaap:RetainedEarningsMember 2021-12-31 0000001800 us-gaap:RetainedEarningsMember 2020-12-31 0000001800 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0000001800 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000001800 us-gaap:NoncontrollingInterestMember 2021-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2020-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-09-30 0000001800 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-09-30 0000001800 2020-12-31 0000001800 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:MolecularMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:MolecularMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:MolecularMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:MolecularMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:HeartFailureMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:HeartFailureMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:HeartFailureMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:VascularMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:VascularMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:VascularMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:VascularMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2021-07-01 2021-09-30 0000001800 us-gaap:CorporateNonSegmentMember country:US 2022-07-01 2022-09-30 0000001800 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0000001800 us-gaap:CorporateNonSegmentMember 2022-07-01 2022-09-30 0000001800 us-gaap:CorporateNonSegmentMember country:US 2021-07-01 2021-09-30 0000001800 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2021-07-01 2021-09-30 0000001800 us-gaap:CorporateNonSegmentMember 2021-07-01 2021-09-30 0000001800 country:US 2022-07-01 2022-09-30 0000001800 us-gaap:NonUsMember 2022-07-01 2022-09-30 0000001800 country:US 2021-07-01 2021-09-30 0000001800 us-gaap:NonUsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherEmergingMarketsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:EstablishedPharmaceuticalProductsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:NutritionalProductsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:NutritionalProductsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:MolecularMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:MolecularMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:MolecularMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:MolecularMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:DiagnosticProductsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:DiagnosticProductsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:HeartFailureMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:HeartFailureMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:HeartFailureMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:HeartFailureMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:VascularMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:VascularMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:VascularMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:VascularMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember country:US abt:MedicalDevicesMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember abt:MedicalDevicesMember 2021-01-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2021-01-01 2021-09-30 0000001800 us-gaap:CorporateNonSegmentMember country:US 2022-01-01 2022-09-30 0000001800 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0000001800 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-09-30 0000001800 us-gaap:CorporateNonSegmentMember country:US 2021-01-01 2021-09-30 0000001800 us-gaap:CorporateNonSegmentMember us-gaap:NonUsMember 2021-01-01 2021-09-30 0000001800 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-09-30 0000001800 country:US 2022-01-01 2022-09-30 0000001800 us-gaap:NonUsMember 2022-01-01 2022-09-30 0000001800 country:US 2021-01-01 2021-09-30 0000001800 us-gaap:NonUsMember 2021-01-01 2021-09-30 0000001800 abt:DiagnosticProductsMember 2022-09-30 0000001800 abt:MedicalDevicesMember 2022-09-30 0000001800 2022-10-01 2022-01-01 2022-09-30 0000001800 2022-10-01 2022-09-30 0000001800 2024-10-01 2022-01-01 2022-09-30 0000001800 2024-10-01 2022-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000001800 us-gaap:EquitySecuritiesMember 2022-09-30 0000001800 us-gaap:EquitySecuritiesMember 2021-12-31 0000001800 us-gaap:OtherInvestmentsMember 2022-09-30 0000001800 us-gaap:OtherInvestmentsMember 2021-12-31 0000001800 abt:StJudeMedicalIncMember us-gaap:EquitySecuritiesMember 2022-09-30 0000001800 abt:WalkVascularLLCMember 2021-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2021-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-06-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-06-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-07-01 2022-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2021-07-01 2021-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-07-01 2022-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-07-01 2021-09-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-07-01 2022-09-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-07-01 2021-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2021-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-09-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-09-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-09-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-09-30 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-09-30 0000001800 abt:EstablishedPharmaceuticalProductsMember 2022-09-30 0000001800 abt:NutritionalProductsMember 2022-09-30 0000001800 abt:MedicalDevicesMember 2022-07-01 2022-09-30 0000001800 abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2021-04-01 2021-06-30 0000001800 abt:FixedAssetWriteDownsMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2021-04-01 2021-06-30 0000001800 abt:InventoryRelatedChargesMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2021-04-01 2021-06-30 0000001800 abt:OtherExitCostsMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2021-04-01 2021-06-30 0000001800 abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2021-07-01 2021-12-31 0000001800 abt:OtherExitCostsMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2021-07-01 2021-12-31 0000001800 abt:InventoryRelatedChargesMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2021-01-01 2021-12-31 0000001800 abt:FixedAssetWriteDownsMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2021-01-01 2021-12-31 0000001800 abt:OtherExitCostsMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2021-01-01 2021-12-31 0000001800 abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2021-01-01 2021-12-31 0000001800 abt:InventoryRelatedChargesMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2021-12-31 0000001800 abt:FixedAssetWriteDownsMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2021-12-31 0000001800 abt:OtherExitCostsMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2021-12-31 0000001800 abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2021-12-31 0000001800 abt:InventoryRelatedChargesMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2022-01-01 2022-09-30 0000001800 abt:FixedAssetWriteDownsMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2022-01-01 2022-09-30 0000001800 abt:OtherExitCostsMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2022-01-01 2022-09-30 0000001800 abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2022-01-01 2022-09-30 0000001800 abt:InventoryRelatedChargesMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2022-09-30 0000001800 abt:FixedAssetWriteDownsMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2022-09-30 0000001800 abt:OtherExitCostsMember abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2022-09-30 0000001800 abt:COVID19TestManufacturingNetworkRestructuringPlanMember 2022-09-30 0000001800 abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember 2022-01-01 2022-09-30 0000001800 abt:CostOfGoodsAndServicesSoldMember abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember 2022-01-01 2022-09-30 0000001800 us-gaap:ResearchAndDevelopmentExpenseMember abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember 2022-01-01 2022-09-30 0000001800 us-gaap:SellingGeneralAndAdministrativeExpensesMember abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember 2022-01-01 2022-09-30 0000001800 abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember 2021-01-01 2021-12-31 0000001800 abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember 2021-12-31 0000001800 abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember 2022-09-30 0000001800 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0000001800 abt:RestrictedStockAwardsMember 2022-01-01 2022-09-30 0000001800 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000001800 us-gaap:EmployeeStockOptionMember 2022-09-30 0000001800 abt:A255LongTermNotesDue2022Member 2022-03-15 2022-03-15 0000001800 abt:A255LongTermNotesDue2022Member 2022-03-15 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2021-12-31 0000001800 abt:YenDenominatedLongTermDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-09-30 0000001800 abt:YenDenominatedLongTermDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-12-31 0000001800 abt:YenDenominatedLongTermDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000001800 abt:YenDenominatedLongTermDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000001800 abt:PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000001800 abt:PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000001800 abt:PrepaidExpensesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000001800 abt:PrepaidExpensesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000001800 abt:PrepaidExpensesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-09-30 0000001800 abt:PrepaidExpensesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2021-12-31 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-09-30 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2021-12-31 0000001800 us-gaap:LongTermDebtMember us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000001800 us-gaap:LongTermDebtMember us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0000001800 us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-07-01 2022-09-30 0000001800 us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-07-01 2021-09-30 0000001800 us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-09-30 0000001800 us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-07-01 2022-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-07-01 2021-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-01-01 2022-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-01-01 2021-09-30 0000001800 us-gaap:ForeignExchangeForwardMember 2022-07-01 2022-09-30 0000001800 us-gaap:ForeignExchangeForwardMember 2021-07-01 2021-09-30 0000001800 us-gaap:ForeignExchangeForwardMember 2022-01-01 2022-09-30 0000001800 us-gaap:ForeignExchangeForwardMember 2021-01-01 2021-09-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2022-09-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2022-09-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2021-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2021-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2022-09-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2022-09-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2021-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2021-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-09-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000001800 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000001800 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000001800 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000001800 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000001800 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000001800 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000001800 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000001800 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000001800 srt:MinimumMember abt:LegalProceedingsAndEnvironmentalExposuresMember 2022-09-30 0000001800 srt:MaximumMember abt:LegalProceedingsAndEnvironmentalExposuresMember 2022-09-30 0000001800 abt:LegalProceedingsAndEnvironmentalExposuresMember 2022-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000001800 srt:MinimumMember 2022-09-30 0000001800 srt:MaximumMember 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember 2022-07-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember 2021-07-01 2021-09-30 0000001800 us-gaap:OperatingSegmentsMember 2022-01-01 2022-09-30 0000001800 us-gaap:OperatingSegmentsMember 2021-01-01 2021-09-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2022-07-01 2022-09-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2021-07-01 2021-09-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2022-01-01 2022-09-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-09-30 0000001800 abt:NutritionalProductsMember 2022-07-01 2022-09-30 0000001800 abt:NutritionalProductsMember 2022-01-01 2022-09-30 0000001800 abt:MedicalDevicesMember 2022-01-01 2022-09-30 shares iso4217:USD iso4217:USD shares abt:segment pure 0000001800 --12-31 2022 Q3 false P12M 10-Q true 2022-09-30 false 1-2189 ABBOTT LABORATORIES IL 36-0698440 100 Abbott Park Road Abbott Park IL 60064-6400 224 667-6100 Common Shares, Without Par Value Common Shares, Without Par Value ABT ABT NYSE CHX Yes Yes Large Accelerated Filer false false false 1743573777 10410000000 10928000000 33562000000 31607000000 4629000000 4423000000 14549000000 13771000000 498000000 520000000 1517000000 1533000000 782000000 672000000 2163000000 1980000000 2731000000 2767000000 8275000000 8276000000 8640000000 8382000000 26504000000 25560000000 1770000000 2546000000 7058000000 6047000000 141000000 133000000 404000000 402000000 55000000 10000000 95000000 32000000 -19000000 -4000000 -16000000 -7000000 93000000 74000000 253000000 214000000 1758000000 2493000000 6986000000 5884000000 323000000 393000000 1086000000 802000000 1435000000 2100000000 5900000000 5082000000 0.82 1.18 3.35 2.85 0.81 1.17 3.32 2.83 1752968000 1774516000 1756209000 1776870000 10685000 14483000 11638000 14407000 1763653000 1788999000 1767847000 1791277000 5445000 2740000 2655000 2694000 1435000000 2100000000 5900000000 5082000000 -1008000000 -391000000 -1429000000 -762000000 -11000000 -36000000 -18000000 -54000000 -56000000 -78000000 -172000000 -211000000 50000000 96000000 50000000 98000000 213000000 139000000 186000000 257000000 -739000000 -174000000 -1071000000 -294000000 696000000 1926000000 4829000000 4788000000 -7268000000 -5839000000 2498000000 2670000000 321000000 135000000 -9445000000 -8374000000 9594000000 9799000000 313000000 450000000 520000000 519000000 6408000000 6487000000 3407000000 3081000000 726000000 694000000 1601000000 1382000000 5734000000 5157000000 2796000000 2346000000 24845000000 24239000000 764000000 816000000 19306000000 19364000000 10617000000 10405000000 8689000000 8959000000 10850000000 12739000000 22284000000 23231000000 5369000000 5212000000 72801000000 75196000000 4133000000 4408000000 1426000000 1625000000 5475000000 5181000000 820000000 831000000 394000000 306000000 1117000000 754000000 13365000000 13105000000 15297000000 17296000000 8255000000 8771000000 1 1 1000000 1000000 0 0 0 0 2400000000 2400000000 1985919440 1985273421 24560000000 24470000000 242345663 221191228 14555000000 11822000000 35115000000 31528000000 -9445000000 -8374000000 35675000000 35802000000 209000000 222000000 35884000000 36024000000 72801000000 75196000000 1985676735 1982553488 24429000000 24153000000 242705 550366 12000000 26000000 123000000 113000000 -4000000 -7000000 1985919440 1983103854 24560000000 24285000000 234456992 209736139 -13720000000 -10340000000 528436 545860 31000000 26000000 8417107 5626606 866000000 685000000 242345663 214816885 -14555000000 -10999000000 34487000000 29053000000 1435000000 2100000000 0.47 0.45 822000000 799000000 -15000000 -22000000 35115000000 30376000000 -8706000000 -9066000000 -739000000 -174000000 -9445000000 -9240000000 226000000 229000000 -17000000 -13000000 209000000 216000000 1985273421 1981156896 24470000000 24145000000 646019 1946958 36000000 91000000 572000000 536000000 -518000000 -487000000 1985919440 1983103854 24560000000 24285000000 221191228 209926622 -11822000000 -10042000000 4808575 5524291 261000000 265000000 25963010 10414554 2994000000 1222000000 242345663 214816885 -14555000000 -10999000000 31528000000 27627000000 5900000000 5082000000 1.41 1.35 2475000000 2403000000 -162000000 -70000000 35115000000 30376000000 -8374000000 -8946000000 -1071000000 -294000000 -9445000000 -9240000000 222000000 219000000 -13000000 -3000000 209000000 216000000 5900000000 5082000000 943000000 1122000000 1517000000 1533000000 570000000 534000000 409000000 194000000 1224000000 471000000 42000000 140000000 7255000000 7466000000 1167000000 1271000000 0 187000000 48000000 134000000 3000000 27000000 -14000000 -14000000 -1108000000 -1337000000 37000000 -7000000 7000000 0 753000000 45000000 3110000000 1325000000 126000000 173000000 2486000000 2404000000 -6179000000 -3608000000 -173000000 -57000000 -205000000 2464000000 9799000000 6838000000 9594000000 9302000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 1 — Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2021. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 2 — Revenue</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide detail by sales category:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,265 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,265 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,795 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,189 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,108 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,741 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,671 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,947 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,965 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,912 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,615 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,496 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,632 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,094 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,410 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,368 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,560 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,928 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,696 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,696 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,515 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,515 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,124 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,518 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,642 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,628 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,624 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,252 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,732 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,951 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,328 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,279 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,743 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,430 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,173 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">823 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,976 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,840 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,097 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,937 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,233 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,618 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,923 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,639 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,562 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,787 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,820 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,607 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $3.9 billion in the Diagnostics segment and approximately $433 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 60 percent of these remaining performance obligations over the next 24 months, approximately 16 percent over the subsequent 12 months and the remainder thereafter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Contract Assets and Liabilities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the contract liabilities during the period are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue from cash received during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized related to contract liability balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4 4 4 4 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide detail by sales category:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">936 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,265 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,265 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,795 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,189 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,108 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics — </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,741 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,671 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,947 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,965 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,912 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,615 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,496 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,136 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,632 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,094 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,410 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,368 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,560 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,928 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,696 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,696 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,515 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,515 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,124 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,518 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,642 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,628 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,624 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,252 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,082 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,732 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,910 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,951 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,328 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,279 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,743 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,430 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,173 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices —</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">823 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,976 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,840 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,097 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,937 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,385 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,233 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,618 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,923 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,639 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,562 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,787 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,820 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,607 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 993000000 993000000 0 936000000 936000000 0 333000000 333000000 0 329000000 329000000 0 1326000000 1326000000 0 1265000000 1265000000 357000000 470000000 827000000 586000000 514000000 1100000000 329000000 639000000 968000000 333000000 675000000 1008000000 686000000 1109000000 1795000000 919000000 1189000000 2108000000 281000000 938000000 1219000000 291000000 1001000000 1292000000 65000000 118000000 183000000 162000000 183000000 345000000 92000000 35000000 127000000 100000000 35000000 135000000 1303000000 839000000 2142000000 1394000000 746000000 2140000000 1741000000 1930000000 3671000000 1947000000 1965000000 3912000000 263000000 270000000 533000000 266000000 305000000 571000000 225000000 244000000 469000000 192000000 293000000 485000000 177000000 51000000 228000000 170000000 59000000 229000000 213000000 393000000 606000000 219000000 425000000 644000000 207000000 213000000 420000000 177000000 215000000 392000000 156000000 36000000 192000000 149000000 41000000 190000000 423000000 744000000 1167000000 323000000 798000000 1121000000 1664000000 1951000000 3615000000 1496000000 2136000000 3632000000 3000000 0 3000000 6000000 5000000 11000000 4094000000 6316000000 10410000000 4368000000 6560000000 10928000000 0 2826000000 2826000000 0 2672000000 2672000000 0 870000000 870000000 0 843000000 843000000 0 3696000000 3696000000 0 3515000000 3515000000 1108000000 1491000000 2599000000 1622000000 1637000000 3259000000 1016000000 2027000000 3043000000 1006000000 1987000000 2993000000 2124000000 3518000000 5642000000 2628000000 3624000000 6252000000 836000000 2788000000 3624000000 845000000 2935000000 3780000000 308000000 507000000 815000000 431000000 651000000 1082000000 284000000 110000000 394000000 289000000 112000000 401000000 5523000000 2923000000 8446000000 3178000000 2732000000 5910000000 6951000000 6328000000 13279000000 4743000000 6430000000 11173000000 775000000 830000000 1605000000 776000000 881000000 1657000000 667000000 773000000 1440000000 580000000 823000000 1403000000 523000000 167000000 690000000 483000000 167000000 650000000 650000000 1228000000 1878000000 684000000 1292000000 1976000000 604000000 667000000 1271000000 537000000 654000000 1191000000 456000000 112000000 568000000 460000000 124000000 584000000 1165000000 2320000000 3485000000 865000000 2292000000 3157000000 4840000000 6097000000 10937000000 4385000000 6233000000 10618000000 8000000 0 8000000 31000000 18000000 49000000 13923000000 19639000000 33562000000 11787000000 19820000000 31607000000 3900000000 433000000 0.60 P24M 0.16 P12M <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the contract liabilities during the period are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue from cash received during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized related to contract liability balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 520000000 466000000 508000000 478000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 3 — Supplemental Financial Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended September 30, 2022 and 2021 were $1.429 billion and $2.092 billion, respectively, and for the nine months ended September 30, 2022 and 2021 were $5.876 billion and $5.061 billion, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2022 includes $362 million of pension contributions and the payment of cash taxes of approximately $987 million. The first nine months of 2021 includes $366 million of pension contributions and the payment of cash taxes of approximately $990 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for the first nine months of 2022 related to the allowance for doubtful accounts as of September 30, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions/charges to income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged off and other deductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term investments as of September 30, 2022 and December 31, 2021 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Abbott’s long-term investments as of September 30, 2022 versus the balance as of December 31, 2021 primarily relates to a decrease in the value of investments held in a rabbi trust and the impact of equity method investment losses partially offset by an investment in long-term time deposits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s equity securities as of September 30, 2022, include $285 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott also holds certain investments as of September 30, 2022 with a carrying value of $228 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $83 million that do not have a readily determinable fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2021, Abbott acquired 100 percent of Walk Vascular, LLC (Walk Vascular), a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots. The purchase price, the allocation of acquired assets and liabilities, and the revenue and net income contributed by Walk Vascular since the date of acquisition are not material to Abbott’s condensed consolidated financial statements.</span></div> 1429000000 2092000000.000 5876000000 5061000000.000 362000000 987000000 366000000 990000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for the first nine months of 2022 related to the allowance for doubtful accounts as of September 30, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions/charges to income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged off and other deductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 313000000 10000000 49000000 274000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term investments as of September 30, 2022 and December 31, 2021 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 604000000 748000000 160000000 68000000 764000000 816000000 285000000 228000000 83000000 1 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 4 — Changes In Accumulated Other Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow<br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,260)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,230)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,554)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,738)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,268)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,621)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,498)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,660)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow <br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,859)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,670)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,871)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(762)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(762)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,268)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,621)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,498)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,660)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 11 for additional details.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow<br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,260)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,230)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,554)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,738)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,268)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,621)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,498)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,660)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow <br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,859)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,670)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,871)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(762)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(762)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,268)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,621)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,498)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,660)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -6260000000 -5230000000 -2554000000 -3738000000 108000000 -98000000 -1008000000 -391000000 15000000 16000000 278000000 70000000 0 0 -41000000 -62000000 65000000 -69000000 -1008000000 -391000000 56000000 78000000 213000000 139000000 -7268000000 -5621000000 -2498000000 -3660000000 321000000 41000000 -5839000000 -4859000000 -2670000000 -3871000000 135000000 -216000000 -1429000000 -762000000 45000000 26000000 289000000 138000000 0 0 -127000000 -185000000 103000000 -119000000 -1429000000 -762000000 172000000 211000000 186000000 257000000 -7268000000 -5621000000 -2498000000 -3660000000 321000000 41000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 5 — Goodwill and Intangible Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of goodwill reported was $22.3 billion at September 30, 2022 and $23.2 billion at December 31, 2021. Foreign currency translation adjustments decreased goodwill by approximately $946 million in the first nine months of 2022. The amount of goodwill related to reportable segments at September 30, 2022 was $2.6 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $15.9 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first nine months of 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross amount of amortizable intangible assets, primarily product rights and technology, was $26.9 billion and $27.7 billion as of September 30, 2022 and December 31, 2021, respectively. Accumulated amortization was $16.9 billion and $15.9 billion as of September 30, 2022 and December 31, 2021, respectively. Foreign currency translation adjustments decreased intangible assets by $250 million in the first nine months of 2022. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.1 billion in 2022, $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025 and $1.6 billion in 2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which relate to in-process R&amp;D (IPR&amp;D) acquired in a business combination, were approximately $807 million as of September 30, 2022 and $919 million as of December 31, 2021. In the third quarter of 2022, $111 million of impairment charges were recorded on the Research and development line of the Condensed Consolidated Statement of Earnings related to certain IPR&amp;D intangible assets associated with the Medical Devices business segment.</span></div> 22300000000 23200000000 -946000000 2600000000 286000000 3500000000 15900000000 0 26900000000 27700000000 16900000000 15900000000 -250000000 2100000000 2000000000 1900000000 1700000000 1600000000 807000000 919000000 111000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 6 — Restructuring Plans </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2021, Abbott management approved a restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with changes in the second quarter in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and the U.S. health authority’s updated guidance on testing for fully vaccinated individuals. In the second quarter of 2021, Abbott recorded charges of $499 million under this plan in Cost of products sold. The charge recognized in the second quarter of 2021 included fixed asset write-downs of $80 million, inventory-related charges of $248 million, and other exit costs, which included contract cancellations and employee-related costs of $171 million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second half of 2021, as the Delta and Omicron variants of COVID-19 spread and the number of new COVID-19 cases increased significantly, particularly in the U.S., demand for rapid COVID-19 tests increased significantly. As a result, in the second half of 2021, Abbott sold approximately $181 million of inventory that was previously estimated to have no net realizable value under the second quarter of 2021 restructuring action. In addition, the estimate of other exit costs was reduced by a net $58 million as Abbott fulfilled its purchase obligations under certain contracts for which a liability was recorded in the second quarter of 2021 or Abbott settled with the counterparty in the second half of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity related to this restructuring action and the status of the related accruals as of September 30, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inventory-<br/>Related<br/>Charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Asset<br/>Write-Downs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Exit<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in Abbott’s diagnostic, established pharmaceutical, and nutritional businesses. In 2022 and 2021, Abbott management approved plans to streamline operations in its medical devices segment. Abbott recorded employees-related severance and other charges of approximately $12 million in the first nine months of 2022 of which approximately $5 million was recorded in Cost of products sold, approximately $2 million was recorded in Research and development, and approximately $5 million was recorded in Selling, general and administrative expense.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for these restructurings:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 499000000 80000000 248000000 171000000 181000000 58000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity related to this restructuring action and the status of the related accruals as of September 30, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inventory-<br/>Related<br/>Charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Asset<br/>Write-Downs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Exit<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 248000000 80000000 113000000 441000000 0 0 90000000 90000000 248000000 80000000 0 328000000 0 0 23000000 23000000 0 0 10000000 10000000 0 0 13000000 13000000 12000000 5000000 2000000 5000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for these restructurings:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 68000000 7000000 61000000 12000000 39000000 34000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 7 — Incentive Stock Program</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first nine months of 2022, Abbott granted 2,634,647 stock options, 514,205 restricted stock awards and 5,427,697 restricted stock units under its incentive stock program. At September 30, 2022, approximately 87 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at September 30, 2022 is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,048,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,310,464 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total unrecognized share-based compensation cost at September 30, 2022 amounted to approximately $600 million which is expected to be recognized over the next three years.</span></div> 2634647 514205 5427697 87000000 Information regarding the number of options outstanding and exercisable at September 30, 2022 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,048,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,310,464 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 29048449 23310464 P5Y4M24D P4Y7M6D 70.22 59.69 901000000 890000000 600000000 P3Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 8 — Debt and Lines of Credit</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.</span></div> 750000000 0.0255 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 9 — Financial Instruments, Derivatives and Fair Value Measures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.9 billion at September 30, 2022 and $8.6 billion at December 31, 2021, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September 30, 2022 will be included in Cost of products sold at the time the products are sold, generally through the next <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNjQ1_49b14940-1788-44d4-b632-7d72eb48a1c0">twelve</span> to eighteen months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At September 30, 2022 and December 31, 2021, Abbott held the gross notional amounts of $10.3 billion and $12.2 billion, respectively, of such foreign currency forward exchange contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott has designated a yen-denominated, 5-year term loan of approximately $413 million and $521 million as of September 30, 2022 and December 31, 2021, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott is a party to interest rate hedge contracts with notional values totaling approximately $2.9 billion at September 30, 2022 and December 31, 2021 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of certain derivative financial instruments as of September 30, 2022 and December 31, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dec. 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dec. 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Post-employment obligations, deferred income taxes and other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">618 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September 30, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain (loss) Recognized in Other <br/>Comprehensive Income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (expense) and Gain (loss)<br/>Reclassified into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Losses of $27 million and $18 million were recognized in the three months ended September 30, 2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Gains of $225 million and $15 million were recognized in the nine months ended September 30, 2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values and fair values of certain financial instruments as of September 30, 2022 and December 31, 2021 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investment Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,414)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,821)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Forward Exchange Contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Hedge Contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the debt was determined based on significant other observable inputs, including current interest rates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding<br/>Balances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,153 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,023 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.</span></div> 7900000000 8600000000 P18M 10300000000 12200000000 P5Y P5Y 413000000 521000000 2900000000 2900000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of certain derivative financial instruments as of September 30, 2022 and December 31, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dec. 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dec. 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Post-employment obligations, deferred income taxes and other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">618 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> 0 87000000 166000000 0 760000000 222000000 66000000 65000000 148000000 70000000 141000000 32000000 413000000 521000000 908000000 379000000 786000000 618000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September 30, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain (loss) Recognized in Other <br/>Comprehensive Income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (expense) and Gain (loss)<br/>Reclassified into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr></table></div> 350000000 96000000 442000000 142000000 79000000 -92000000 149000000 -207000000 24000000 4000000 108000000 41000000 -85000000 -14000000 -253000000 -81000000 -27000000 -18000000 225000000 15000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values and fair values of certain financial instruments as of September 30, 2022 and December 31, 2021 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investment Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,414)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,821)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Forward Exchange Contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Hedge Contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 604000000 604000000 748000000 748000000 160000000 160000000 68000000 68000000 16414000000 15821000000 18050000000 21152000000 908000000 908000000 292000000 292000000 207000000 207000000 97000000 97000000 0 0 87000000 87000000 166000000 166000000 0 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding<br/>Balances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,153 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,023 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 293000000 293000000 0 0 908000000 0 908000000 0 1201000000 293000000 908000000 0 2685000000 0 2685000000 0 166000000 0 166000000 0 207000000 0 207000000 0 138000000 0 0 138000000 3196000000 0 3058000000 138000000 402000000 402000000 0 0 87000000 0 87000000 0 292000000 0 292000000 0 781000000 402000000 379000000 0 2926000000 0 2926000000 0 97000000 0 97000000 0 130000000 0 0 130000000 3153000000 0 3023000000 130000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 10 — Litigation and Environmental Matters</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.</span></div>Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $40 million to $50 million. The recorded accrual balance at September 30, 2022 for these proceedings and exposures was approximately $45 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations. 4000000 10000000 40000000 50000000 45000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 11 — Post-Employment Benefits</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three and nine months ended September 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical and Dental Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months <br/>Ended Sept. 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months <br/>Ended Sept. 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost - benefits earned during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost on projected benefit obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(633)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization of:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial loss, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first nine months of 2022 and 2021, $362 million and $366 million, respectively, were contributed to defined benefit plans. In the first nine months of 2022 and 2021, $28 million</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$26 million, respectively</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span> were contributed to the post-employment medical and dental plans. Net cost recognized for the three and nine months ended September 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical and Dental Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months <br/>Ended Sept. 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months <br/>Ended Sept. 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost - benefits earned during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost on projected benefit obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(633)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization of:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial loss, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 92000000 98000000 282000000 294000000 13000000 14000000 38000000 42000000 74000000 62000000 225000000 186000000 9000000 8000000 27000000 25000000 231000000 211000000 701000000 633000000 8000000 6000000 23000000 20000000 -58000000 -79000000 -174000000 -238000000 -2000000 -7000000 -8000000 -21000000 0 0 1000000 1000000 -6000000 -7000000 -18000000 -21000000 -7000000 28000000 -19000000 86000000 10000000 16000000 32000000 47000000 362000000 366000000 28000000 26000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 12 — Taxes on Earnings</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2022 and 2021, taxes on earnings include approximately $36 million and $97 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2022, taxes on earnings also include approximately $20 million of tax expense as the result of the resolution of various tax positions related to prior years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $75 million to $100 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.</span></div> 36000000 97000000 20000000 75000000 100000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 13 — Segment Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s reportable segments are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Established Pharmaceutical Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— International sales of a broad line of branded generic pharmaceutical products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nutritional Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Worldwide sales of a broad line of adult and pediatric nutritional products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diagnostic Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales to External Customers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended Sept. 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended Sept. 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Established Pharmaceutical Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutritional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Reportable Segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,917 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,558 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,536 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,928 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,562 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,607 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate functions and benefit plan costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (a) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,493 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,986 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,884 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. </span></div></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other, net for the three and nine months ended September 30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment and $111 million of charges related to the impairment of IPR&amp;D intangible assets. Other, net for the three and nine months ended September 30, 2022 and 2021 also includes integration costs associated with the acquisition of Alere and restructuring charges. Restructuring charges in 2021 include Abbott’s restructuring plan for its COVID-19 test manufacturing network. Other, net for the nine months ended September 30, 2021 also includes costs related to certain litigation.</span></div></td></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales to External Customers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended Sept. 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended Sept. 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Established Pharmaceutical Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutritional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,279 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,429 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Reportable Segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,917 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,558 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,536 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,928 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,562 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,607 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate functions and benefit plan costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (a) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,493 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,986 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,884 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. </span></div></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other, net for the three and nine months ended September 30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment and $111 million of charges related to the impairment of IPR&amp;D intangible assets. Other, net for the three and nine months ended September 30, 2022 and 2021 also includes integration costs associated with the acquisition of Alere and restructuring charges. Restructuring charges in 2021 include Abbott’s restructuring plan for its COVID-19 test manufacturing network. Other, net for the nine months ended September 30, 2021 also includes costs related to certain litigation.</span></div></td></tr></table></div> 1326000000 1265000000 3696000000 3515000000 331000000 293000000 831000000 682000000 1795000000 2108000000 5642000000 6252000000 69000000 431000000 550000000 1388000000 3671000000 3912000000 13279000000 11173000000 1352000000 1652000000 5631000000 4429000000 3615000000 3632000000 10937000000 10618000000 1039000000 1160000000 3272000000 3375000000 10407000000 10917000000 33554000000 31558000000 2791000000 3536000000 10284000000 9874000000 3000000 11000000 8000000 49000000 10410000000 10928000000 33562000000 31607000000 115000000 204000000 352000000 450000000 -86000000 -123000000 -309000000 -370000000 123000000 114000000 570000000 534000000 498000000 520000000 1517000000 1533000000 211000000 82000000 550000000 1103000000 1758000000 2493000000 6986000000 5884000000 0.45 0.45 0.45 0.45 10000000 172000000 111000000 111000000 EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
F2O(4W2M .OWWK?]WC](WB7W&1"F5HCW.*#A:50V1T\Q@1^+E;&:BJ= M7X>\#^"#P^"NG2:F8AG.(NH7@_H>H_FK%[U1\K:#^J"E/NA"I\3Y+@*U#I7- M;5@+:C-*(@(E$')5K^RZ%G0E4[6TYI 7G78.>W%;.'QGBLM-T]#\+QJP)&CI M. ;N8,VUL2 )&,I0#T3499"Z6C"+.5@5-+O) _.:5 06RQ7JMA(F<,(E=8<0 M5*_F%!9/<"YW.(L&9P)+)KR86;C$K 'K>; >O*1E'ZZUNN=N])@X*YC>..<4 M<)FI$J&7P*(,G((P)V(4?$E_-P;'4Q'O#=H2Z2\N^>$:L"50IBY[6G[8BW"H'Z\'IZ[ MSU0VG,I#X)I4D[-S2H,.3TC86%7YL;U2EAX!ORSHU47M+I!\K93=;9R!]AV? M_P-02P,$% @ QX!A582_L#6I P Z0D !D !X;"]W;W)K&ULS5;;CMLV$/V5@1($-F"L1,JZ>&,;\&YO*9IDD=VV#T4? M:&EL"9%(AZ36F[_OD-)ZO8#CMFD>^B(-+W/FG.'P,M\K_=%4B!8>VD::15!9 MN[L,0U-4V ISH78H:62C="LL-?4V-#N-HO1.;1/R*$K#5M0R6,Y]WXU>SE5G MFUKBC0;3M:W0GZ^P4?M%P(+'C@_UMK*N(US.=V*+MVA_W=UH:H4'E+)N49I: M2="X600K=GDU=?/]A-]JW)LC&YR2M5(?7>--N0@B1P@;+*Q#$/2[QVML&@=$ M-#X-F,$AI',\MA_1?_#:2]U::M%D =0XD9TC?V@]C_AH"=Q>(5J MC/_"OI^;\0"*SEC5#L[$H*UE_Q=Q_(L_Q.6+&<:[4' M[683FC.\5.]-Y&KI%N76:AJMR<\NKRLAMVB@EK JBJ[M&F&QA/>V0@W7JJ65 MKMP2W".\D85J$4:_*&/&,+H3ZP;->!Y:HN' PF((>=6'Y%\(.8.W2MK*P/>R MQ/*Y?TCT#QKXHX8K?A;P%G<7$$<3X!'G9_#B0TYBCQ=_ >]?)6("[VCKJ W< MB0?X8[4V5E.E_7DJ+7W4Z>FH;O==FITH M0U_>TFXNNP8=4W&D3WE]Q3-]]:"OZ?7)7I\5#VA.R3H;^+2LNPJA>*J\KR,T M]'I>$Q :01C8J(;.&7,)=Y5&?%9I0'5BL5T3?!S!=1_1P=/VILTK_4*N"ML) M78NF7UXJM*]$(61!/"S]W$AV- MES!*)SR-QLY*)CSN+3Y)DJFWXDD6Y\YB4>[:,VJ\_[LD%Y//,RII,\F0W2TBP: MI.69E\OBQ(^P]+\6RI13D%&6\C%,$^!4*/F,X/-O7RF,9\#RA()&,54E^YIJ M.6++,DHE8P1)G)/L6];+J:,X/+I^6]1;_\@PQ)>2U-_$A][#.V;57]]/T_M' MT%NAMZYP&MR0:W21)0'H_F'1-ZS:^)MSSI S'(\WQGYS%2+!?:VTFT05 MT?HRCEU182WUT+J:#H.4DFJ675V=^?]CPI\2-V^F#]V1AS#<_^%1.HL0+0H4%>03!GSM\ATIY();Q M;X<9]93><+>_1?\8?&=?%L+A.Z/^DB55DV@408E+T2BZ-IO?L?,G""R,UU*W7W'?G<..P2AYQB#K#+*@NR4**M\+$M.Q-1NP?C>C M^4YP-5BS.*G]I=R0Y57)=C2]1D>V*:BQ4J]@KH1V,+@5"X7N9!P3,_A]<=&A M7;5HV3-H%_#9:*HH!&$),Q\>DB0Z^'NVX%T<+U_WG4!+,-Q/X'/HTJU%@9.(D\2A MO<-H^O)%>IZ\/2!_V,L?'D*?WG!.EHU",$O.B%U7.J[@DNU<*HRC?1X%ZZ)Q)%EX>LT%LY$M0X[XD?;4U% M4=A&* :C'UX#1_EO;](Y_@M^\*@ M%C[<2X);0T+!XYLO*F%7Z!46QG*H F,R>@J_038<<3M*N$G3G-OA,(6Y>."7 MB!R\?#'*TNQM_QU<)"=MTS)JHU\7PE4P8!Q>&?%*OS?/>&KF/63&A>!D*_CT M"-YCT3F9OFIE/*7)SA]/EEW=6N[VPAEP MA/R5:.6*YB< M''G_Y^EQM!FDV4])\XOC(R ?[KWH>*?"U,A*?!UU_,(TFMIBT\_VI7K65JC_ MM[=U_C,[(KG**%RR:7+ZAB_8MK6S'9!9AWJU,,35+W0K_KN!UF_@]:4QM!UX M@OX/S/0[4$L#!!0 ( ,> 854!;45ZU ( "(& 9 >&PO=V]R:W-H M965TA=I.@$QPV'GA>6+<13L<5RW&)]ENUT+0*&Y:,ER@-5Q(TKB?! MK#.:)\[>&WSGN#-'>,VA< M.N#Q_,#^T<=.L:R8P1LE'GEFBTDP""##-=L(^Z!VGW ?3\_QI4H8_X5=;=M+ M D@WQJIR#R8%)9?UR)[W]W $&$2O .(](/:Z:T=>Y0=FV72LU0ZTLR8V-_&A M>C2)X](E96DUG7+"V>F=3%&ZBX&E5>D3++3*-2OA\BM;"317X]"2%V<;IGO& M>OY MNJ_Q%4SCNSFE,H,%>Z$79F&F-9,Y^OF/VYM&Z!R,Y;)C,L< M: !\1IURXW)X*HBS;DX'<2?K#E 78\ZT]V4+!+DI5ZB=IO]0 \P")=2BQQRR M"MP ,[!6@IJ$&<&7(X+;(_#GQI5Q2300#UM1,F@ER1#B;JO;B5I)/X%'7XN4 M7K9%3:V%!+O^Y-@$7R-;4H5+8,K$A9BZI2H5PUW!%]L.H0]_!,()3Z0^/ZK9$G?ON M9"!5&VGK$FYVFP8XJ^O^CWG=/>^9SDD("%P3-&I?]P+0=4>J%U95O@NLE*6> MXJ<%-7'4SH#.UTK9P\(Y:'X+T]]02P,$% @ QX!A50%^1*]/!P (!< M !D !X;"]W;W)K&ULK5A;;]LV%/XKA%<,-N#& MDGS/D@"YM&N =<[' M0YYLE/[;K(6P[#Z)4W/:65N;'0\&)ER+A)LCE8D47Y9*)]SB5:\&)M."1XXH MB0>!YTT&"9=IY^S$C=WHLQ.5VUBFXD8SDR<)UP\7(E:;TX[?J09NY6IM:6!P M=I+QE;@3]M?L1N-M4'.)9")2(U7*M%B>=L[]XXLIS7<3?I-B8QI]1I8LE/J; M7JZCTXY'"HE8A)8X<#R^B$L1Q\0(:OQ3\NS4(HFPV:^XOW>VPY8%-^)2Q;_+ MR*Y/.[,.B\22Y[&]59L/HK1G3/Q"%1O7LDTYU^NP,#=6)24Q-$AD6CSY?>F' MEQ $)4'@]"X$.2VON.5G)UIMF*;9X$8=9ZJCAG(RI46YLQI?)>CLV7N9\C24 M/&;7J;$ZA[^MZ;,KH>473@XSC*<1>\^E9K_Q.!?LH^ FUQCO?N:+6)C>R&3I^PR?X;)^=E=D'5-+ M9M>"\43EE4FQ"KE+$7P+A;9(901V[8%E'2)RZXLV\PXJT&[>9ZBR5#&@@7QJ M*:!*?)#_PK/?0E/U'B%B1+(2NX\1QO!)A.>J[4?^X&>MOV;DQ CQVQGZ2 M?"'C8NV[T""1<0RE3&]/"'@?.;X7/(9>@MTYF+WDF;/A59.O4RO@-D8U+4O&+4W&-&(5N;]CWW\T"/_@!O=D4$I9":TR6::@2 6_? ME]FMX&<-'L[4-\R?3!JT-\K8MR+)8O5 _F1J$SXM'>F/9FSJO52: M/_+9,#@@[DHL]@7Q0A0%:HI5ERF USIW([XX^<5PM3_5,!YR- M_"$;!S[[J?9Z1*+>L+DW0SN 4VQ6H_!SE]XK-!I4'/0QA69DVWC*B>F]#T'>(J1E[*I70Y9E5%0C82 M9[O60C@R.%:PI-A7!>VK3T$>H=P1^[$AY5:$:I7"D9%;+&?C=9MJ3:+/3G*Y MD?],PLO^DQ]VL=+I0[H\TRL5N;-8()<1%22^ D6>6V+DQMBC/*'4&(T" D'7 MNHSISH.>&W$O@3?ML4N (BU@IE64DP"CXNC;)'8P8B/F(V$!(_M)WI;T7[,S M$%WSWYV->ZSKC] $XR':F=_;,BY#X !<3&JXF+P8+D*N]0,EL].LR(VMIJ:Y MQ;^X CDH_>D*Y/^J\LH2@W%4BF:M-BD%@7V,;$>L32M(X("4 H*>T"-#0-[+ MA"(!TV !UL^][AA4\B=,$CKCVNU*P)9VIL@B(XMP+TY3.'_\!?B11)TZ+ /% M+JVTN:L0CMCY8J$LLD*)8H.E8 (+GCXPPA&,+K5*\"E]FPGM3IE4_2P>R "S MK^51FY,?.W@7:2XK1[HJ;O=MNU5>;U/S3@!3W%Y]S-[]D].>8NHAVCR]4=U. M1[.R+7 3Y;K[3V;T^ZPL/+(5XA"BZT_Z(Y=L_KB/1*;.K.^-/4H_O^^/ 3<5 MN%U6X/:^!+=W%;A=;DNDV[KZ8)DRTJ$C;?GT#^:!^W=O^ /-Z&VG%%!6MO.J MJ=/^EJ+H@T.O9V3MPQ**3?S:)**T[)7M/M$!>)G6\#)],;R4U:S;<1NU5U*< M7H&+MHF+=#] FRV\3:&!<[YL!9B#\K_ZB$/7"H;E!FHA"TL5:\AYPI+G#:C0 M95&>*-PMP3$.&/0-+GI\J'?1OYL\GW)K+&03UU]R14ARA\!$11)R2I5F_U%J MMJ=/,!_6[?:$4O5>LZU3@%=TS7Z1=N?U@:8?>'XMLBB&:W$-'RZ+_3%J'%O* M CKH3V;C'77W1QYOP\^?3.F@5=$W^Z]Q ;*WIFOV*66Q9K2@#L"A3%%V:A&[ M_0"1ML@-(M@0Q"<+64 YM!K.'B4GC958U@A!E$U]?S[9\N7N9DVQX1<7F/5H??U[ M7MQZ;J<7=\"PQ,T =^7 M"LA6OI" ^E+\[#]02P,$% @ QX!A53J^6A&= P . @ !D !X;"]W M;W)K&ULK5;?;QLW#/Y7B&O1Q4";NY,=_XIMP&DR MK \IC+K;'H8]R'>TK58GW22Y3OK7C]2=/0=PO3T,07B41'[Z2)&2)WOKOOHM M8H"G2AL_3;8AU.,T]<46*^FO;8V&5M;653+0T&U27SN4972J="JRK)]64IED M-HES"S>;V%W0RN#"@=]5E73/=ZCM?IKDR6'BD]IL T^DLTDM-[C$\&N]<#1* MCRBEJM!X90TX7$^3>3Z^Z[%]-/A-X=Z?Z,"1K*S]RH,/Y33)F!!J+ (C2/I\ MP_>H-0,1C;]:S.2X)3N>Z@?TGV/L%,M*>GQO]>^J#-MI,DR@Q+7?@O#J)U$)%WLU%D>2^#G$V< MW8-C:T)C)88:O8F<,GPHR^!H59%?F"VL#^\>JEK;9TIU@#LTN%;!P]5GN=+H M.Y,TT#9LG!8MY%T#*7X .8)':\+6PX,IL7SIGQ*](T=QX'@G+@(NL;Z&;O86 M1";$!;SN,>9NQ.M>B!G/A/S'?.6#HSKY\US0#6;O/";WSMC7LL!I0LWAT7W# M9/;F5=[/;B\P[AT9]RZASY;4B^5.(]@U%+:JK2'BGD=ABV"H=VMTRI:J@%43 M#9GY -2TT8*L57C^R5/E?*$IJEK:H#S:UEH:#]*44',YG.2F0L*4.JZ5-$'J M"Z=SB;H8ROE$?<26L,/";HSZ3N0.W,/6(48"AJ"@:FH+N;: *H-.F[0PB4-.F8;;ESRFQBY)>N])J(_G. M]3#H09](B1O(AWT8P1#$ &CT\%0W3@[#SID(1"FBY'KDRT=T\P[)G.4@8]GO M=DD.6>,5'HBL UPYLK(NJ.]Q2^J),_SF]!=W']!_/HP$&P8O_5Y'"\XDJ_F( M=8J>,IFQ8*W+.>X-X-S=D)[ F =>\4\T@V#J^#=PUMHKJEIYV=&Q ZVMKPV' &QQ_+,S^ M!E!+ P04 " #'@&%5YBVJ%>(% #H# &0 'AL+W=OGQ^'=M3T] M-KUOE);7EKF^;85].I>->3B9\,GFQ8U:K3V]F)X>=V(E;Z7_O;NV>)IN46K5 M2NV4T3F C)1E:>$ 2F>WDA MFX: 0./SB#G9FB3%W?4&_=?@.WQ9"",8AQV%(OZ.0C(J)('W8"BPO!1> MG!Y;\\ L20.-%L'5H UR2M.FW'J+KPIZ_O16KA!BSZ[TL,$4J8,[L6BD.SR> M>E@@N6DUHIT/:,EWT$KVSFB_=NRMKF7];_TIF&WI)1MZY\FS@+>R.V)I'+$D M3I)G\-*MNVG 2W_@[HWLC/5*K]B?9POG+9+CKWWN#FC9?C0JF->N$Y4\F: B MG+3W0S^]10'6?2.963(W\E8[V_2*:12M$]@J)G3- M4*A6!)^DL!JSV^?1\S;OUI(M38-2)9Q]5M?"L864FL'C3EA9XRMJJS*V%KJ2 M2%^_9AXP2GMIM6C"QUX'8IUI5*7 %RZ=+1;&^X@!KY:NLFH!++$P]S(*[BC' MM/$L!!90>^VLI(;/3?-$7V1'4KO6K-*5ZD)\NJY1^.I-X%89[4"E%J2Q5!J( M"DR=QPORV!VQ]XCM;8@M=-X^CKY-0M'7['HML#.5[+VJP._:FKJOO&,O&(_2 M9!;F9)9C3J-9.0MSSL-SRC$F98JQ".M9D;#WO;>*-GH7C$?S,F=)Q.."Y=$L M2]@L2G*,)JTH&!##&F$(ZCLIT3M.,%]"-4\!%J#A&T G&=)ZS M.^.A/Q0Y]3(VUKTCQ2P.^B6?(P91GFSD@@*3)61L4\8Q^0 M,Y:!,&<%R\J0&T/=O0B /!X695*$P$;Y+*$%7(.M"V/! YG%EKT.9]%0KPLD M[U(APQNAD9$.[ XXSP_901)G&!$'P:#H9ZD\TP^XD1VDAT4,WSG24JR M<4GC'+*WR CYBDZJ&J@MR8YM76S%.2<#.8D?Y"G69RVUPR^#((H3QH1>*0J= M<$X2M:PL2#HA'<2+SX3[(\QARVTI92#04R;QX M'&(8S7.*7!)E(1UG45E0JN91@3WX^Z=^P;VSKK/F4:%52?2$+&Y-@_Z)"QIYC0"$3CMZO;<[;$Z)P2!J9,-@OX5P-K2=4+8==^;J^N:E M:+LWE_]-NZ/_(3HD&/JF:)SY&BNJIY4=,GZH/I@T. >(Y_84$]7G7CFUJ8NS M!C48$*D4+?SO+6WOZ.<1>LZ>UY0T@<%H?#S[7OY2)'S^QGV#%?H!^:K Z>+# MQZO+5[QDGDJ_%;I?BHT@8D)7WKTQ^HG(?!N0(0@[.U5)=$]0;^#^*@3J:-^U M9KIS^\31N IW;()#&@T7T>W;[37^;+B]?A4?_@.\0[@4VF,CEU"-C^;YA-GA M7CT\>-.%NRR%S[1AN<9?$6E) -^7QOC- QG8_KDY_0=02P,$% @ QX!A M532%RQ^:! /!\ !D !X;"]W;W)K&ULS9EM M;]LV$,>_"J$50PHDD2@[SL-L W&D8066+HC7[471%[1TEHE*HD;2=C;LPX^4 M9%G*%"9>F2%O$DOB_7B\/WD$C^,MXU_%"D"BARS-Q<1925E,9D>J1)ZXH.)"X-,I2U_>\D9L1FCO3]@A2B*1&$/5O S>0IIJD_/BCACI-G]JP M_7M'_[$GO-):KB7/AH!B69)W*>[;]">H!G6E>Q%)1_D7;NJWG MH&@M),MJ8^5!1O/J/WFH ]$R&#QEX-<&_B,#WW_"8% ;#%[:P[ V&+ZTA[/: MH!RZ6XV]#%Q ))F..=LBKELKFOY11K^T5O&BN9XH<\G55ZKLY/0>-I"O 9V@ MCX1SHE5#1P%(0E/Q'KU#-$>W-$V5IF+L2M6A-G.C&CZKX/X3\ &Z9;E<"13F M,<0]]H'9_M)@[ZJ!-J/U=Z.=^4;@'(I3-/".D>_Y/OHT#]#1N_=(0**FONSQ M[^;E.&S !':]"K_9JT[P!LU4&93<@7FJ'*-[T!F(Y@FZ U[FJCP"],LBI0G1 MJ_\8A0^%2@00HU]IIMNQ)9JK3V))JO3P^6?%1A\D9.)+W[2J'!GV.Z)SYY4H M2 031R5' 7P#SO3[[_#(^Z%/0YNPP"8LM 3KJ#ELU!R:Z-./ZVP!7"O#H6!< MDD4*N\DBT-^&Z3>KP&7'K>HS1B[/?0>+^DQ]!2CYTX7C1Q MO##&\19B&I$4!;"A$?1&S0@X=#;;A 4V8:$E6$>%RT:%R[>2FRYMJFD3%MB$ MA99@'36QMS_?>/:S4\UL)XOA8/ H.YD[/C3D+^DRM-5E-Y:MLR)^)I:VUL8Q MFDO")5)G5D"?KQ^H^')5'G].L'?BX5Y-C+X=NERLT@*KM- 6K:NROU?9?RL9 ML/;$EJ8V:8%56FB+UM5T?W3'QK/D5 D8J=,<2: Z\9ES(H*=KI*A!:CV$4MR M^I=Z07-M0UE?-6=F=N)@.:T>W&O:12N_>J>CQ_GU-4[D>'\DQ^8S>;.<9+.< M1'LY59%'1TJ$K"R,O>]5P=R)/ZR->V-NM#TXYO_=D]"6)UTI]K4";"X6O/Y6 M-S1L=59K$%9I@55::(O657E?A\!OIA"!K58BK-("J[30%JVKZ;X:@KP__:ZUZCUH'WQ0YLKG98VNO,G6#?M-=9+8!\@R>A+4\J M*=S6;6 &/"FO806*V#J7U6U/\[:YZKTN+S@?O9_AJQO<\S[05\/E[>,>7]TK MWQ*>T%R@%):J*^_T7*5W7EW55@^2%>5=Y())R;+RYPI(#%PW4-^7C,G=@^Z@ MN3"?_@-02P,$% @ QX!A5?93YCX@%@ NQ8! !D !X;"]W;W)K&ULM9U1;^,XEH7_BI$=+&: W8Y)2I14FPK0'7(PC9G: M+52A9Q\6^^!*5(G1CIVUE:HI8'[\RDXW#_7C8O?3YJE>MW_S=;-]7#3M'[?W ME[NG;;VX.QSTN+J4\[F^?%PLUQ?75X???=Q>7VV>F]5R77__/7W\:B M_=^W^J9>K?:H]H7\WROUXFW0_8'^ST?ZGP]GWY[-E\6NOMFL_GMYUSR\OR@O M9G?UU\7SJOFT^?Z7^O6,\CWO=K/:'?X[^_ZJG5_,;I]WS>;Q]>#V%3PNUR__ M7_SC]9WP#F@Y_ 'R]0!)#\@Z#E"O!ZAS1\A>#\C.'2%_/>!PZICV_=KN=[/E,_-MOW;97M<<_VI_E:OG^O9O\\^ MU_?M#&AVLS^:NEDL5[L_M;_\[;.9_?$/?YK]8;97_\ MY>WK*+^\C"([1E&S#YMU\[";V?5=?<<<;]+'5XGC+]LS?CMM>3SM7V02^+E^ M^FFFYO\VDW,IF==S<_[A@CN=<:/;P:,';X9ZFP/JP%.=O$/E9Y_JI\VV6:[O M9[^N7WK0_J/\/W]KY;-?F_IQ][]-[IWNZ?%;?W^HNUDNWK[K;ZX M_M=_$7K^']S;CH09),R"8$&!LK<"92GZ]7^V_V+L%JN:_>2]'*H/A^[_7?AV M+>:9F%]=?O/?6$Y5R3)4F5BE5*YEJ+*,JCW1XDT5G&/^=HYY\AS_ZZG>+@Z3 M[]B(N)--,OI.-B3,(&$6! L*H=\*H2?L!AI9("3,(&$6! L*5+P5J!C>#5X. MS<-NX'TV7]Y83E4)HC*QJNT&>4:Z :,2>5[RW:!\.\SS\VBZ3B_Y/%]IQB49J TBZ*% ME9"N$G+"1O *1Y4)23-0FD71PC(Y]R:2WN-$,U#Q1W1>9;0?,"JEJ3M@5$)5 M4M&NP,A$47;X ^%,D$B[H* QS/XYZ[Q&2'-ZSSPDS4!I%D4+*^(LF\BG;!!0 M,P>E&2C-HFAAF9RA$TD[T(\0J46E5T:[ R4HYYQN#= Y)IAU2T!A2%PMI3M^9 M!Z49*,VB:&%%G*^38L(&(:&F#THS4)I%T<(R.=,GDVXEW2!>C_4_K72A@9'D MI#66A?Q\6'13KW;^KE9WK8-XN-V<_=\ MVQQLQ5D+$>FA>L]'Z+H7E&91M+!HSO7);,JV ;6"4)J!TBR*%I;)64&97KY+ MMXV4193=A2HH832#)1F4;2P3,Y0RO028+JCE*3*8]V'E=)'(PYW41Z/H;E&:@-(NBA9$I9S#5?,(NHJ"N$THS4)I%T<(R M.=>ITJN)R2[R>NR)ZQ).%5^7,"KFNH13=5Z7*&?:U G3]MQLEZ^=HK>52;-[ MST7H0AV49E&TL$I>S'+2G"4V:(E-6F*CEE,X3N4N,IBT9E9:Y[&@9SK"I$X:-;QG#O$MZK-YS$[J4!Z59%"VLFC.@ M:LIPIH):3"C-0&D610O+Y"RF&A'15'%B4I?114D.=RPJI*V$$;5&A*:W>!4VFLTX5DZ+\IBBRJ(8L2YLSOH,,\RWIH7I/3>AJ()1F4;2P:,YM9E/&2S.HO832 M#)1F4;2P3,Y>9B/BI1F7]531D^IL<)0NMS JK>CS[)939:IC 3=W[BQ/N[,/ M]=UAM=;4WY:W/:XWTMC>CZ]#5_V@-(NBA05RQC*?,FN:0ZTEE&:@-(NBA65R MUC(?D37-XPBHTH*NM+ J13T+HQ+S2I'+$LO*=%?P-'?>+$][L[A?#/,KZ6%Z M3TSH$B"49E&TL&#.9.93ADYSJ*V$T@R49E&TL$S>EC$C0J/85XE/4SO:0E=_8/2+(H6%LP9S'S* M@&D.M910FH'2+(H6ELE9RGQ$P#2/'VQW(9V'2KZ#WC(6N"D)I%D4+-^9R MOE-/F3G54/<)I1DHS:)H89F<^]0C,J2--?*B,J"7KMPHJY\2>'L7Y&V?R/;RC!SE'Y-?>8,@Y;0#TLE&:@-(NBA65R'K88$8G)>:TQ"8E MX9DYVU>D;=_(]C+,'J5?4^]Y"UW2A-(LBA96UUG?8LJD; %UL5":@=(LBA:6 MR;G88D12MF!V.HVO8AA1?!7#;*L:7\4PHLZK&.]+)M(&\&-]MUPTV^7MS'O0 M;]] 1NTUD!ZT]P2%+FY":19%"\OGO&TQ95ZV@)I6*,U :19%"\OD3&LQ(B]; MQ.G54D9?Y<+$9<4\NE:)53*OZ#,[C$JULHZO63&PVIZV%$>5THP+# MB$2TU8GE5%IVW,$MGE0HS4!I%D4+R^0\:CDB=ELR(5AJ66X842XRVEG8:"Y]2)!3:=7Q93.E,WAE MVN#]?/>\:J#6)SU@[^D)7;J$TBR*%I;..==RROAM"76H4)J!TBR*%I;)^X;' M$?';,@[#5O3[J&X84>M\Z"YKC$K-,T7;")/D]=>TPY-T_JY,^[L^;62@[8$N M7$)I!DJS*%KXI9C.Q593AF\KJ#N%T@R49E&TL$S.G58CPK<5L_TJO>EZPXGH M[5O#B,25REF[*FWM^G25898G_0)Z3U?H.B649E&TL)3.P593 M9FTKJ#.%T@R49E&TL$S.F58CLK95'(&-ONCJAA,5=%<#1B3G]):O952BZOI^ MSK#>4Q.Z% FE610M+)MSJM64 M@=H*ZDJA- .E610M+)-SI=6(0&T5!UR%I-N]WK"JBNYUP*B"O1I?WPU&590= MX93*F;HJ;>K.[2'#O$YZ\-Z3%;HL":59%"TLH[.MU919V@IJ2:$T Z59%"W\ M,L^Y\Z3[GP=WE>/!8;J>/L/,JNAM5L.I2AKGMZPJZ]@!H?5+WGFF7=VY?668 MVSDQ>M\9B\49+,["<*28TBOFE!':(QU6+*@YQ>(L#$>*I;QBC0C2'@\.'_*A M]VDY5=LIXA83RV111M\CSLDJU=ED,N]4TR;OPV95WSZO%MN1UN?$./UG*'0I M$HNS,!PI6^Z5;L48$9X\'!XVBI,E93J4R>BN% M4Y5T^SC+CC@O.X(I8EYX)YKV>Z>;R3 /=&+<_O,5ND*)Q5D8CI2Q],HX98[V M2(<5"VI9L3@+PY%B55ZQ1J1ICP<'=V#I=I*<2&AZBX53J2CSQJDR)3I:B_!, MGSBQ_>S)UC+0!J7'[3U;H3B#Q5D8CI31\[1BRASMD0XK%M:S0G$6AB/%\CRK M&)&F/1X'Y/I/W>>?UDH!5*C]U_RD)7+[$X"\.14GJ. M5DR9JSW28<7"^E8HSL)PI%B>;Q4CTK7'@X/;MC)J+VR\-FHO3'"VC-L+I^IX ML% (S_&)M.,[K[T,M4/0=4PLSF!Q%H8+2RD]5RNGS-<>Z:AB07$&B[,P'"F6 MYUWEB)3M\>#PZ4+:7LX0&4[4&G?:75A5USU/TG*7;I$HJS,!PIG^=EY939VB,=5BRL>X7B+ Q'BN6Y5SDB87L\.-QH/XLN M67A9=,W"R,HLB\(LC"RO1$=&3DC/_,FT^3N_KPPT1NGQ^T]=[)HF%&=A.%). MS^/**1.X1SJL6%@7"\59&(X4RW.Q$ME'JU LS)Z4\5PLCR7]-%# M3J9$T?&M8T)Z)E"F3>#Y?6:@0TJ/WW_J8IF973IG*/=)AQ<+: M62C.PG!AL91G9]689*[BTK0T[\^I"GJ98CB5K.(NP\D*U>62E.<%5=H+?GKX MT3P\SCXLUHO[^C!!_SD;^@VI)\;J/4FA.(/%61B.E,XSN&K2)*["VEDHSF!Q M%H8CQ?+LK!J3Q%5Q*C:/-IUD5444Q&54[7E$V3E6EG<\ARB4YP55V@N>UU$& M>J/TV/TG+7:=$XJS,!PII6=UU:3A7(4ULE"

(L#$>*Y1E9-2:UU\&>J+TV/VG+':=$XJS,!PII6=Q MU:3Y7(4UL%"

(L#$>*Y1E8-2:?JY@]:J.=XSB5HI9V6S24&Z& MM:]0G,'B+ Q'BN79UVQ,*#>+([*9CNZQ<*HRZB>,2F31%\#S,N_V,3E3S_ME M:>]W7D<9Z(C28_>?M-B%3BC.PG"DE)ZYS2:-Z698^PK%&2S.PG"D6)Y]S<;$ M=+,X-"ME%'1A5"+:M853:1W%_AE5WK5KB\@\YY>EG=]Y_66@(TJ/W7_*8AN8VFS2FFV'M*Q1GL#@+PY%B>?8U&Q/3S9C4;)9%_87;NC9ZK(A1 M%46T2,2H2MEY_>(YORSM_/Y2+[;-[,^+Y>KYD-,=[H:PBYA0G,'B+ P7EBWW MC&P^:28WQUI7*,Y@<1:&(\7RK&L^)I.;QQE9*:-'%%D5_58R3J6KR QQJKSK M6B7W7%^>=GVG>\E 'Y0>M_]TQ2YG0G$6AB-E]"QM/FDZ-\>:5BC.8'$6AB/% M\DQK/B:=F\=!65%$CRNRJBB;RZB8R!RCRLJNZY3<\WMYVN^=[BT#/5!ZW/[3 M%;N0"<59&(Z4T;.S^:2)W!QK6*$X@\59&(X4RS.L^9A$;LYD:*,M+#E1?-7" MA';C.RPG5.0L/:>7IYW>WQ>[XYXM@\U/>HC^\Q*[6@G%61B.5,SSK/FD<=L< MZU2A.(/%61@N+);VG*H>$[?5K.L,KVK-Y M.FWSDHUDH/-)#]E[KD)Q!HNS,!RIH&=@]:2I6XVUJ5"

(L#$>*Y=E4/29U MJYF]:$64B6-5T?4)H_+OEQS?$$;E[;= SM-S>#KM\))M9:#I20_9?Z9BURJA M. O#D0IZWE5/&K756(<*Q1DLSL)PI%B>0]5CHK::V>&6+NG<<*J,+C\;3B6B M.[^6EU5=CP=IS][IM+UK?WZ^;9ZW;>-XN;LRP@"EA^H_1[&+DU"%(Y3S+ MJB?-UFJL6X7B#!9G83A2+,^MZC'96LUL12NC;"VC4G%2A5$)21\BLJQ,5%WI MVL*S>D7:ZIW54 8:H?30O>P. O#D4IZ5K:8-&Q;8%TK%&>P. O#D6)Y MKK48$[8MXN2KI+O6WG"J:*'(<"H]C[:48U1YU_>^B\(S?$7:\)W57@8:HO30 M_6/WO-T\;NZ>5R_3<(0;2H_4?X)BERFA. O#D<)Y M/K:8-%=;8*TK%&>P. O#D6)YUK48DZLMF)UMX_UO65645V%4N8[NKG"JSKNV MA>?ZBE.N[W0W&6J%L.N74)S!XBP,%Q:R]$QM.6G2ML3Z5BC.8'$6AB/%\GQK M.29I6S*[T>;18C.GRJ(U(4:5499E5;HK:5MZEJ\\9?E.=Y>!3B@](L#$>*Y=G6G]!\KIS_V 7E!ZG_^3$KEM"<1:&(V7S M[&LY:;*VQ%I6*,Y@<1:&(\7R+&LY)EE;,DG7*!![P\MDW$V836RCC10L*Q.= M>\:5GN,KTX[O=#\9Z(/2X_:?LMAE3"C.PG"DC)ZA+2<-W998TPK%&2S.PG!A ML2K/M%9C0K=5G(#-Z),\-YQ*497A5&VOBKH+(RMUUS?#5Y[AJ]*&[W1S&6B# MTN/VGJ]0G,'B+ Q'RNCYV6K2X&V%]:Q0G,'B+ Q'BN5YUFI,\/;U8.U]THMX M:P1.5951U_?U*O5;G:[>5XW^YGI M_7:VK;_NWXAW/\N+R^CWOXAW-X+YO1'O[.'WEPY_??6TN*\_++;WR_5NMJJ_ MMD/-?]HO86V7]P]O?V@V3VT-+F9?-DVS>3S\^% O[NKM7M#^_=?-ICG^83_ M]\WV]\/I7/\_4$L#!!0 ( ,> 856+P""KH ( &8& 9 >&PO=V]R M:W-H965T._LNDYW2CZ9$M/!4"6FF06EM M/0Y#DY=8,7.A:I1TLE*Z8I:6>AV:6B,KO%,EPCB*DK!B7 ;9Q._-=391&RNX MQ+D&LZDJII]G*-1N&EP&AXU[OBZMVPBS2 52L.5!(VK M:7!].9ZESMX;?.>X,T=S<)$LE7ITBR_%-(B<(!286X? :-CB#0KA@$C&SSUF MT%(ZQ^/Y ?V3CYUB63*#-TK\X(4MI\%5 6NV$;8>[7[C/MX1@XO5\+X+^P: MVS0.(-\8JZJ],RFHN&Q&]K3/PY%#_)I#O'>(O>Z&R*N\999E$ZUVH)TUH;F) M#]5[DS@NW:4LK*933GXVN\ .V@P-/.[@%=PV(T=I&'?% MV\ ,NV%<<8U-S7* =M;RC7MX'B4Q++*@^FW>TTJJ"G)F2=G*D@BN@ MV&@GC)X7U*BY*KJT-32C(VW#).G6EK3:DEYMAZ=-0M1:\E]>I6"61JL@/URK MV%_K^M-67]NJCA_^?"TM?7-@P_9NF=_PQ;SKP'=/TB@P(7)%K=)%2O+KI:LW"JMIWDJ6RU)?\M*0? M 6IG0.QAX0C:7TOV&U!+ P04 " #'@&%5_,MQH<8$ "9&0 &0 M 'AL+W=O4%-FR92W>B'RQ*>KN.=YSQY>C MQGLNOLLM(0H]Q2R1$VNK5'IGVS+QL64J"(YRI9C9 MGN/T[1C3Q)J.\[Z%F(YYIAA-R$(@F<4Q%L\SPOA^8KG62\=GNMDJW6%/QRG> MD"517]*%@">[0HEH3!))>8($64^LC^Y=X/:U0B[QE9*]/&HC[$6$D5!H"P]^.S EC&@G&\:,$M2J;6O&X_8)^GSL/SJRP)'/.OM%(;2?6 MT$(16>.,J<]\_QLI'>IIO) SF?^B?2GK6"C,I.)QJ0PCB&E2_..GDH@C!]4H7M!H5,J=%YKH5LJ=%]KH5\Y<3Y6>#H6?(^$E@8TW M^T1ARN0'Z/VR]-'[=Q_0.T03]$@9 V$YMA6,2F/;83F"63$"[\((.NB1)VHK M49!$)&K0]]OU1RWZ-K!14>*]4#+S6@&7)+U%'><&>8[G-8QG_GIUM\F=_V<] M^,_6:V1TJOSHY'B="WAS#JPFDD1HCN46WR12'9&+!>B>)V!%K^O-/;M_YM2D")L%\DV"!(;!: MK+I5K+IMZ--/L*\0+!*:;"3"C/$0XA0AQ5'(XQAFLMQBL-H4G0*XGP/KO64W M=;O>:&SOCED_%_*L-!ORX4- @Y?;<2JGG?J[SOM7J_P,\Z)Q%? MHU"GJL)/S;ZVPER;B2;!_ *L=T3+:#@XH:YW1MUHY#0SUZ^8Z[][P)&]:K5_+T2L,!H8,UL@< M5&0.7D/F@478T('73"%]CJ/L&8XQB@C8RO&*$;3&5%QF=W#F[+!S0F[K:*XE M]]_M!8;LU;@=5MP.6[E=JEOT>Q81]$@B&L(QY6]4TBU)F FJ:/.,;T6]=L:; M!/--@@6&P&JA&56A&;W-.6%D,E8FP7R38($AL%JL7.=PZ'?:)U(U7?39/&Y02D2H[RHP:#58)W/0SWHMA>$/EE#3X1F)(&60@N&+]S0M.)< MS9U)--\H6F *K1Z10XWJ]MYH33):Q1I%\XVB!:;0ZA$[U,9N>W&\*"_%0YXH M05>9NGC+:;+,G1M%\TNTX[-:I^^='IR:A/HG:Y!]=-4<$[')[_@EL),EJKA5 MK'JK[P@?\]OSD_Z9>S=W&_I]_=TAO]H^P!#]FG/U\J -5%]CIO\ 4$L#!!0 ( ,> M8547B0\0E@( %L& 9 >&PO=V]R:W-H965TYK5EB(&E6K \%@@;=GA6;CH7*DB?)2??WHR3'RU;7 M?;%NY.$YE$C/CU(]ZP+ D)>2"[T("F.J61CJM("2ZFM9@<"37*J2&ERJ?:@K M!31S3B4/XRB:A"5E(DCF;F^CDKFL#6<"-HKHNBRI^KT"+H^+8!"<-A[9OC!V M(TSF%=W#%LQ3M5&X"EN4C)4@-)."*,@7P7(P6TVMO3/XP>"HS^;$*ME)^6P7 M]]DBB"PAX) :BT!Q., M<&Z!D,:O!C-H0UK'\_D)_*GDVGW)L;&- I+6VLBR<48&)1-^I"]-'LX ($=\E:UCN3UYPLTU36PFARN09#&=>?R 5A M@CPPSM%1ST.##&V<,&W8K#R;^ TV-^1!"E-H\DUDD/WK'Z*R5EY\DK>*>P&W M4%V38?29Q%$?.K!';9I&SK.N.,V[K@W[D;) [,%K,.TH&H/FAB);R2592<%CS8^HS"(NAE,6@:37@;+ MTK]1'SXC,L\)%3B: A36;U:[]M#Y6">OV%R-;KKI3%LZTUXZ^+#?N87IJUN( MIZ/_@H9G!5\"ZK)M#35:J;[VV]VV 856E MXG2CM ( "@* 9 >&PO=V]R:W-H965TVPG1 D-U1#A MI;6=>T[..;Y)'&ZYN),)@$(/*65RZB1*92>N*^,$4BR/>09,7UEQD6*EIV+M MRDP 7EI02EW?\P(WQ80Y46C7KD04\EQ1PN!*()FG*1:/IT#Y=NKTG.>%:[). ME%EPHS##:UB NLFNA)ZY%E4MS3 ^OB9_ ?@EP/]?0+\$]*W10IFU-<<*1Z'@6R1,M68S YN-16LWA)E=7"BAKQ*- M4]$BSS(*>EL4INB,,,QBHD<7K&@0D_17/=N 5*9(HL,Y*$RH/-+K-XLY.CPX M0@>(,'1)*-7E,G25UF78W;C4<%IH\%_3 -DQZGM?D._Y?@M\MA\^AUC#>Q;> M:\)=G485B5]%XEN^_JN1V(9&?%4SCLXY71*VENCO3UV/+A2D\E^;UX)\T$YN M'LH3F>$8IHY^ZB2(#3C1YT^]P/O6YKPCLD8._2J'_C[VJ+;K;3X+<&#!YEVQ MB4;!('0W=?F[->->4-4T5 TJ58.]JG[5V^)&]..PRAX[(&CD$50[!>WJQ ]K?19X+WMQMV8T&+?WXJA2-=JKZI=* M0+3IV0M[:^X=D344__37;><_J^+_IOMR9X MV7YN[3MNSE"76*P)DXC"2H.\XY'N7E&<2XJ)XIG]M-]RI0\*=ICHHQP(4Z"O MKSA7SQ-S6J@.A]$34$L#!!0 ( ,> 855=]6!4'P8 '$D 9 >&PO M=V]R:W-H965T4K M0@1X*O*27XU60JPOQF.>KDB!^3E=DU)>65!68"$/V7+,UXS@>3VHR,?(_[6DHZW-:N#N[V?V=[7STIE[S$E$\W^R MN5A=C<(1F),%WN3B,WU\3UJ'O(HOI3FO_X+'%NN,0+KA@A;M8#F#(BN;__BI M#<3. ,FC'X#: 4@=,-DSP&T'N,=:F+0#)L=:\-H!M>OCQO';)Z"-@ M%5JR53_JZ->C9;RRLBJ4.\'DU4R.$[-HAH->%71?,SR7)8 MOQP+.;_*RCAMYW+3S 7MF8L+/M)2K#A(RCF9:\;'YO%3P_BQC,LV..@Y.#?( M2'A'UN? ==X"Y""DF4]T_'"H<^?[K"@E.L=73R?%?B):(NC,3_1FZ\6S N^QBFY&DE+G+ ',IK]^@OT MG=]TF;%)%MLD2RR1]7(XV>9P8F*?W9!E5I99N:SR(1,'UH1E5'>KW1B)3LV& M3;*X(?-KLFH??)BY7NC(.^1A-\R63/;"[&W#[!G#_.G0/:$+N#=PZRQPIWVO M(@T(!I,^*&Y 7@_D!% )D(8*33NJGN/^UG'?Z+A<> ]7EC^8GNOY@:=X:C1T M:LD<93*Q9+(7N6 ;N< 8N:A94*M*D0)(RIL21!O&2)E^ W\Q7/+JHA16[>Y[ M/?]7:@,IV(1V*37:.O7FM4D6VR1++)'U$A9N$Q;^W.TPM)E#FV2Q3;+$$EDO MA]-M#J>VML/I<$WUD>\HBY8&Y2%70<4Z5*@N]8D&-0F]J7Z!ADZG]YWOVYO M/9'])Y%=8)ICSK-%EM9+CU[0.[J]Q@F5N.A@[E39D6(MV02I@='! A_M"0/_-7 /!\-'#Z*+3G(UO>X MZPZ@N3WX4^Y,UZG88);AO)$:1"X(6 ;B5@: @3NY &>IS']$N6BO1(S,,[T, M,9L[=0^SRA9;94MLL?43U_4;T/NY8@0:&YZ3,VF3+;;*EMABZV>R:Z"@N8,Z M09+ 85=SACQOHBX]&I@;N*&Z].C8_&"PT>C8PF#?TM.U/]#<_UB6)<%@EE!M M,'487PW*$#-1NT8-!OE[PM$U%]"H>W^,& F'SD U*$.,C]2@##$0!6I4-*#0 MVQ.63J]#LV!_F209*FG/5_T>8H+!'3+$P$!][*0!(;CG[D"=:$=FT7Z4%$$: M78PF4U6*Z&"NK[8R\7%LR4&VOL>=&D=F-;[S/.1WG)6\4R.T!+&,P4-S\4/) M!=O4#T+D:9XMR_K.P!Q$F*_ NUP:?D_FU>98B96Z@+3!,T[GU W.*EMLE2VQ MQ=9/;-=5(/1SI0HR=C4G9](F6VR5+;'%UL]DUQ\AA, M76]B'9.K;LDZ)@3W;,JH:X^0N3VRJU%:8[V=0MUS(@U(E62QCBA4>V0-".YH MP'Y$NKX#F5]T_ B9@C2O+WQ5O&E _E2-B_8]B*L&9HB"<,]3-M3)>&26\2\2 M*FBHK1%T5<^'(*@^.XQUH-!7/=>8\X(]GG="'IF%_'%2)1B^PU,?AD0:D*I7 MXV.($C-1X^=XYQ.*@K!E_>T*EQF4]=V\(]^>W7X?RH$+>J?*X+GA%4 M>7U!J7@^J QLOS*:_0]02P,$% @ QX!A5?.[_SR.!0 &"( !D !X M;"]W;W)K&ULM5I=;]LV%/TKA%<4+=!&$OW=.@:2 ML-T"+$/0H-O#L =&HFVN$NF25)SNUX^4%,FR&$9QF9=$LNX]O/>0O#RDM-AQ M\4UN"%'@/DN9/!ULE-I^" (9;TB&Y0G?$J:?K+C(L-*W8AW(K2 X*9RR-(!A M. DR3-E@N2A^NQ;+!<]52AFY%D#F68;%CW.2\MWI(!H\_/"%KC?*_! L%UN\ M)C=$?=U>"WT7U"@)S0B3E#,@R.ITAB8BD)%8& NM_=^2"I*E!TG%\KT '=9O&#V0 D9(7S5'WAN]](E=#8X,4\E<5?L*MLPP&($!8X>5"\!T0QEJCF8N"S,); MIT^9Z?<;)?13JOW4\E?.DQU-4X!9 BZ9PFQ-;U,"SJ0D2H(WB"A,4_D6O =? M;Q!X\^HM> 4H U?:1_>;7 1*1V&P@KAJ\;QL$3[2XA!<<:8V$GQB"4DL_A=N M_[G#/]#9UQ3 !PK.H1/PAFQ/P#!\!V (H2V>GW-';G=$8NT>%>Z1(YMAW:'# M F]X7(?^_;NV!Y>*9/(?6]^5X",[N"E"'^06Q^1TH*N,).*.#):O?XDFX4<; M<3[!D">P%JFCFM21"[TFU<98Z3DI/$V5O5M""&>C17"W3T4O*V2Q&L)A5%NU M@A_7P8^=P>L1IE<$2YL];E#I00;[V4^'TT.V/'48(O$24WBQ$GB6<9SI@!?Z<4NR8LU M2YJ[FE!!#&ML;5BEV193\2AQSI:>2]RD0UQX0)NGYEJT36O:INZ)([B4 -?D MZ2NAZ'_85"3:%"=<%"<;5]-.>G R#P]2O.AEA2Q6T^F>52O#69WAS#TPXCC/ MV2T\<*N8,_EIQ&OT9N ?M3Y$RL MY(PL*U*7G#Y6R!W\L>0T^CAR"^1+O9%<4485>9_2.\U1=Y4KU)U^8L0=>[\5 M/"9:UWQYC;/M1P1P_#VGHG $&-SF4C>@'\<\NZ6LH-C*8%?SSL+I(8$]C%!E MM+]OF$=S^ZH?-8HW/6:T3J-RHQ.[WF"1Z1[(%8WUZ+D6W(A@^^[?J[SU MBH9\H;49;<1P-'W)O7GDU-K/9M8G&O*%UF:V$>&16X6[-NA15Q5#2Z7J8X7< M81R;9J/$([<4_R-7@IIZ\M0<]"JIO:(A7VCML[Y&?<@]"2/JY-%GVC( M%UJ;V4:Z0[=T=\U!:)'7LX/SG8L^1L@=Q+%)-A( M/4Q\HB%?:&T&&YT.7_2 &GH]H?:*AGRAM9EM1#X\_I0:=H7X<-Q9!'M9(7<8 MQZ;9R'7HENM7)"E$*")W5,MP:[9>SZ:]HB%?:&WV&E4/)R\Z_;RJ>Z]HR!=: MF]E&W<,GSKI=TZ][]MP^F:WXZ&6&W($;DP# M]<<@R_\!4$L#!!0 ( ,> 856(22/Y]P4 !PP 9 >&PO=V]R:W-H M965T< M&_28I4)?-A;&+-]%D9XL>,;T6[GDPAZ9294Q8S?5/-)+Q=DT#\K2"#>;W2AC MB6@,!_F^.S4:R$3>>=MPG\X5Q.Z+A8,GF?,S- MI^6=LEM129DF&1MEH MNA'QE$^,0S#[9\U'/$T=R8[CKP+:*/MT@;N?G^CO\Y.W)_/ -!_)]$LR-8O+ M1J^!IGS&5JFYEYM?>'%"'<>;R%3GO]&F:-MLH,E*&YD5P78$62*V?]ECD8B= M ,NI#\!% 'YI0*L(:+TTH%T$M/<#N@<".D5 ?NK1]MSSQ!%FV'"@Y 8IU]K2 MW(<\^WFTS536R<&=YS;=1J8E8J$7-TES*AT3GZP)1B3D'TFG## MDE2_L7L_C0EZ_>H->H42@6Z3-+5*ZT%D[# <+)H475YON\0'NFRA6RG,0B,J MIGQ:$S\*QW>_%T_"\?WOQ=-P?(P#@,CFOQ0!/XEPC8/$7U?B+6HUSQ!NXK@N M(>%PPB\=UZ?C/O7O):)579"OGM0_P1A\_WY#SN(]^MY;/]5) M DCD# *!//$:I=BM7-ZZT7E8R2M8DQ,G3ZN(_3';[8]NC$\TW_6*=2&5 @2 M1B!A% CF*=0I%>H$;R=?H+];#=[P^B]6Z*@UT=FV)( M&*T9?3LN1^]EKEMFKAO,W(U8?G7_)X]6JRNMK41?5&+X.9&;^F>8X B.50<21B!A% CF MR=@K9>R=?<'D_SN65T.._A41Q[$X#2""B-0M%\/7=LET8*V6ZWBN'6@6E4./0Y;]'L^76V_<) SZ[EW MD_EDS6NS"6J]X^?>N[,WD1#0'BD4S<]ZY;[CL/VNJ?]N[?<,V4:<9:ZYT^/C MDKLO$:30>?&YR99*VN)#9[-DDG!A?^HO=5#G#4HCH#0*1?-EK-QW?%+['8/Z M;U : :51*)JO4^7!8R 3'N8T: MC65:]QWM=7A01XL&ZJA!:12*YLM;.6J,3SE-8$C3.P*E$5 :A:+Y.E7.'8>= M^TL*':C_!J61@K9;Z#K[=>X4IAI7IAH'S2!LG7.W#U.31=Z&6.E2NK22H.L!H#0*1?-%K]8#\$G7 S#H>@ HC8#2*!3-UZE:#\#A]8"7 M5#_0E0!0&L'/7?ZS!SV@#K<)CG;>CLZXFN>OI6N;O)4PVQ>ER[WEJ^]7^0O? M4=5\^][\+5/SQ%:[E,]L://MA:WA:OLJ^G;#R&7^KO6#-$9F^<<%9U.N7 -[ M?":E>=IP'93_$##\%U!+ P04 " #'@&%5;@&G0=@& ">-P &0 'AL M+W=OOMVKM2D.3PHR/< M);B]9;>LN61M7^SV0C$B>+4M9HN0W.V/GVP<"V'S@(AXT0:#GN]C?7DD?Y#L MT4JD/[(YYQ(]Q5&2G;?F4BX^=CI9,.33H>B:6,PH3?I"A;QC%+GR]Y)%;G+=QZ>>,V?)C+ M_(W.>+1@#_R.RZ^+FU0==2J5:1CS) M%@E(^.V]=X(^^=Y8'%"V^A7R5;;Q& M>5?NA?B1'UQ-SUO=_(QXQ .92S#UYY%/>!3E2NH\_BU%6U7./'#S]8OZYZ+S MJC/W+.,3$7T/IW)^WAJTT)3/V#*2MV+U*R\[5)Q@(**L^!^MRK;=%@J6F11Q M&:S.( Z3]5_V5!JQ$:!TF@-(&4 .#:!E -T.Z.T(\,H KW!FW97"!Y])-AZE M8H72O+52RU\49A;1JOMADG_O=S)5GX8J3HYO>2;392"7:9@\H)N()1EJ(]6" MLSAOB\0,?5GPE.7?4H98,D57\2(5CQQ]FLW"(.2)^I>AMSZ7+(RR=RKZZYV/ MWKYYA]Z@,$'7813EH:..5*>;)^T$Y:E=KD^-[#@UBJY%(N<9^I1,^;0A?@+' M#_?%^W \)H! 1_ES+XDH.)OR^0#HMWWB'0);NH0''['%U4X:>H/'.[S M0(7CINQ&;VA5.K30\W;H3;Y\N_+;>(C^5#6$KEFRG+&70OJ#RWR\HWIY-=4! MF">?^3YF"Q;P\Y::VC*>/O+6^.>?<*_[2Y.'+L5\1V*&OU[EKU>HTX.&YD0H MD_/A=[M.A/[Z/1^>5Y+'V=]-IGHN374IYCL2,TP]JTP] XO6-#68L_1!S5XI M#T2JQG@^8>T8FY=KW5ZAFU]-'\?><#CJ/&[:!.:VM:DAH8>KA$;O>U7O>V#O M;]BSNF;+QLD8C+2M%Y=B_EKL;,.(]K#;;$2_,J(/&O%%SGF*$I&T Y;-F^P MXVWM<"GF]^MV4#)H]F-0^3&PF&NJ*>961!%2?+5BZ;1QDAFX=,FEF.](S'!S M6+DY!*OK(@C2I9I-[IFZX 4<,8GN^4.8)+FY"JA4\2'%5*%HHI)+4-O6TV%M M$B'4G+1\1_D,IW!7\V?WH"FIN+:)8EBRZ3\*?'=.5+"@K4&EFC&<<'?+(EKJ6&-AOU9G:?Z.Z3$X F^@]=)8^JB$3Z MW%:?1TPJ"R?K*WZC6^!96+OE4LUWI69^ YKT,3TEBF*G@.]4S7>E9CJK&1^# MM/L*'BV%C:'F#;: %,YN[16K+_]!3* J@:*PG.;;UM[U+- M=Z5F^JY_$5!\2B2E3F'?J9KO2LUT5L,^A?<"CD?24GAS*PSW\1:3PMFMO2+U M'1.\8SN$;MQV U,Y!*5PJ'7EN+V7ID[H._?QJ49T"B/Z?BR%!:P]<0KJ]&!0 MIQK4Z=E)H)0ZQ7>G:KXK-=-2S?D47I9_'93"XM;&UA?9:UOZKC*:=FF&IS## MVU,I+&AM4<,M,K4]?50-UYA?N]_:W'C>:Y!3>G:KYKM3,>TKU3P*O>THT]9Q"OU,UWY6:Z:R&?@_> M!C@>36%A:U,;[M,A6V.ZH4UOQSZMI]G?SAXP(+6%M5QODV'VQXU-.KO&'L: M^CUX=?Y8G(!EK?M?OV>=>MO=K[?I;=_6WMEXH"GF:A[-'PS+4""6B5P_VU2] M6SU\=E$\R&EB(N7 M<\ZF/,T;J,]G0LB7@SQ!]4C>^']02P,$% @ QX!A53%L8WZ, P !@T M !D !X;"]W;W)K&ULQ5=M;]LV$/XK!RT8$B"- M7FS+=F8;B),5"["T1MRL'X9]H*6S1$0B-9**FV$_OB2ER&HC:T6Z(OY@B2]W M]]S=BL25A4 2 M6Z$\

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end XML 66 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 473 258 1 false 79 0 false 5 false false R1.htm 0000001 - Document - Cover Sheet http://www.abbott.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited Condensed Consolidated Statement of Earnings (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited Condensed Consolidated Statement of Comprehensive Income (Unaudited) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited Condensed Consolidated Balance Sheet (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) Sheet http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited Condensed Consolidated Statement of Shareholders' Investment (Unaudited) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) Statements 8 false false R9.htm 0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) Sheet http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited Condensed Consolidated Statement of Cash Flows (Unaudited) Statements 9 false false R10.htm 0000010 - Disclosure - Basis of Presentation Sheet http://www.abbott.com/role/BasisofPresentation Basis of Presentation Notes 10 false false R11.htm 0000011 - Disclosure - Revenue Sheet http://www.abbott.com/role/Revenue Revenue Notes 11 false false R12.htm 0000012 - Disclosure - Supplemental Financial Information Sheet http://www.abbott.com/role/SupplementalFinancialInformation Supplemental Financial Information Notes 12 false false R13.htm 0000013 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) Sheet http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLoss Changes in Accumulated Other Comprehensive Income (Loss) Notes 13 false false R14.htm 0000014 - Disclosure - Goodwill and Intangible Assets Sheet http://www.abbott.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 14 false false R15.htm 0000015 - Disclosure - Restructuring Plans Sheet http://www.abbott.com/role/RestructuringPlans Restructuring Plans Notes 15 false false R16.htm 0000016 - Disclosure - Incentive Stock Program Sheet http://www.abbott.com/role/IncentiveStockProgram Incentive Stock Program Notes 16 false false R17.htm 0000017 - Disclosure - Debt and Lines of Credit Sheet http://www.abbott.com/role/DebtandLinesofCredit Debt and Lines of Credit Notes 17 false false R18.htm 0000018 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures Financial Instruments, Derivatives and Fair Value Measures Notes 18 false false R19.htm 0000019 - Disclosure - Litigation and Environmental Matters Sheet http://www.abbott.com/role/LitigationandEnvironmentalMatters Litigation and Environmental Matters Notes 19 false false R20.htm 0000020 - Disclosure - Post-Employment Benefits Sheet http://www.abbott.com/role/PostEmploymentBenefits Post-Employment Benefits Notes 20 false false R21.htm 0000021 - Disclosure - Taxes on Earnings Sheet http://www.abbott.com/role/TaxesonEarnings Taxes on Earnings Notes 21 false false R22.htm 0000022 - Disclosure - Segment Information Sheet http://www.abbott.com/role/SegmentInformation Segment Information Notes 22 false false R23.htm 0000023 - Disclosure - Revenue (Tables) Sheet http://www.abbott.com/role/RevenueTables Revenue (Tables) Tables http://www.abbott.com/role/Revenue 23 false false R24.htm 0000024 - Disclosure - Supplemental Financial Information (Tables) Sheet http://www.abbott.com/role/SupplementalFinancialInformationTables Supplemental Financial Information (Tables) Tables http://www.abbott.com/role/SupplementalFinancialInformation 24 false false R25.htm 0000025 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossTables Changes in Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLoss 25 false false R26.htm 0000026 - Disclosure - Restructuring Plans (Tables) Sheet http://www.abbott.com/role/RestructuringPlansTables Restructuring Plans (Tables) Tables http://www.abbott.com/role/RestructuringPlans 26 false false R27.htm 0000027 - Disclosure - Incentive Stock Program (Tables) Sheet http://www.abbott.com/role/IncentiveStockProgramTables Incentive Stock Program (Tables) Tables http://www.abbott.com/role/IncentiveStockProgram 27 false false R28.htm 0000028 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables Financial Instruments, Derivatives and Fair Value Measures (Tables) Tables http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures 28 false false R29.htm 0000029 - Disclosure - Post-Employment Benefits (Tables) Sheet http://www.abbott.com/role/PostEmploymentBenefitsTables Post-Employment Benefits (Tables) Tables http://www.abbott.com/role/PostEmploymentBenefits 29 false false R30.htm 0000030 - Disclosure - Segment Information (Tables) Sheet http://www.abbott.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.abbott.com/role/SegmentInformation 30 false false R31.htm 0000031 - Disclosure - Revenue - Narrative (Details) Sheet http://www.abbott.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 31 false false R32.htm 0000032 - Disclosure - Revenue - Segments (Details) Sheet http://www.abbott.com/role/RevenueSegmentsDetails Revenue - Segments (Details) Details 32 false false R33.htm 0000033 - Disclosure - Revenue - Other Contract Assets and Liabilities (Details) Sheet http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails Revenue - Other Contract Assets and Liabilities (Details) Details 33 false false R34.htm 0000034 - Disclosure - Supplemental Financial Information - Narrative (Details) Sheet http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails Supplemental Financial Information - Narrative (Details) Details 34 false false R35.htm 0000035 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details) Sheet http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails Supplemental Financial Information - Allowance for Doubtful Accounts (Details) Details 35 false false R36.htm 0000036 - Disclosure - Supplemental Financial Information - Investments (Details) Sheet http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails Supplemental Financial Information - Investments (Details) Details 36 false false R37.htm 0000037 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails Changes in Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossTables 37 false false R38.htm 0000038 - Disclosure - Goodwill and Intangible Assets (Details) Sheet http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails Goodwill and Intangible Assets (Details) Details http://www.abbott.com/role/GoodwillandIntangibleAssets 38 false false R39.htm 0000039 - Disclosure - Restructuring Plans - Narrative (Details) Sheet http://www.abbott.com/role/RestructuringPlansNarrativeDetails Restructuring Plans - Narrative (Details) Details 39 false false R40.htm 0000040 - Disclosure - Restructuring Plans - Streamline of Operations and Improve Efficiencies (Details) Sheet http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails Restructuring Plans - Streamline of Operations and Improve Efficiencies (Details) Details 40 false false R41.htm 0000041 - Disclosure - Incentive Stock Program - Narrative (Details) Sheet http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails Incentive Stock Program - Narrative (Details) Details 41 false false R42.htm 0000042 - Disclosure - Incentive Stock Program - Options (Details) Sheet http://www.abbott.com/role/IncentiveStockProgramOptionsDetails Incentive Stock Program - Options (Details) Details 42 false false R43.htm 0000043 - Disclosure - Debt and Lines of Credit (Details) Sheet http://www.abbott.com/role/DebtandLinesofCreditDetails Debt and Lines of Credit (Details) Details http://www.abbott.com/role/DebtandLinesofCredit 43 false false R44.htm 0000044 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details) Details http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables 44 false false R45.htm 0000045 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details) Details 45 false false R46.htm 0000046 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details) Details 46 false false R47.htm 0000047 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) Details 47 false false R48.htm 0000048 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) Sheet http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) Details 48 false false R49.htm 0000049 - Disclosure - Litigation and Environmental Matters (Details) Sheet http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails Litigation and Environmental Matters (Details) Details http://www.abbott.com/role/LitigationandEnvironmentalMatters 49 false false R50.htm 0000050 - Disclosure - Post-Employment Benefits (Details) Sheet http://www.abbott.com/role/PostEmploymentBenefitsDetails Post-Employment Benefits (Details) Details http://www.abbott.com/role/PostEmploymentBenefitsTables 50 false false R51.htm 0000051 - Disclosure - Post-Employment Benefits - Narrative (Details) Sheet http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails Post-Employment Benefits - Narrative (Details) Details 51 false false R52.htm 0000052 - Disclosure - Taxes on Earnings (Details) Sheet http://www.abbott.com/role/TaxesonEarningsDetails Taxes on Earnings (Details) Details http://www.abbott.com/role/TaxesonEarnings 52 false false R53.htm 0000053 - Disclosure - Segment Information (Details) Sheet http://www.abbott.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.abbott.com/role/SegmentInformationTables 53 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: abt:MinimumLengthOfTimeHedgedInCashFlowHedge - abt-20220930.htm 4 abt-20220930.htm abt-20220930.xsd abt-20220930_cal.xml abt-20220930_def.xml abt-20220930_lab.xml abt-20220930_pre.xml q3202210qex311.htm q3202210qex312.htm q3202210qex321.htm q3202210qex322.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 71 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abt-20220930.htm": { "axisCustom": 0, "axisStandard": 24, "contextCount": 473, "dts": { "calculationLink": { "local": [ "abt-20220930_cal.xml" ] }, "definitionLink": { "local": [ "abt-20220930_def.xml" ] }, "inline": { "local": [ "abt-20220930.htm" ] }, "labelLink": { "local": [ "abt-20220930_lab.xml" ] }, "presentationLink": { "local": [ "abt-20220930_pre.xml" ] }, "schema": { "local": [ "abt-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd" ] } }, "elementCount": 454, "entityCount": 1, "hidden": { "http://www.abbott.com/20220930": 1, "http://xbrl.sec.gov/dei/2022": 5, "total": 6 }, "keyCustom": 19, "keyStandard": 239, "memberCustom": 34, "memberStandard": 45, "nsprefix": "abt", "nsuri": "http://www.abbott.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "role": "http://www.abbott.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Basis of Presentation", "role": "http://www.abbott.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Revenue", "role": "http://www.abbott.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Supplemental Financial Information", "role": "http://www.abbott.com/role/SupplementalFinancialInformation", "shortName": "Supplemental Financial Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss)", "role": "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLoss", "shortName": "Changes in Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Goodwill and Intangible Assets", "role": "http://www.abbott.com/role/GoodwillandIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Restructuring Plans", "role": "http://www.abbott.com/role/RestructuringPlans", "shortName": "Restructuring Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Incentive Stock Program", "role": "http://www.abbott.com/role/IncentiveStockProgram", "shortName": "Incentive Stock Program", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Debt and Lines of Credit", "role": "http://www.abbott.com/role/DebtandLinesofCredit", "shortName": "Debt and Lines of Credit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures", "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures", "shortName": "Financial Instruments, Derivatives and Fair Value Measures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Litigation and Environmental Matters", "role": "http://www.abbott.com/role/LitigationandEnvironmentalMatters", "shortName": "Litigation and Environmental Matters", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited)", "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "shortName": "Condensed Consolidated Statement of Earnings (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Post-Employment Benefits", "role": "http://www.abbott.com/role/PostEmploymentBenefits", "shortName": "Post-Employment Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Taxes on Earnings", "role": "http://www.abbott.com/role/TaxesonEarnings", "shortName": "Taxes on Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Segment Information", "role": "http://www.abbott.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Revenue (Tables)", "role": "http://www.abbott.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Supplemental Financial Information (Tables)", "role": "http://www.abbott.com/role/SupplementalFinancialInformationTables", "shortName": "Supplemental Financial Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Changes in Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Restructuring Plans (Tables)", "role": "http://www.abbott.com/role/RestructuringPlansTables", "shortName": "Restructuring Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Incentive Stock Program (Tables)", "role": "http://www.abbott.com/role/IncentiveStockProgramTables", "shortName": "Incentive Stock Program (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables)", "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables", "shortName": "Financial Instruments, Derivatives and Fair Value Measures (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Post-Employment Benefits (Tables)", "role": "http://www.abbott.com/role/PostEmploymentBenefitsTables", "shortName": "Post-Employment Benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited)", "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited", "shortName": "Condensed Consolidated Statement of Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Segment Information (Tables)", "role": "http://www.abbott.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:NumberOfReportableSegments", "us-gaap:NumberOfReportableSegments", "us-gaap:NumberOfReportableSegments", "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Revenue - Narrative (Details)", "role": "http://www.abbott.com/role/RevenueNarrativeDetails", "shortName": "Revenue - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:NumberOfReportableSegments", "us-gaap:NumberOfReportableSegments", "us-gaap:NumberOfReportableSegments", "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Revenue - Segments (Details)", "role": "http://www.abbott.com/role/RevenueSegmentsDetails", "shortName": "Revenue - Segments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "ibf27976a942a4fc19586a8236e981bc0_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i161741e7e8f046ff9a2cc29b1a64a357_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Revenue - Other Contract Assets and Liabilities (Details)", "role": "http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails", "shortName": "Revenue - Other Contract Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i161741e7e8f046ff9a2cc29b1a64a357_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Supplemental Financial Information - Narrative (Details)", "role": "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails", "shortName": "Supplemental Financial Information - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i161741e7e8f046ff9a2cc29b1a64a357_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details)", "role": "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails", "shortName": "Supplemental Financial Information - Allowance for Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i161741e7e8f046ff9a2cc29b1a64a357_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "abt:ScheduleOfLongTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Supplemental Financial Information - Investments (Details)", "role": "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails", "shortName": "Supplemental Financial Information - Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "abt:ScheduleOfLongTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "ie7c97d1edcfa444cb20aa7be67ab0d50_I20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:LongTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i161741e7e8f046ff9a2cc29b1a64a357_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Details)", "role": "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Changes in Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i495e1acb6ab646e1be98f86d888adf7c_I20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Goodwill and Intangible Assets (Details)", "role": "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "ib718c9002df547a9bb6009289d5ab871_D20210401-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Restructuring Plans - Narrative (Details)", "role": "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "shortName": "Restructuring Plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i53e8568bc39d4cb19a2c23541737716d_D20210701-20211231", "decimals": "-6", "lang": "en-US", "name": "abt:InventoryNoNetRealizableValueSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical)", "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical", "shortName": "Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "ib718c9002df547a9bb6009289d5ab871_D20210401-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Restructuring Plans - Streamline of Operations and Improve Efficiencies (Details)", "role": "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails", "shortName": "Restructuring Plans - Streamline of Operations and Improve Efficiencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "icd32e0ec232449a093586b6ac423eb4f_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:PaymentsForRestructuring", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Incentive Stock Program - Narrative (Details)", "role": "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails", "shortName": "Incentive Stock Program - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i33f19560992c435a88092f47daf02b5b_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Incentive Stock Program - Options (Details)", "role": "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails", "shortName": "Incentive Stock Program - Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i33f19560992c435a88092f47daf02b5b_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "ib0b29ca98ef14de0a3be8cd36653449b_D20220315-20220315", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Debt and Lines of Credit (Details)", "role": "http://www.abbott.com/role/DebtandLinesofCreditDetails", "shortName": "Debt and Lines of Credit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "ib0b29ca98ef14de0a3be8cd36653449b_D20220315-20220315", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i362cc950c402435b85ccd22cc23f812e_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details)", "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i362cc950c402435b85ccd22cc23f812e_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details)", "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i5397677ab93a49019eae8c9a0bb21d79_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details)", "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i5397677ab93a49019eae8c9a0bb21d79_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "abt:ScheduleOfLongTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)", "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i132737fb549d49b2af4b792fb9883efb_I20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "ie6d54ddc609d499383aafcf6ba76dd93_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)", "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "ie6d54ddc609d499383aafcf6ba76dd93_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Litigation and Environmental Matters (Details)", "role": "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails", "shortName": "Litigation and Environmental Matters (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited)", "role": "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "shortName": "Condensed Consolidated Balance Sheet (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "ic55e17708b144d149c97d0b172bd426e_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Post-Employment Benefits (Details)", "role": "http://www.abbott.com/role/PostEmploymentBenefitsDetails", "shortName": "Post-Employment Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "ic55e17708b144d149c97d0b172bd426e_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Post-Employment Benefits - Narrative (Details)", "role": "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "shortName": "Post-Employment Benefits - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "ib6b147cc106249baa28781e370ab66ec_D20220101-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "abt:ExcessTaxBenefitFromShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Taxes on Earnings (Details)", "role": "http://www.abbott.com/role/TaxesonEarningsDetails", "shortName": "Taxes on Earnings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "abt:ExcessTaxBenefitFromShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Segment Information (Details)", "role": "http://www.abbott.com/role/SegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930", "decimals": "2", "lang": "en-US", "name": "abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)", "role": "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i161741e7e8f046ff9a2cc29b1a64a357_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited)", "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "shortName": "Condensed Consolidated Statement of Shareholders' Investment (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "ife5c2b9c51b24905939dfe6b3d3e4056_I20220630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i161741e7e8f046ff9a2cc29b1a64a357_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockCommonShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical)", "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical", "shortName": "Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "ife5c2b9c51b24905939dfe6b3d3e4056_I20220630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)", "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statement of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abt-20220930.htm", "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 79, "tag": { "abt_A255LongTermNotesDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.55% Long-term Notes Due 2022", "label": "2.55% Long-term Notes Due 2022 [Member]", "terseLabel": "2.55% Long-term Notes Due 2022" } } }, "localname": "A255LongTermNotesDue2022Member", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "xbrltype": "domainItemType" }, "abt_AdultNutritionalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the adult nutritionals, segment of the entity.", "label": "Adult Nutritionals [Member]", "terseLabel": "Adult Nutritionals" } } }, "localname": "AdultNutritionalsMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the annual cost of share-based awards which will typically be recognized in the first quarter.", "label": "Annual Share Based Awards Recognized in First Quarter Percent", "terseLabel": "Annual share-based awards recognized in first quarter (as a percent)" } } }, "localname": "AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "percentItemType" }, "abt_COVID19TestManufacturingNetworkRestructuringPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with recent changes in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and recent U.S. health authority guidance on testing for fully vaccinated individuals.", "label": "COVID-19 Test Manufacturing Network Restructuring Plan [Member]", "terseLabel": "COVID-19 Test Manufacturing Network Restructuring Plan" } } }, "localname": "COVID19TestManufacturingNetworkRestructuringPlanMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "domainItemType" }, "abt_ContractLiabilitiesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Liabilities", "label": "Contract Liabilities [Roll Forward]", "terseLabel": "Contract Liabilities:" } } }, "localname": "ContractLiabilitiesRollForward", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized arising from contract liability from change in cash received to be satisfied.", "label": "Contract With Customer Liability, Change In Unearned Revenue From Cash Received Recognized", "terseLabel": "Unearned revenue from cash received during the period" } } }, "localname": "ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abt_CoreLaboratoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the core laboratory, segment of the entity.", "label": "Core Laboratory [Member]", "terseLabel": "Core Laboratory" } } }, "localname": "CoreLaboratoryMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_CorporateAndBenefitPlanCosts": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The reconciling item from aggregate segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to corporate functions and benefit plan costs.", "label": "Corporate and Benefit Plan Costs", "negatedLabel": "Corporate functions and benefit plan costs" } } }, "localname": "CorporateAndBenefitPlanCosts", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "abt_CostOfGoodsAndServicesSoldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost of Goods and Services Sold", "label": "Cost of Goods and Services Sold [Member]", "terseLabel": "Cost of Products Sold" } } }, "localname": "CostOfGoodsAndServicesSoldMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "abt_DeferredIncomeTaxesAndOtherAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Deferred Income Taxes and Other Assets line item in the statement of financial position in which the amounts are included.", "label": "Deferred income taxes and other assets [Member]", "terseLabel": "Deferred income taxes and other assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abt_DefinedBenefitPlanNetAmortizationCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Defined Benefit Plan Net Amortization Costs [Abstract]", "terseLabel": "Net amortization of:" } } }, "localname": "DefinedBenefitPlanNetAmortizationCostsAbstract", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "stringItemType" }, "abt_DiabetesCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the Diabetes Care, segment of the entity.", "label": "Diabetes Care [Member]", "terseLabel": "Diabetes Care" } } }, "localname": "DiabetesCareMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_DiagnosticProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The diagnostics products segment of the entity.", "label": "Diagnostic Products [Member]", "terseLabel": "Diagnostic Products" } } }, "localname": "DiagnosticProductsMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSegmentsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "abt_EffectOfCommonAndTreasuryShareTransactions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the effect on retained earning due to common and treasury stock transactions.", "label": "Effect of Common and Treasury Share Transactions", "negatedLabel": "Effect of common and treasury share transactions" } } }, "localname": "EffectOfCommonAndTreasuryShareTransactions", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "abt_ElectrophysiologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the electrophysiology, segment of the entity.", "label": "Electrophysiology [Member]", "terseLabel": "Electrophysiology" } } }, "localname": "ElectrophysiologyMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_EstablishedPharmaceuticalProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Established Pharmaceutical Products, segment of the entity.", "label": "Established Pharmaceutical Products [Member]", "terseLabel": "Established Pharmaceutical Products" } } }, "localname": "EstablishedPharmaceuticalProductsMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueSegmentsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "abt_ExcessTaxBenefitFromShareBasedCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefits related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation", "terseLabel": "Excess tax benefits associated with share-based compensation" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensation", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "xbrltype": "monetaryItemType" }, "abt_FixedAssetWriteDownsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to fixed asset write-downs cost .", "label": "Fixed asset write-downs [Member]", "terseLabel": "Fixed Asset Write-Downs" } } }, "localname": "FixedAssetWriteDownsMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "domainItemType" }, "abt_GoodwillAndIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill and Intangible Assets", "label": "Goodwill and Intangible Assets [Line Items]", "terseLabel": "Goodwill and Intangible Assets [Line Items]" } } }, "localname": "GoodwillAndIntangibleAssetsLineItems", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "abt_HeartFailureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the Heart Failure, segment of the entity.", "label": "Heart Failure [Member]", "terseLabel": "Heart Failure" } } }, "localname": "HeartFailureMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_InventoryNoNetRealizableValueSold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory sold that was previously estimated to have no net realizable value.", "label": "Inventory No Net Realizable Value Sold", "terseLabel": "Inventory sold that was previously estimated to have no net realizable value" } } }, "localname": "InventoryNoNetRealizableValueSold", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "abt_InventoryRelatedChargesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to fixed asset inventory related charges .", "label": "Inventory-related charges [Member]", "terseLabel": "Inventory- Related Charges" } } }, "localname": "InventoryRelatedChargesMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "domainItemType" }, "abt_KeyEmergingMarketsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the key emerging markets, segment of the entity.", "label": "Key Emerging Markets [Member]", "terseLabel": "Key Emerging Markets" } } }, "localname": "KeyEmergingMarketsMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_LegalProceedingsAndEnvironmentalExposuresMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss contingencies related to legal proceedings and environmental exposures.", "label": "Legal proceedings and environmental exposures [Member]", "terseLabel": "Legal proceedings and environmental exposures" } } }, "localname": "LegalProceedingsAndEnvironmentalExposuresMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "domainItemType" }, "abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The estimated maximum loss, for all sites, from the contingency related to the environmental clean up in the United States and Puerto Rico.", "label": "Loss Contingency Range of Possible Loss, Maximum Aggregate Sites", "terseLabel": "Maximum expected cleanup exposure in aggregate" } } }, "localname": "LossContingencyRangeOfPossibleLossMaximumAggregateSites", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "monetaryItemType" }, "abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The estimated maximum loss, per individual site, from the contingency related to the environmental clean up in the United States and Puerto Rico.", "label": "Loss Contingency Range of Possible Loss, Maximum Individual Site", "terseLabel": "Maximum expected cleanup exposure for individual site" } } }, "localname": "LossContingencyRangeOfPossibleLossMaximumIndividualSite", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "monetaryItemType" }, "abt_MedicalDevicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The medical devices segment of the entity.", "label": "Medical Devices [Member]", "terseLabel": "Medical Devices" } } }, "localname": "MedicalDevicesMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSegmentsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "abt_MinimumLengthOfTimeHedgedInCashFlowHedge": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Minimum Length Of Time Hedged In Cash Flow Hedge", "terseLabel": "Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold" } } }, "localname": "MinimumLengthOfTimeHedgedInCashFlowHedge", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails" ], "xbrltype": "durationItemType" }, "abt_MolecularMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the molecular, segment of the entity.", "label": "Molecular [Member]", "terseLabel": "Molecular" } } }, "localname": "MolecularMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_NeuromodulationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the neuromodulation, segment of the entity.", "label": "Neuromodulation [Member]", "terseLabel": "Neuromodulation" } } }, "localname": "NeuromodulationMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represent Noncontrolling Interests' share of income, net of distributions, share repurchases and business combinations.", "label": "Noncontrolling Interests Share of Income Net of Distributions and Share Repurchases and Business Combinations", "terseLabel": "Noncontrolling Interests\u2019 share of income, business combinations, net of distributions and share repurchases" } } }, "localname": "NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "abt_NutritionalProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The nutritional products segment of the entity.", "label": "Nutritional Products [Member]", "terseLabel": "Nutritional Products" } } }, "localname": "NutritionalProductsMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueSegmentsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "abt_OtherCostAndExpenseOperatingAndNonoperating": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The reconciling item from segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to net other income or expenses.", "label": "Other Cost and Expense, Operating and Nonoperating", "negatedLabel": "Other, net" } } }, "localname": "OtherCostAndExpenseOperatingAndNonoperating", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "abt_OtherEmergingMarketsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Emerging Markets", "label": "Other Emerging Markets [Member]", "terseLabel": "Other Emerging Markets" } } }, "localname": "OtherEmergingMarketsMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_OtherExitCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to fixed asset other exit cost .", "label": "Other exit costs [Member]", "terseLabel": "Other Exit Costs" } } }, "localname": "OtherExitCostsMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "domainItemType" }, "abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase, and research and development assets.", "label": "Payments to Acquire Businesses, Net of Cash Acquired, And Research and Development in Process", "negatedLabel": "Acquisitions of businesses and technologies, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abt_PediatricNutritionalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the pediatric nutritionals, segment of the entity.", "label": "Pediatric Nutritionals [Member]", "terseLabel": "Pediatric Nutritionals" } } }, "localname": "PediatricNutritionalsMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_PointOfCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the point of care, segment of the entity.", "label": "Point of Care [Member]", "terseLabel": "Point of Care" } } }, "localname": "PointOfCareMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Post-employment obligations and amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer.", "label": "Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities", "verboseLabel": "Post-employment obligations, deferred income taxes and other long-term liabilities" } } }, "localname": "PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Postemployment Obligations Deferred Income Taxes And Other Long Term Liabilities", "label": "Postemployment Obligations Deferred Income Taxes And Other Long Term Liabilities [Member]", "terseLabel": "Post-employment obligations, deferred income taxes and other long-term liabilities" } } }, "localname": "PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abt_PrepaidExpenseAndOtherReceivables": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other receivables that are expected to be realized within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Receivables", "verboseLabel": "Prepaid expenses and other receivables" } } }, "localname": "PrepaidExpenseAndOtherReceivables", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "abt_PrepaidExpensesAndOtherReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid expenses and other receivables.", "label": "Prepaid expenses and other receivables [Member]", "terseLabel": "Prepaid expenses and other receivables" } } }, "localname": "PrepaidExpensesAndOtherReceivablesMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abt_RapidDiagnosticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the rapid diagnostics, segment of the entity.", "label": "Rapid Diagnostics [Member]", "terseLabel": "Rapid Diagnostics" } } }, "localname": "RapidDiagnosticsMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_RestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock awards.", "label": "Restricted stock awards [Member]", "terseLabel": "Restricted Stock Awards" } } }, "localname": "RestrictedStockAwardsMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails" ], "xbrltype": "domainItemType" }, "abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The restructuring plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses.", "label": "Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies [Member]", "terseLabel": "Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies" } } }, "localname": "RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "domainItemType" }, "abt_RestructuringReservePeriodCashSettledAndOtherAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.", "label": "Restructuring Reserve Period Cash Settled and Other Adjustments", "negatedLabel": "Payments and other adjustments" } } }, "localname": "RestructuringReservePeriodCashSettledAndOtherAdjustments", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "monetaryItemType" }, "abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of revenue recognized for remaining performance obligations.", "label": "Revenue Remaining Performance Obligation Expected Timing Percentage", "terseLabel": "Percentage of remaining performance obligation expected to be recognized in period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingPercentage", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "xbrltype": "percentItemType" }, "abt_RhythmManagementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the rhythm management, segment of the entity.", "label": "Rhythm Management [Member]", "terseLabel": "Rhythm Management" } } }, "localname": "RhythmManagementMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_ScheduleOfGoodwillAndIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Goodwill and Intangible Assets", "label": "Schedule of Goodwill and Intangible Assets [Table]", "terseLabel": "Schedule of Goodwill and Intangible Assets [Table]" } } }, "localname": "ScheduleOfGoodwillAndIntangibleAssetsTable", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "abt_ScheduleOfLongTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the investments which are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Schedule of Long Term Investments [Table Text Block]", "terseLabel": "Schedule of long-term investments" } } }, "localname": "ScheduleOfLongTermInvestmentsTableTextBlock", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "abt_StJudeMedicalIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to acquisition of St. Jude Medical, Inc.", "label": "St. Jude Medical, Inc. [Member]", "terseLabel": "St. Jude Medical" } } }, "localname": "StJudeMedicalIncMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Incentive Stock Programs", "label": "Stock Issued During Period, Shares, Incentive Stock Programs", "terseLabel": "Issued under incentive stock programs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIncentiveStockPrograms", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "abt_StockIssuedDuringPeriodValueIncentiveStockPrograms": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Incentive Stock Programs", "label": "Stock Issued During Period, Value, Incentive Stock Programs", "terseLabel": "Issued under incentive stock programs" } } }, "localname": "StockIssuedDuringPeriodValueIncentiveStockPrograms", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "abt_StructuralHeartMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the structural heart, segment of the entity.", "label": "Structural Heart [Member]", "terseLabel": "Structural Heart" } } }, "localname": "StructuralHeartMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_VascularMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the vascular products, segment of the entity.", "label": "Vascular [Member]", "terseLabel": "Vascular" } } }, "localname": "VascularMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "abt_WalkVascularLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents information pertaining to its Walk vascular llc.", "label": "Walk Vascular, LLC [Member]", "terseLabel": "Walk Vascular" } } }, "localname": "WalkVascularLLCMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "abt_YenDenominatedLongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to yen denominated Long-term debt.", "label": "Yen-denominated long-term debt [Member]", "terseLabel": "Yen-denominated long-term debt" } } }, "localname": "YenDenominatedLongTermDebtMember", "nsuri": "http://www.abbott.com/20220930", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document and Entity Information" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r658" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r658" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r658" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]", "terseLabel": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r658" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r658" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r658" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r658" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r657" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NYSE CHICAGO, INC. [Member]", "terseLabel": "CHICAGO STOCK EXCHANGE, INC" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]", "terseLabel": "NEW YORK STOCK EXCHANGE, INC." } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2022", "presentation": [ "http://www.abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "srt_CondensedCashFlowStatementTable": { "auth_ref": [ "r105", "r478" ], "lang": { "en-us": { "role": { "label": "Condensed Cash Flow Statement [Table]", "terseLabel": "Condensed Cash Flow Statement [Table]" } } }, "localname": "CondensedCashFlowStatementTable", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CondensedCashFlowStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Cash Flow Statements, Captions [Line Items]", "terseLabel": "Condensed Cash Flow Statements, Captions [Line Items]" } } }, "localname": "CondensedCashFlowStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r105", "r140", "r153", "r154", "r155", "r156", "r158", "r160", "r164", "r249", "r250", "r251", "r252", "r253", "r254", "r256", "r257", "r259", "r261", "r262" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r105", "r140", "r153", "r154", "r155", "r156", "r158", "r160", "r164", "r249", "r250", "r251", "r252", "r253", "r254", "r256", "r257", "r259", "r261", "r262" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r241", "r243", "r244", "r245", "r267", "r299", "r402", "r407", "r567", "r568", "r569", "r570", "r571", "r572", "r574", "r618", "r620", "r654", "r655" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails", "http://www.abbott.com/role/TaxesonEarningsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r241", "r243", "r244", "r245", "r267", "r299", "r402", "r407", "r567", "r568", "r569", "r570", "r571", "r572", "r574", "r618", "r620", "r654", "r655" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails", "http://www.abbott.com/role/TaxesonEarningsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r217", "r241", "r243", "r244", "r245", "r267", "r299", "r354", "r402", "r407", "r438", "r439", "r440", "r567", "r568", "r569", "r570", "r571", "r572", "r574", "r618", "r620", "r654", "r655" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails", "http://www.abbott.com/role/TaxesonEarningsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r217", "r241", "r243", "r244", "r245", "r267", "r299", "r354", "r402", "r407", "r438", "r439", "r440", "r567", "r568", "r569", "r570", "r571", "r572", "r574", "r618", "r620", "r654", "r655" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails", "http://www.abbott.com/role/TaxesonEarningsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r168", "r169", "r321", "r325", "r619", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r168", "r169", "r321", "r325", "r619", "r643", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Changes in accumulated other comprehensive income (loss), net of income taxes" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r10", "r37" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade accounts payable" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Summary of activity of allowance for doubtful accounts" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r173", "r174" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Trade receivables, less allowances of $520 in 2022 and $519 in 2021" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r21", "r582", "r603" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "verboseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Other accrued liabilities" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r53", "r59", "r66", "r67", "r68", "r486" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Net Actuarial (Losses) and Prior Service (Costs) and Credits" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r15", "r213" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r59", "r66", "r67", "r68", "r69", "r485" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r54", "r59", "r374" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedLabel": "Net actuarial (losses) and prior service (costs) and credits" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r50", "r56", "r58", "r59", "r537" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "terseLabel": "Cumulative foreign currency translation (loss) adjustments" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r56", "r58", "r59", "r605", "r625", "r626" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)", "totalLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r66", "r67", "r547", "r548", "r549", "r550", "r551", "r553" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r55", "r59", "r66", "r67", "r68", "r106", "r107", "r108", "r486", "r560", "r621", "r622" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r51", "r59", "r66", "r67", "r68", "r486", "r548", "r549", "r550", "r551", "r553" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Cumulative Foreign Currency Translation (Loss) Adjustments" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Supplemental Financial Information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings to net cash from operating activities \u2014" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r442" ], "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "negatedLabel": "Share-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r30", "r175", "r182", "r183", "r186" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r30", "r175", "r182" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Trade receivables, allowances" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedLabel": "Amounts charged off and other deductions" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r96", "r203", "r206" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.abbott.com/role/SegmentInformationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization of intangible assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Outstanding Common Stock Options Having No Dilutive Effect (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "auth_ref": [ "r56" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "verboseLabel": "Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other" } } }, "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r18", "r102", "r148", "r155", "r162", "r180", "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r258", "r260", "r262", "r263", "r483", "r487", "r541", "r561", "r563", "r580", "r602" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r36", "r102", "r180", "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r258", "r260", "r262", "r263", "r483", "r487", "r541", "r561", "r563" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r527" ], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total Assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r412", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r425", "r426", "r427", "r428", "r429", "r430", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r500", "r505" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r398", "r403", "r474" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r398", "r403", "r472", "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Business acquisition, percentage acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r475", "r476", "r477" ], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "verboseLabel": "Contingent consideration related to business combinations" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r539", "r540" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r11", "r98" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r92", "r98", "r99" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and Cash Equivalents, End of Period", "periodStartLabel": "Cash and Cash Equivalents, Beginning of Year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r92", "r546" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Increase (Decrease) in Cash and Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r43", "r588", "r610" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r235", "r236", "r237", "r246", "r644" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Litigation and Environmental Matters" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMatters" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared on common shares (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r106", "r107", "r523" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common shares, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesHeldInEmployeeTrust": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.", "label": "Common Stock, Shares Held in Employee Trust", "terseLabel": "Securities in mutual funds held in a rabbi trust" } } }, "localname": "CommonStockSharesHeldInEmployeeTrust", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common shares, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r24", "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24", "r563" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common shares, without par value Authorized \u2014 2,400,000,000 shares Issued at stated capital amount \u2014 Shares: 2022: 1,985,919,440; 2021: 1,985,273,421" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r62", "r64", "r65", "r74", "r592", "r613" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r73", "r83", "r591", "r612" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Changes in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of changes in contract liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r308", "r309", "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedTerseLabel": "Revenue recognized related to contract liability balance" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r153", "r154", "r155", "r156", "r158", "r164", "r166" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Other" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r78", "r576" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold, excluding amortization of intangible assets" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "verboseLabel": "Cost of products sold" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r77" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating cost and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r100", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r281", "r288", "r289", "r291", "r297" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt and Lines of Credit" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCredit" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r19", "r21", "r22", "r101", "r105", "r264", "r265", "r266", "r267", "r268", "r269", "r271", "r277", "r278", "r279", "r280", "r282", "r283", "r284", "r285", "r286", "r287", "r293", "r294", "r295", "r296", "r558", "r581", "r583", "r599" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r41", "r265" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r42", "r101", "r105", "r264", "r265", "r266", "r267", "r268", "r269", "r271", "r277", "r278", "r279", "r280", "r282", "r283", "r284", "r285", "r286", "r287", "r293", "r294", "r295", "r296", "r558" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r42", "r101", "r105", "r264", "r265", "r266", "r267", "r268", "r269", "r271", "r277", "r278", "r279", "r280", "r282", "r283", "r284", "r285", "r286", "r287", "r290", "r293", "r294", "r295", "r296", "r301", "r302", "r303", "r304", "r555", "r556", "r558", "r559", "r598" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates.", "label": "Debt [Member]", "terseLabel": "Debt" } } }, "localname": "DebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r459" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Decrease reasonably possible in gross unrecognized tax benefits" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Deferred Income Taxes and Other Assets, Noncurrent", "terseLabel": "Deferred income taxes and other assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r332", "r369", "r388", "r394", "r395" ], "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedTerseLabel": "Actuarial loss, net" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r332", "r370", "r389", "r394", "r395" ], "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "verboseLabel": "Prior service cost (credit)" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r347", "r355", "r356", "r392", "r394", "r395" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Company contributions", "verboseLabel": "Pension contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsDetails", "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r332", "r368", "r387", "r394", "r395" ], "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r332", "r336", "r367", "r386", "r394", "r395" ], "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost on projected benefit obligations" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r365", "r384", "r394", "r395" ], "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net cost (credit)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r334", "r366", "r385", "r394", "r395" ], "calculation": { "http://www.abbott.com/role/PostEmploymentBenefitsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost - benefits earned during the period" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r96", "r211" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r47", "r48", "r49", "r503", "r573" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Fair Value - Assets" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r47", "r48", "r49", "r503", "r573" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Fair Value - Liabilities" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r48", "r501", "r504", "r509", "r513" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r522", "r526" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Financial Instruments, Derivatives and Fair Value Measures" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r498", "r501", "r509" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r498", "r501", "r509", "r513", "r514", "r518", "r520" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r508", "r510" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Gain (loss) recognized related to derivatives not designated as hedge" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r492", "r494" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r491", "r493", "r494", "r498", "r499", "r506", "r509", "r516", "r517", "r520", "r522" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of reportable segment included under sales category" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r411", "r412", "r443", "r444", "r446", "r452" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Incentive Stock Program" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgram" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Text Block Supplement [Abstract]", "terseLabel": "Disclosure Text Block Supplement [Abstract]" } } }, "localname": "DisclosureTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r305" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Cash dividends declared on common shares" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r75", "r111", "r112", "r113", "r114", "r115", "r119", "r122", "r128", "r129", "r130", "r132", "r133", "r524", "r525", "r593", "r614" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic Earnings Per Common Share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r75", "r111", "r112", "r113", "r114", "r115", "r122", "r128", "r129", "r130", "r132", "r133", "r524", "r525", "r593", "r614" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted Earnings Per Common Share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r546" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Salaries, wages and commissions" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r445" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Total unrecognized compensation cost, recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Share-based Payment Arrangement, Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r66", "r67", "r68", "r106", "r107", "r108", "r110", "r116", "r118", "r134", "r181", "r300", "r305", "r449", "r450", "r451", "r462", "r463", "r523", "r547", "r548", "r549", "r550", "r551", "r553", "r560", "r621", "r622", "r623" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r12", "r149", "r179" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments carrying value" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r7", "r20", "r535" ], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r177", "r600", "r640", "r641", "r642" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r178" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity investment without readily determinable fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r279", "r293", "r294", "r538" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r527", "r528", "r532" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r527", "r539", "r540" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r527", "r539" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of carrying values and fair values of certain financial instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r279", "r293", "r294", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r394", "r528", "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r279", "r293", "r294", "r527", "r533" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r527", "r528", "r529", "r530", "r534" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r279", "r293", "r294" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair Value Hedging" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r279", "r355", "r356", "r361", "r394", "r528", "r564" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r279", "r293", "r294", "r355", "r356", "r361", "r394", "r528", "r565" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r279", "r293", "r294", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r394", "r528", "r566" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r279", "r293", "r294", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r394", "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r531", "r534" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r17", "r205" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated amortization of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Estimated annual amortization expense, intangible assets, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Estimated annual amortization expense, intangible assets, 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Estimated annual amortization expense, intangible assets, 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Estimated annual amortization expense, intangible assets, 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r207" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Estimated annual amortization expense, intangible assets, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Decrease in intangible assets due to foreign currency translation adjustments" } } }, "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r205", "r577" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross amount of amortizable intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue": { "auth_ref": [ "r504" ], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments.", "label": "Foreign Currency Cash Flow Hedge Asset at Fair Value", "terseLabel": "Foreign currency forward exchange contracts, receivable position", "verboseLabel": "Foreign currency forward exchange contracts" } } }, "localname": "ForeignCurrencyCashFlowHedgeAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue": { "auth_ref": [ "r504" ], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments.", "label": "Foreign Currency Cash Flow Hedge Liability at Fair Value", "negatedLabel": "Foreign currency forward exchange contracts, (payable) position", "verboseLabel": "Foreign currency forward exchange contracts" } } }, "localname": "ForeignCurrencyCashFlowHedgeLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r542", "r543", "r544", "r545" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Net foreign exchange (gain) loss" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign Exchange Forward" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r16", "r189", "r191", "r198", "r201", "r563", "r579" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r196" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Decrease in goodwill due to foreign currency translation adjustments" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r96", "r190", "r195", "r200", "r201" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Amount of reductions of goodwill relating to impairments" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgedLiabilityFairValueHedge": { "auth_ref": [ "r515" ], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability hedged in fair value hedging relationship.", "label": "Hedged Liability, Fair Value Hedge", "terseLabel": "Fair value of hedged long-term debt" } } }, "localname": "HedgedLiabilityFairValueHedge", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r498", "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r96", "r209" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "terseLabel": "Impairment of indefinite-lived intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r71", "r148", "r154", "r158", "r161", "r164", "r578", "r589", "r596", "r615" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.abbott.com/role/SegmentInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Earnings before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r215", "r222" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r103", "r457", "r460", "r461", "r464", "r466", "r468", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Taxes on Earnings" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/TaxesonEarnings" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r117", "r118", "r146", "r456", "r465", "r467", "r616" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Taxes on earnings" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r95" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade receivables" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r95" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r95" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Shareholders' Investment" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r123", "r124", "r125", "r130", "r410" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Dilutive Common Stock Options (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r208" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets related to in-process R&D acquired in a business combination" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r202", "r204" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net of amortization" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r70", "r142", "r554", "r557", "r595" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r594" ], "calculation": { "http://www.abbott.com/role/SegmentInformationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Net interest expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateDerivativeAssetsAtFairValue": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.", "label": "Interest Rate Derivative Assets, at Fair Value", "terseLabel": "Interest rate swap derivative financial instruments" } } }, "localname": "InterestRateDerivativeAssetsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.", "label": "Interest Rate Derivative Liabilities, at Fair Value", "terseLabel": "Interest rate swap derivative financial instruments" } } }, "localname": "InterestRateDerivativeLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateFairValueHedgeAssetAtFairValue": { "auth_ref": [ "r504" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments.", "label": "Interest Rate Fair Value Hedge Asset at Fair Value", "terseLabel": "Interest rate hedge contracts, receivable position" } } }, "localname": "InterestRateFairValueHedgeAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue": { "auth_ref": [ "r504" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all derivative liabilities designated as interest rate fair value hedging instruments.", "label": "Interest Rate Fair Value Hedge Liability at Fair Value", "negatedTerseLabel": "Interest rate hedge contracts, (payable) position" } } }, "localname": "InterestRateFairValueHedgeLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r31", "r188" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished products" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r6", "r34", "r563" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r33", "r188" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRecallExpense": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise.", "label": "Inventory Recall Expense", "terseLabel": "Inventory recall expense" } } }, "localname": "InventoryRecallExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r32", "r188" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r81", "r141" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedLabel": "Interest (income)" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r638", "r639", "r640", "r641", "r642" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r638", "r639", "r640", "r641", "r642" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r102", "r180", "r541", "r563", "r585", "r608" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Shareholders' Investment" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Investment" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r9", "r40", "r102", "r180", "r249", "r250", "r251", "r254", "r255", "r256", "r258", "r260", "r262", "r263", "r484", "r487", "r488", "r541", "r561", "r562", "r563" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r527" ], "calculation": { "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Total Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r22", "r278", "r292", "r293", "r294", "r583", "r604" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-Term Debt, Fair Value", "negatedLabel": "Total Long-term Debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long-Term Debt [Member]", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r13" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-Term Investments", "terseLabel": "Investments", "verboseLabel": "Long-term Investment Securities:" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails", "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r238", "r240", "r241", "r242", "r243", "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r238", "r240", "r241", "r242", "r243", "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r238", "r239" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Recorded accrual balance for legal proceedings and exposures" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "auth_ref": [ "r241", "r243", "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "label": "Loss Contingency, Estimate of Possible Loss", "terseLabel": "Estimation of possible loss" } } }, "localname": "LossContingencyEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r238", "r240", "r241", "r242", "r243", "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling Items" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maximum Length of Time Hedged in Cash Flow Hedge", "terseLabel": "Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold" } } }, "localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r46", "r102", "r180", "r249", "r254", "r255", "r256", "r262", "r263", "r541", "r584", "r607" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "verboseLabel": "Noncontrolling Interests in Subsidiaries" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "Allowance for Doubtful Accounts:" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r92" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash From (Used in) Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flow From (Used in) Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r92" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash From (Used in) Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flow From (Used in) Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r92", "r94", "r97" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash From Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flow From (Used in) Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r3", "r60", "r63", "r68", "r72", "r97", "r102", "r109", "r111", "r112", "r113", "r114", "r117", "r118", "r126", "r148", "r154", "r158", "r161", "r164", "r180", "r249", "r250", "r251", "r254", "r255", "r256", "r258", "r260", "r262", "r263", "r525", "r541", "r590", "r611" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net earnings", "totalLabel": "Net Earnings" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r111", "r112", "r113", "r114", "r119", "r120", "r127", "r130", "r148", "r154", "r158", "r161", "r164" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net earnings allocated to common shares" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r106", "r107", "r108", "r305", "r479" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails", "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r148", "r154", "r158", "r161", "r164" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.abbott.com/role/SegmentInformationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating Earnings", "totalLabel": "Operating earnings" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r153", "r154", "r155", "r156", "r158", "r164" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r4", "r490" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAggregatedInvestmentsMember": { "auth_ref": [ "r628", "r631", "r634" ], "lang": { "en-us": { "role": { "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests.", "label": "Other Security Investments [Member]", "verboseLabel": "Other" } } }, "localname": "OtherAggregatedInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r54", "r56", "r481", "r485" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $11 and $36 in 2022 and $18 and $54 in 2021" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r481", "r482", "r485" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation gain (loss) adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r59", "r66", "r67", "r69", "r547", "r549", "r553" ], "calculation": { "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r56" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $50 and $96 in 2022 and $50 and $98 in 2021" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "auth_ref": [ "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "terseLabel": "Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r52", "r56", "r502", "r507", "r519" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Gain (loss) Recognized in Other Comprehensive Income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r61", "r64", "r481", "r482", "r485" ], "calculation": { "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": { "auth_ref": [ "r54", "r57", "r481" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "negatedTerseLabel": "Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "verboseLabel": "Other" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r328", "r331", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r381", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Medical and Dental Plans" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsDetails", "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForOtherTaxes": { "auth_ref": [ "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for taxes classified as other.", "label": "Payments for Other Taxes", "terseLabel": "Payment of cash taxes" } } }, "localname": "PaymentsForOtherTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromInvestments": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.", "label": "Payments for (Proceeds from) Investments", "negatedLabel": "Sales (purchases) of other investment securities, net" } } }, "localname": "PaymentsForProceedsFromInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r84", "r86" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r89" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchases of common shares" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r91", "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r89" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r85" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisitions of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r327", "r331", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r381", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r403", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Defined Benefit Plans" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsDetails", "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Postemployment Benefits [Abstract]", "terseLabel": "Postemployment Benefits [Abstract]" } } }, "localname": "PostemploymentBenefitsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PostemploymentBenefitsDisclosureTextBlock": { "auth_ref": [ "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.", "label": "Postemployment Benefits Disclosure [Text Block]", "terseLabel": "Post-Employment Benefits" } } }, "localname": "PostemploymentBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23", "r298" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred shares, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred shares, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23", "r298" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred shares, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23", "r563" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred shares, one dollar par value Authorized \u2014 1,000,000 shares, none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r88" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-Term Debt", "verboseLabel": "Net borrowings (repayments) of short-term debt and other" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": { "auth_ref": [ "r84" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.", "label": "Proceeds from Sales of Business, Affiliate and Productive Assets", "terseLabel": "Proceeds from business dispositions" } } }, "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r87", "r448" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r14", "r212" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r214", "r563", "r597", "r609" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Net property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r76", "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provisions/charges to income" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "auth_ref": [ "r59", "r66", "r67", "r547", "r551", "r553" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "terseLabel": "Income (expense) and Gain (loss) Reclassified into Income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r59", "r66", "r67", "r69", "r547", "r551", "r553" ], "calculation": { "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedLabel": "Amounts reclassified from accumulated other comprehensive income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "verboseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/DebtandLinesofCreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r90" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Repayments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r453", "r575", "r656" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r219", "r221", "r224", "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring Plans" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r96", "r218", "r227", "r230" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring charges", "verboseLabel": "Restructuring charges recorded in 2021" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r220", "r221", "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r221", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Accrued balance at end of the period", "periodStartLabel": "Accrued balance at beginning of the period" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r221", "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Reduction of restructuring estimate" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "auth_ref": [ "r221", "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.", "label": "Restructuring Reserve, Settled without Cash", "negatedTerseLabel": "Other non-cash" } } }, "localname": "RestructuringReserveSettledWithoutCash2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r305", "r563", "r606", "r624", "r626" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Earnings employed in the business" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r106", "r107", "r108", "r110", "r116", "r118", "r181", "r449", "r450", "r451", "r462", "r463", "r523", "r621", "r623" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r327", "r328", "r331", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r381", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r403", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsDetails", "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r327", "r328", "r331", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r381", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r403", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsDetails", "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails", "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r139", "r140", "r153", "r159", "r160", "r167", "r168", "r171", "r320", "r321", "r576" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Net Sales to External Customers" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited", "http://www.abbott.com/role/RevenueSegmentsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r310", "r311", "r312", "r313", "r314", "r315", "r318", "r319", "r324", "r326" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligations" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Expected timing of satisfaction period (in months)" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r59", "r552", "r553" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of accumulated other comprehensive income (loss), net of taxes" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r380", "r381", "r382", "r383", "r394" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsDetails", "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r501", "r509", "r514" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of derivatives gain (loss) in OCI and earnings" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Summary of the amounts and location of certain derivative financial instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r527", "r528" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of components of the net periodic benefit cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/PostEmploymentBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r220", "r221", "r222", "r223", "r230", "r231", "r232" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r225", "r226", "r229" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of restructuring activity" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r221", "r231" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of restructuring reserve and related cost" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r148", "r151", "r157", "r199" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r148", "r151", "r157", "r199" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of segment information - net sales and operating earnings" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r408", "r409", "r412", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r425", "r426", "r427", "r428", "r429", "r430", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r415", "r431", "r434" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock options outstanding and exercisable" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r135", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r153", "r154", "r155", "r156", "r158", "r159", "r160", "r161", "r162", "r164", "r171", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r201", "r223", "r232", "r617" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSegmentsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r135", "r137", "r138", "r148", "r152", "r158", "r162", "r163", "r164", "r165", "r167", "r170", "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expense" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r96" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r95" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted stock awards granted during the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "terseLabel": "Restricted stock units granted during period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Incentive stock program, shares reserved for future grants (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable options, number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable options, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Stock options granted during the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r447" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "terseLabel": "Stock options outstanding, number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Stock options outstanding, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r412", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r425", "r426", "r427", "r428", "r429", "r430", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails", "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r447" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "verboseLabel": "Aggregate intrinsic value of options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable options, weighted-average remaining life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Stock options outstanding, weighted-average remaining life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r35", "r586", "r587", "r601" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]", "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "A summary of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return for which the resultant tax benefit has not been recognized in the financial statements because it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table]", "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table]" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r2", "r135", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r153", "r154", "r155", "r156", "r158", "r159", "r160", "r161", "r162", "r164", "r171", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r201", "r216", "r223", "r232", "r617" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails", "http://www.abbott.com/role/RevenueNarrativeDetails", "http://www.abbott.com/role/RevenueSegmentsDetails", "http://www.abbott.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r44", "r66", "r67", "r68", "r106", "r107", "r108", "r110", "r116", "r118", "r134", "r181", "r300", "r305", "r449", "r450", "r451", "r462", "r463", "r523", "r547", "r548", "r549", "r550", "r551", "r553", "r560", "r621", "r622", "r623" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r106", "r107", "r108", "r134", "r576" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r300", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted stock awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r23", "r24", "r305", "r432" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r27", "r28", "r102", "r176", "r180", "r541", "r563" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "End of the period", "periodStartLabel": "Beginning of the period", "totalLabel": "Total Abbott Shareholders\u2019 Investment" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r67", "r102", "r106", "r107", "r108", "r110", "r116", "r180", "r181", "r305", "r449", "r450", "r451", "r462", "r463", "r479", "r480", "r489", "r523", "r541", "r547", "r548", "r553", "r560", "r622", "r623" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total Shareholders\u2019 Investment" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Shareholders\u2019 Investment:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RevenueSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SummaryOfInvestmentHoldingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Summary of Investment Holdings [Line Items]", "terseLabel": "Summary of Investment Holdings [Line Items]" } } }, "localname": "SummaryOfInvestmentHoldingsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfInvestmentHoldingsTable": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "The summary of investment holding table is used for any listing of investment in a summary form. Table lists the 50 largest investments and any other investment the value of which exceeded 1 percent of net asset value of the registrant as of the close of the period.", "label": "Summary of Investment Holdings [Table]", "terseLabel": "Summary of Investment Holdings [Table]" } } }, "localname": "SummaryOfInvestmentHoldingsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "auth_ref": [ "r454", "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.", "label": "Tax Adjustments, Settlements, and Unusual Provisions", "terseLabel": "Tax expense from prior year tax positions" } } }, "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/TaxesonEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock, Common" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "periodEndLabel": "Ending balance, treasury stock, common (in shares)", "periodStartLabel": "Beginning balance, treasury stock, common (in shares)", "terseLabel": "Common shares held in treasury (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical", "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r45", "r306", "r307" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "negatedLabel": "Common shares held in treasury, at cost \u2014 Shares: 2022: 242,345,663; 2021: 221,191,228" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r24", "r300", "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Purchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r300", "r305", "r306" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Purchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r220", "r221", "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/RestructuringPlansNarrativeDetails", "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r121", "r130" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r119", "r130" ], "calculation": { "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r172": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r237": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r246": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r297": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410195&loc=d3e80090-111668" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "https://asc.fasb.org/topic&trid=2197446" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r452": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28511-109314" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28446-109314" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r470": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r490": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r526": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r657": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r658": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r659": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r660": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r661": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r662": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" } }, "version": "2.1" } ZIP 72 0001628280-22-027550-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-027550-xbrl.zip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end